var title_f31_31_32240="Atypical atrioventricular nodal reentrant tachycardia";
var content_f31_31_32240=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atypical atrioventricular nodal reentrant tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 279px; height: 424px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown are three simultaneous ECG leads (I, II, and III) during an uncommon or atypical form of an atrioventricular nodal reentrant tachycardia (AVNRT) in which antegrade conduction to the ventricle is via the fast pathway and retrograde atrial activation is by the slow pathway. As a result of delayed atrial activation, there is a long RP and short PR interval and a negative P wave in the inferior leads II and III.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_31_32240=[""].join("\n");
var outline_f31_31_32240=null;
var title_f31_31_32241="Osteomyelitis progression";
var content_f31_31_32241=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Progression of radiographic findings in a 6-year-old boy with osteomyelitis of the fibula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 502px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Plain radiographs (after one week of swelling and pain in the calf) were initially interpreted as normal. B) A plain radiograph obtained four days after the initial films demonstrates periosteal reaction and cortical thickening. C) T1 weighted MRI with gadolinium demonstrates enhancement of the fibula marrow space and surrounding soft tissues.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marvin B Harper, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_31_32241=[""].join("\n");
var outline_f31_31_32241=null;
var title_f31_31_32242="Uncomplicated cesarean delivery of fetus cephalic presentation";
var content_f31_31_32242=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Uncomplicated cesarean delivery of fetus in cephalic presentation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 401px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_31_32242=[""].join("\n");
var outline_f31_31_32242=null;
var title_f31_31_32243="Naphazoline and pheniramine: Drug information";
var content_f31_31_32243=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Naphazoline and pheniramine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/60/9156?source=see_link\">",
"    see \"Naphazoline and pheniramine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F15512119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Issues Warning on Accidental Ingestion of Imidazoline Derivative Eye Drops and Nasal Sprays",
"     </span>",
"     <span class=\"collapsible-date\">",
"      October 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The U.S. Food and Drug Administration (FDA) has issued a warning that accidental ingestion by children of over-the-counter (OTC) imidazoline derivative eye drops and nasal sprays may result in serious harm. The eye drops and nasal sprays involved in cases of accidental ingestion contain the imidazoline derivatives tetrahydrozoline, oxymetazoline, or naphazoline. Serious adverse reactions (eg, coma, bradycardia, respiratory depression, sedation) requiring hospitalization were reported in children &le;5 years who had ingested even small amounts (eg, 1-2 mL). These products should be stored out of reach of children at all times; parents and caregivers should note that not all products are packaged in child-resistant packaging. If a child accidentally ingests these products, parents and caregivers should contact a poison control center at 1-800-222-1222 and seek emergency medical care immediately.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For more information, please refer to:",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm325257.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm325257.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F199791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Naphcon-A&reg; [OTC];",
"     </li>",
"     <li>",
"      Opcon-A&reg; [OTC];",
"     </li>",
"     <li>",
"      Visine-A&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F199792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Naphcon-A&reg;;",
"     </li>",
"     <li>",
"      Visine&reg; Advanced Allergy",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F199802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alkylamine Derivative;",
"     </li>",
"     <li>",
"      Alpha;",
"      <sub>",
"       1",
"      </sub>",
"      Agonist",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"     <li>",
"      Imidazoline Derivative;",
"     </li>",
"     <li>",
"      Ophthalmic Agent, Vasoconstrictor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F199794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic: 1-2 drops into the affected eye(s) up to 4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F199799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic: Children &ge;6 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F199795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F199783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Naphcon-A&reg;: Naphazoline hydrochloride 0.025% and pheniramine maleate 0.3% (5 mL) [contains benzalkonium chloride; 2 bottles/box], (15 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Opcon-A&reg;: Naphazoline hydrochloride 0.027% and pheniramine maleate 0.3% (15 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Visine-A&reg;: Naphazoline hydrochloride 0.025% and pheniramine maleate 0.3% (15 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F199772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13854492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For ophthalmic use only. Contact lenses should be removed prior to administering products containing benzalkonium chloride.  Instruct patients to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures. Ocular solutions can become contaminated by common bacteria known to cause ocular infections.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F199784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of ocular congestion, irritation, and itching",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F199809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Visine&reg; may be confused with Visken&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Accidental ingestion: Serious adverse reactions (eg, coma, bradycardia, respiratory depression, sedation) requiring hospitalization have been reported in children &le;5 years of age who have accidentally ingested even small amounts (eg, 1-2 mL) of imidazoline-derivative (ie, tetrahydrozoline, oxymetazoline, or naphazoline) eye drops or nasal sprays. Store these products out of reach of children at all times. Contact poison control or seek medical attention if accidental ingestion occurs.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F199800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Ocular: Pupillary dilation, tingling",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F199787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to naphazoline, pheniramine, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F199775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzalkonium chloride: May contain benzalkonium chloride which may be absorbed by soft contact lenses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For ophthalmic use only. Inadvertent contamination of multiple-dose ophthalmic solutions, has caused bacterial keratitis; avoid contamination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): When used for self medication (OTC), patients with cardiovascular disease, hypertension, narrow-angle glaucoma, or prostatic hyperplasia should consult healthcare provider before use. Do not use &gt;72 hours. Notify healthcare provider if eye pain or vision changes occur.  Do not use with contact lenses. Do not use if solution changes color or becomes cloudy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F199779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F199788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Naphcon-A Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025-0.3% (5 mL): $3.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Opcon-A Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.027-0.315% (15 mL): $5.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Visine-A Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025-0.3% (15 mL): $4.96",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F199789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Flamergi (ID);",
"     </li>",
"     <li>",
"      Irazol (PH);",
"     </li>",
"     <li>",
"      Naphcon-A (AU, BE, CL, CN, EC, HK, ID, MY, NZ, PE, PH, PK, SG, TH);",
"     </li>",
"     <li>",
"      Oqifresh (CO);",
"     </li>",
"     <li>",
"      Visine Allergy (NZ);",
"     </li>",
"     <li>",
"      Visine Allergy with Antihistamine (AU);",
"     </li>",
"     <li>",
"      Vistallerg (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13854461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pheniramine, a nonselective histamine antagonist, inhibits the effect of histamine on conjunctival epithelial cells by preventing its release from mast cells.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Naphazoline, an alpha",
"     <sub>",
"      1",
"     </sub>",
"     -agonist, stimulates alpha-adrenergic receptors in the arterioles of the conjunctiva to produce vasoconstriction.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10166 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-D795AC79FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_31_32243=[""].join("\n");
var outline_f31_31_32243=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15512119\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199791\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199792\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199802\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199794\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199799\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199795\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199783\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199772\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854492\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199784\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199809\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199800\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199787\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199775\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299743\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199779\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199788\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199789\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854461\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10166\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10166|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/60/9156?source=related_link\">",
"      Naphazoline and pheniramine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_31_32244="Sarcoidosis - facial";
var content_f31_31_32244=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F69405&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F69405&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Papular sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple small papules are present on the nose and cheeks of this patient with cutaneous sarcoidosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc. Original photo provided by NYU (Tisch) Department of Dermatology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_31_32244=[""].join("\n");
var outline_f31_31_32244=null;
var title_f31_31_32245="Malignant stenosis MRI";
var content_f31_31_32245=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Squamous cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 340px; height: 602px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal and sagittal MR sequences of the chest demonstrate a mass in the lower trachea with near occlusion of the lumen and tumor extending into the surrounding mediastinum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_31_32245=[""].join("\n");
var outline_f31_31_32245=null;
var title_f31_31_32246="Tetrabenazine: Drug information";
var content_f31_31_32246=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tetrabenazine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/15/13557?source=see_link\">",
"    see \"Tetrabenazine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F6458844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6458845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Xenazine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nitoman&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F855280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Central Monoamine-Depleting Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F855097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose should be individualized; titrate slowly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Chorea associated with Huntington&rsquo;s disease:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial: 12.5 mg once daily, may increase to 12.5 mg twice daily after 1 week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance: May be increased by 12.5 mg/day at weekly intervals; doses &gt;37.5 mg/day should be divided into 3 doses (maximum single dose: 25 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Patients requiring doses &gt;50 mg/day:",
"     </i>",
"     Genotype for CYP2D6:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Extensive/intermediate metabolizers: Maximum: 100 mg/day; 37.5 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Poor metabolizers: Maximum: 50 mg/day; 25 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Concomitant use with strong CYP2D6 inhibitors (eg, fluoxetine, paroxetine, quinidine):",
"     </i>",
"     Dose of tetrabenazine should be reduced by 50% in patients receiving strong CYP2D6 inhibitors, follow dosing for poor CYP2D6 metabolizers. Use caution when adding a CYP2D6 inhibitor to patients already taking tetrabenazine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     If treatment is interrupted for &gt;5 days, retitration is recommended. If treatment is interrupted for &lt;5 days resume at previous maintenance dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Canadian labeling: Hyperkinetic movement disorders:",
"     </b>",
"     Initial: 12.5 mg twice daily (may be given 3 times/day); may be increased by 12.5 mg/day every 3-5 days; should be titrated slowly to maximal tolerated and effective dose (dose is individualized)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Usual maximum tolerated dosage: 25 mg 3 times/day; maximum recommended dose: 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     If there is no improvement at the maximum tolerated dose after 7 days, improvement is unlikely; discontinuation should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F855098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Canadian labeling: Elderly and/or debilitated patients: Consider initiation at lower doses; must be titrated slowly to individualize dosage.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F6458859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F6458860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For toxicity/adverse reaction, including akathisia, restlessness, parkinsonism, insomnia, depression, suicidality, anxiety, sedation (intolerable): Suspend upward dosage titration and reduce dose; consider discontinuing if adverse reaction does not resolve (may be discontinued without tapering).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F855100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xenazine&reg;: 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xenazine&reg;: 25 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F6458864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Nitoman&trade;: 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11234345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Xenazine&reg; is available only through specialty pharmacies. For more information regarding the procurement of Xenazine&reg;, healthcare providers, patients, and caregivers may contact the Xenazine&reg; Information Center (XIC) at 1-888-882-6013 or at:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Healthcare providers: file://www.xenazineusa.com/HCP/PrescribingXenazine/Default.aspx",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Patients and caregivers: file://www.xenazineusa.com/AboutXenazine/Getting-Your-Prescription.aspx",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089827.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089827.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6458862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May administer without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F855069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of chorea associated with Huntington&rsquo;s disease",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Treatment of hyperkinetic movement disorders, including Huntington's chorea, hemiballismus, senile chorea, Tourette syndrome, and tardive dyskinesia",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F855077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Many adverse effects are dose-related and may resolve at lower dosages. Adverse effects reported for adults with chorea associated with Huntington&rsquo;s disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Extrapyramidal symptoms (15% to 33%), sedation (31%), somnolence (31%), fatigue (22%), insomnia (22%), akathisia (19%), depression (19%), anxiety (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Falls (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory tract infection (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Parkinsonism (3% to 10%), irritability (9%), dizziness (4%), headache (4%), obsessive reaction (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Bruising (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Dysphagia (4% to 10%), vomiting (6%), appetite decreased (4%), diarrhea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Dysuria (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Balance difficulty (9%), bradykinesia (9%), dysarthria (4%), gait disturbance (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Bronchitis (4%), dyspnea (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Aspiration pneumonia, hyperprolactinemia, orthostatic hypotension, neuroleptic malignant syndrome, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, restlessness, suicidal ideation, suicide, syncope, transaminases increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F855072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients who are actively suicidal or with untreated or inadequately treated depression; hepatic impairment; use with or within 14 days of MAO inhibitors; use with or within 20 days of reserpine",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Hypersensitivity to tetrabenazine or any component of the formulation; history or current episode of clinical depression; use with or within 14 days of MAO inhibitors",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F855073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Box warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">",
"     &bull; Depression/suicidal ideation: See &ldquo;Concerns related to adverse effects&rdquo; below.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Akathisia: Use has been associated with akathisia; monitor for signs and symptoms of restlessness and agitation. Dosage reduction or discontinuation may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression/suicidal ideation: [",
"     <b>",
"      U.S. Boxed Warning]: May increase risk for depression and suicidal ideation; evaluate immediately if signs and/or symptoms of depression or suicidality are noted. Use with caution in patients with a history of depression; monitor patients closely for new or worsening signs or symptoms of depression.",
"     </b>",
"     Reduce dose if depression occurs; consider discontinuing if depression/suicidal ideation does not resolve.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Esophageal dysmotility/aspiration: Use has been associated with esophageal dysmotility, dysphagia, and aspiration; use with caution in patients at risk of aspiration pneumonia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic malignant syndrome (NMS): Use may be associated with NMS; monitor for mental status changes, fever, muscle rigidity and/or autonomic instability. Discontinue with confirmed NMS; may reoccur with reintroduction of treatment; monitor carefully.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension; monitor patients at risk closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT prolongation: Has been shown to prolong the QT interval alone (minimal) and with other drugs with comparable effects on the QT interval (additive). Avoid use in patients with congenital QT prolongation, a history of cardiac arrhythmias, or concomitant drugs known to cause QT prolongation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Use with caution in patients with Parkinson's disease; may induce/exacerbate symptoms of parkinsonism (more common in elderly patients). Dose reduction or discontinuation of therapy may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prolactin-dependent tumors: Use with caution in patients with breast cancer or other prolactin-dependent tumors; elevates prolactin levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disease: Due to the possibility of comorbid psychiatric disorders and potential psychiatric adverse effects, patients should be carefully monitored for potential changes in psychiatric status during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic drugs: Has not been studied with concomitant use of neuroleptic drugs (eg, haloperidol, olanzapine); adverse effects may be additive.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP2D6 poor metabolizers: Patients should be tested for the CYP2D6 gene prior to initiating doses &gt;50 mg/day; maximum dosage should not exceed 50 mg/day in poor metabolizers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Should not be used to treat levodopa-induced dyskinesia.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F855082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: Tetrabenazine may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May increase the serum concentration of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased. Management: Tetrabenazine adult dose should be reduced by 50% when starting a strong CYP2D6 inhibitor.  Maximum tetrabenazine adult dose is 50 mg/day when used with a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: Tetrabenazine may enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Tetrabenazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Tetrabenazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the adverse/toxic effect of Tetrabenazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F855085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6458846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F855070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal studies. There are no adequate and well-controlled studies in pregnant women. Avoid use in pregnant women unless the potential benefit justifies the potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F855071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in  breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F6458861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Xenazine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg (112): $6620.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (112): $13240.09",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F855099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Improvement in movement disorder; signs and/or symptoms of depression or suicide ideation; signs and/or symptoms of NMS; orthostatic blood pressure. Due to the possibility of comorbid psychiatric disorders, and potential psychiatric adverse effects, patients should be carefully monitored for potential changes in psychiatric status during therapy. CYP2D6 genotyping for evaluation of metabolizer status.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Nitoman (DE, DK, IE, PT, TW);",
"     </li>",
"     <li>",
"      Revocon (IN);",
"     </li>",
"     <li>",
"      Xenazina (IT);",
"     </li>",
"     <li>",
"      Xenazine (FR, GB, IL, NL, NZ)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F855088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Within basal ganglia, interferes with and depletes monoamine neurotransmitters (including dopamine, serotonin, and norepinephrine) in presynaptic vesicles (likely through actions on vesicle monoamine transporter). Tetrabenazine inhibits presynaptic dopamine release and also blocks CNS dopamine receptors. The effects resemble reserpine but with less peripheral activity and a shorter duration of action. Treatment results in symptomatic improvement of hyperkinetic movement disorders, including Huntington&rsquo;s chorea, hemiballismus, senile chorea, Tic and Hille&rsquo;s de la Tourette syndrome, and tardive dyskinesia.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F855090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: 16-24 hours (at steady-state); chorea may recur within 12-18 hours after discontinuation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 82% to 85%; Metabolites: 59% to 68%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic (rapid and extensive), to alpha and beta hydroxytetrabenazine (HTBZ) via CYP2D6 (primary active moiety)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Low and erratic (due to extensive first-pass effects); unaffected by food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Alpha-HTBZ: 4-8 hours; Beta-HTBZ: 2-4 hours (increased with hepatic impairment)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: Within 1-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (75% as metabolites, &lt;10% as alpha and beta HTBZ); feces (7% to 16%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chatterjee A and Frucht SJ, \"Tetrabenazine in the Treatment of Severe Pediatric Chorea,\"",
"      <i>",
"       Mov Disord",
"      </i>",
"      , 2003, 18(6):703-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/31/32246/abstract-text/12784277/pubmed\" id=\"12784277\" target=\"_blank\">",
"        12784277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Furukawa T, Ushizima I, and Ono N, \"Modifications by Lithium of Behavioral Responses to Methamphetamine and Tetrabenazine,\"",
"      <i>",
"       Psychopharmacologia",
"      </i>",
"      , 1975,  42(3):243-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/31/32246/abstract-text/1161982/pubmed\" id=\"1161982\" target=\"_blank\">",
"        1161982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jankovic J and Beach J, \"Long-Term Effects of Tetrabenazine in Hyperkinetic Movement Disorders,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 1997, 48(2):358-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/31/32246/abstract-text/9040721/pubmed\" id=\"9040721\" target=\"_blank\">",
"        9040721",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ondo WG, Hanna PA, and Jankovic J, \"Tetrabenazine Treatment for Tardive Dyskinesia: Assessment by Randomized Videotape Protocol,\"",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1999,  156(8):1279-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/31/32246/abstract-text/10450276/pubmed\" id=\"10450276\" target=\"_blank\">",
"        10450276",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paleacu D, Giladi N, Moore O, et al, \"Tetrabenazine Treatment in Movement Disorders,\"",
"      <i>",
"       Clin Neuropharmacol",
"      </i>",
"      , 2004, 27(5):230-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/31/32246/abstract-text/15602104/pubmed\" id=\"15602104\" target=\"_blank\">",
"        15602104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shannon KM, \"Hemiballismus,\"",
"      <i>",
"       Curr Treat Options Neurol",
"      </i>",
"      , 2005, 7(3):203-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/31/32246/abstract-text/15814073/pubmed\" id=\"15814073\" target=\"_blank\">",
"        15814073",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9476 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-F836DB8729-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_31_32246=[""].join("\n");
var outline_f31_31_32246=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6458844\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6458845\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855068\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855280\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855097\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855098\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6458859\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6458860\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855100\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6458864\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234345\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874999\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6458862\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855069\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855077\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855072\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855073\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300121\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855082\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855085\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6458846\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855070\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855071\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6458861\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321905\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855099\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869447\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855088\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855090\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9476\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9476|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/15/13557?source=related_link\">",
"      Tetrabenazine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_31_32247="Spontaneous intestinal perforation of the newborn";
var content_f31_31_32247=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Spontaneous intestinal perforation of the newborn",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/31/32247/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/31/32247/contributors\">",
"     Eugene S Kim, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/31/32247/contributors\">",
"     Mary L Brandt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/31/32247/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/31/32247/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/31/32247/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/31/32247/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/31/32247/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous intestinal perforation (SIP) of the newborn, also referred to as isolated perforation of the newborn, is a single intestinal perforation that is typically found at the terminal ileum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. SIP occurs primarily in premature infants with very low birth weight (VLBW, birth weight &lt;1500 g) and extremely low birth weight (ELBW, birth weight &lt;1000 g). SIP is a separate clinical entity from necrotizing enterocolitis, the most severe gastrointestinal complication of premature infants. This differentiation is important because of management considerations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/39/41591?source=see_link\">",
"     \"Clinical features and diagnosis of necrotizing enterocolitis in newborns\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology, clinical features, diagnosis, and management of spontaneous intestinal perforation of the newborn will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous intestinal perforation (SIP) is most commonly found in very low birth weight (VLBW) and extremely low birth weight (ELBW) premature infants. The risk appears to be about 2 to 3 percent of VLBW infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/1,6,7\">",
"     1,6,7",
"    </a>",
"    ] and about 5 percent in ELBW infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/8\">",
"     8",
"    </a>",
"    ]. The median gestational age varies from 25 to 27 weeks, and median birth weight from 670 to 973 g [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/1-3,9,10\">",
"     1-3,9,10",
"    </a>",
"    ]. SIP occurs more frequently in male infants (ranging from 65 to 71 percent of affected infants) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prematurity is the only well established risk factor for SIP. Several reported antenatal and postnatal risk factors are based upon limited data that include findings from case series and a single data set from the Pediatrix Medical Group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/1,11-13\">",
"     1,11-13",
"    </a>",
"    ]. This data set is based upon clinical progress notes of premature infants (range of gestational age 23 to 34 weeks) who were born and cared for at 98 sites in the Pediatrix Medical Group between 1998 and 2000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Antenatal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe placental chorioamnionitis appears to be an antenatal risk factor for SIP. In one case control study of 16 premature infants with SIP, infants with SIP versus matched controls were more likely to have severe placental chorioamnionitis with evidence of fetal vascular response based upon a blinded retrospective histologic examination of the placenta and umbilical vessels (40 versus 12 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/11\">",
"     11",
"    </a>",
"    ]. In this study, mothers of infants with SIP were more likely to have received antibiotics before or at delivery (93 versus 57 percent).",
"   </p>",
"   <p>",
"    Although it has been postulated that antenatal administration of glucocorticoids and nonsteroidal antiinflammatory drugs (NSAIDs) increases the risk of SIP, data have not demonstrated a clear association of SIP with either of these factors.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study from the Pediatrix group, administration of antenatal glucocorticoids did not appear to increase the risk of SIP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/13\">",
"       13",
"      </a>",
"      ]. There is a small case series of 13 neonates with gastrointestinal perforation (10 confirmed as SIP) in which antenatal NSAIDs suggested an increased risk of SIP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/7\">",
"       7",
"      </a>",
"      ]. However, this finding has not been confirmed in other case series.",
"     </li>",
"     <li>",
"      In a large multicenter retrospective study of 11,960 ELBW preterm infants from the Neonatal Intensive Care Units from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Neonatal Research Network, 280 patients were identified with SIP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/15\">",
"       15",
"      </a>",
"      ]. Multivariate analysis found that the administration of antenatal steroids was not associated with SIP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another small retrospective study, additional reported risk factors for SIP in VLBW infants in 8 cases versus 32 controls included oligohydramnios, velamentous cord insertion, lower one minute Apgar scores, and primigravidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/16\">",
"     16",
"    </a>",
"    ]. However, these findings need to be confirmed in a larger cohort of cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Postnatal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early administration of postnatal glucocorticoids increases the risk of SIP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. This was best illustrated in a meta-analysis of four trials of prophylactic",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    for the prevention of bronchopulmonary dysplasia in which VLBW infants treated with dexamethasone before 48 hours of life had an increased risk of SIP compared with controls (odds ratio [OR] 1.91, 95% CI 1.21-3.07) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/17\">",
"     17",
"    </a>",
"    ]. In one of the included trials with 220 infants with birth weights &lt;1000 g, SIP occurred in 13 percent of the patients who received a moderate dose of dexamethasone (0.15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) within 24 hours of life for three days compared with 4 percent who received placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/17/3353?source=see_link&amp;anchor=H5#H5\">",
"     \"Postnatal use of glucocorticoids in bronchopulmonary dysplasia\", section on 'Short-term adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the postnatal use of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    has been reported to increase the risk of SIP, this association remains uncertain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/1002?source=see_link&amp;anchor=H1214592#H1214592\">",
"     \"Management of patent ductus arteriosus in premature infants\", section on 'Indomethacin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an analysis of the Pediatrix database, infants with SIP (n = 633) compared with matched controls (n = 581) were more likely to have received",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/27/17848?source=see_link\">",
"       indomethacin",
"      </a>",
"      within the first three days of life (OR 1.86, 95% CI 1.4-2.5) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/12\">",
"       12",
"      </a>",
"      ]. However, treatment with indomethacin in the period between days of life four and seven was not associated with an increased risk of SIP.",
"     </li>",
"     <li>",
"      In the previously mentioned retrospective review from the NICHD Neonatal Research Network from 1998 to 2005, multivariate analysis demonstrated that the administration of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/27/17848?source=see_link\">",
"       indomethacin",
"      </a>",
"      for the treatment of PDA was associated with SIP (adjusted OR 1.61, 95% CI 1.25-2.08), but the prophylactic use of indomethacin for intraventricular hemorrhage was not associated with SIP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The largest multicenter trial of prophylactic use of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/27/17848?source=see_link\">",
"       indomethacin",
"      </a>",
"      to prevent patent ductus arteriosus found that treatment with indomethacin was not associated with an increased risk of SIP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/1002?source=see_link&amp;anchor=H1214592#H1214592\">",
"       \"Management of patent ductus arteriosus in premature infants\", section on 'Indomethacin'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are conflicting data regarding whether the addition of glucocorticoids to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    increases the overall risk of SIP compared to either drug alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/13,19,21\">",
"     13,19,21",
"    </a>",
"    ]. One retrospective study demonstrated that VLBW infants with SIP compared with matched controls were 9.6 times more likely to have received three or more doses of indomethacin and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In very low birth weight (VLBW) neonates with spontaneous intestinal perforation (SIP), there is a single isolated perforation that is typically found at the terminal ileum, but has also been reported in the jejunum and colon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. At the area of perforation, focal hemorrhagic necrosis with well-defined margins is observed in contrast to the ischemic and coagulative necrosis seen in necrotizing enterocolitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/4,22\">",
"     4,22",
"    </a>",
"    ]. In SIP, the bowel proximal and distal to the perforation appears normal (",
"    <a class=\"graphic graphic_picture graphicRef69039 \" href=\"mobipreview.htm?31/47/32500\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The etiology of SIP remains unknown. Several studies have explored a variety of different pathogenetic pathways.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although thinning or absence of the muscularis propria at the perforation site has been reported in several cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/2,22-24\">",
"       2,22-24",
"      </a>",
"      ], it is unclear whether these changes are involved in the pathogenesis of SIP.",
"     </li>",
"     <li>",
"      A role for nitric oxide synthase (NOS) has been suggested based upon a single study of a NOS knock-out mouse model that demonstrated ileal perforation with exposure to",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/27/17848?source=see_link\">",
"       indomethacin",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The profiles of immunoregulatory protein expression were examined using cytokine antibody assay, and measuring specific protein concentration (ELISA) and mRNA expression in serum and intestinal tissue of preterm infants with SIP and necrotizing enterocolitis (NEC) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/26\">",
"       26",
"      </a>",
"      ]. Gene expression for inflammation, angiogenesis, wound healing, and apoptosis were markedly different between the NEC group and the SIP group of patients. Specifically, interleukin (IL)-6, angiopoietin-2, soluble type II interleukin-1 receptor (sIL-1RII), and soluble urokinase-type plasminogen activator receptor were markedly higher in the NEC group. This abnormal upregulation in the immune response to NEC may account for the differences in mortality and morbidity observed in NEC and SIP patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous intestinal perforation (SIP) and necrotizing enterocolitis (NEC) are gastrointestinal complications that typically occur in very low birth weight (VLBW) and extremely low birth weight (ELBW) premature infants with a gestational age between 25 and 27 weeks. These two conditions result in significant morbidity and mortality. Since the management of these two disorders may differ, it is important to distinguish between SIP and NEC. In addition, early identification and treatment of SIP significantly reduces mortality and morbidity.",
"   </p>",
"   <p>",
"    Although there can be overlap, the following common findings of SIP typically distinguish it from NEC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/1,4,9,23,27,28\">",
"     1,4,9,23,27,28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Presentation generally within the first week of life. In contrast, NEC typically presents after the first week of life after the infant has begun to feed.",
"     </li>",
"     <li>",
"      Physical finding of abdominal distention, often accompanied by a bluish discoloration (",
"      <a class=\"graphic graphic_picture graphicRef82076 \" href=\"mobipreview.htm?25/54/26464\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Abdominal imaging may demonstrate pneumoperitoneum, but there is no evidence of pneumatosis intestinalis or portal venous gas, which are radiograph hallmarks of NEC. Imaging demonstrates a gasless abdomen in some patients with SIP. (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef66483 \" href=\"mobipreview.htm?14/1/14353\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Age at presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In several case series of SIP, the median age at perforation is seven days with a range of 0 to 15 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/1,2,4,10,12,28,29\">",
"     1,2,4,10,12,28,29",
"    </a>",
"    ]. An analysis from the Pediatrix Medical Group data set demonstrated that neonates with SIP presented earlier in life than those with NEC (median age, 7 versus 15 days of life) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk factor for SIP and birth weight may vary according to the time of presentation. In a Pediatrix analysis of 633 neonates with SIP, patients with SIP were divided into two groups based upon their age of presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/29\">",
"     29",
"    </a>",
"    ]. Infants in the first group (n = 116), who presented between zero and three days of life, were larger (median birth weight 1.4 kg) and less likely to have received antenatal glucocorticoids,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    , surfactant, or mechanical ventilation compared with infants in the second group who presented between 7 and 10 days of age with a median birth weight of 775 g.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with SIP present with an acute onset of abdominal distension and hypotension. Abdominal distention usually occurs without the abdominal wall erythema, crepitus, and induration commonly seen in patients with NEC.",
"   </p>",
"   <p>",
"    A black-bluish discoloration of the abdominal wall is often seen in SIP, and is not typical of NEC (",
"    <a class=\"graphic graphic_picture graphicRef82076 \" href=\"mobipreview.htm?25/54/26464\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/1,4,23,27,28,30\">",
"     1,4,23,27,28,30",
"    </a>",
"    ]. The discoloration may extend into the groin and, in males, the scrotum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Associated infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;In several case series, concomitant sepsis due to coagulase-negative Staphylococcus or fungemia due to Candida albicans have been reported in neonates with SIP and may be a major cause of morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/1,2,11,28\">",
"     1,2,11,28",
"    </a>",
"    ]. It is unknown whether the infections precede or are a result of bowel perforation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory findings are nonspecific and are not useful in the diagnosis of SIP. They include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leukocytosis (white cell counts between 14, 000 to",
"      <span class=\"nowrap\">",
"       25,000/microL)",
"      </span>",
"      occurs in most infants with SIP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/28,30\">",
"       28,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serum alkaline phosphatase and bilirubin are often increased [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A decrease in platelet count and hematocrit may be observed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis for suspected spontaneous intestinal perforation (SIP) is based upon the presence of the characteristic clinical features in a premature infant within the first 10 days of life. These findings include hypotension and abdominal distension often with the classical bluish discoloration of the abdominal wall in the absence of abdominal wall erythema, crepitus, and induration. Imaging studies are useful in supporting the diagnosis of SIP if there are findings that differentiate SIP from necrotizing enterocolitis (NEC).",
"   </p>",
"   <p>",
"    The diagnosis of SIP is strongly suspected if there are clinical and radiologic findings of pneumoperitoneum in the absence of pneumatosis intestinalis and portal venous air. The diagnosis of SIP is made by operative findings that demonstrate an isolated bowel perforation in the setting of otherwise normal bowel, which is confirmed by histopathologic examination. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Surgical treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal radiographs help to distinguish SIP from NEC. They are obtained in the supine position and, to detect pneumoperitoneum, in either the supine cross-table lateral view or in the lateral decubitus position with the left side down (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59853 \" href=\"mobipreview.htm?7/42/7855\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Specific radiographic findings associated with NEC are not observed in patients with SIP, such as pneumatosis intestinalis, portal venous air, transient thickening of the intestinal wall, and fixed dilated small bowel loops. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/39/41591?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical features and diagnosis of necrotizing enterocolitis in newborns\", section on 'Radiographic studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In both disorders, pneumoperitoneum is a common radiologic finding, occurring in about 30 to 50 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/4,28\">",
"     4,28",
"    </a>",
"    ]. A gasless abdomen may be seen in patients with SIP when the perforation is walled off and free air is not present, but is not a typical finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/4,28\">",
"     4,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial management of a patient with suspected spontaneous intestinal perforation (SIP) is directed toward stabilization of the patient and includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cessation of all feeds and enteral medications",
"     </li>",
"     <li>",
"      Nasogastric suction to decompress the abdomen",
"     </li>",
"     <li>",
"      Supportive care including fluid resuscitation and inotropic medications to correct hypotension",
"     </li>",
"     <li>",
"      Intravenous antibiotics",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Surgical treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is the definitive treatment for SIP. The traditional approach has been exploratory laparotomy with bowel resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/4,23,31\">",
"     4,23,31",
"    </a>",
"    ]. An alternate option is primary peritoneal drainage (PPD). If successful, PPD, which is performed at the bedside, avoids laparotomy and the need for general anesthesia and transport to the operating room for these very premature and often severely ill patients. Many pediatric surgeons support the use of PPD in infants with SIP, as many of these patients will recover without any further surgical intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no randomized clinical trials (RCTs) comparing these two surgical interventions only in infants with SIP. Two case series reported that in infants with SIP, PPD generally was both a stabilizing and definitive treatment, and most infants did not need further surgical intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a review of the literature, two RCTs were identified that compared PPD and exploratory laparotomy in newborns with SIP and NEC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/35\">",
"     35",
"    </a>",
"    ]. Despite combining newborns with different preoperative diagnoses, there was no difference in benefit or mortality between the two treatment groups. However, nearly 50 percent of newborns who underwent PPD avoided the need for a laparotomy during the time period of both studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     PPD technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary peritoneal drainage (PPD) is performed at the bedside in the neonatal intensive care unit. After the administration of pain medication and muscle relaxant, the abdomen is prepped with iodine solution, and local anesthesia is administered. A small transverse incision is made at McBurney's point (two thirds of the distance from the umbilicus to the anterior superior iliac crest in the right lower quadrant). The layers of the abdominal wall are bluntly dissected to enter the peritoneal cavity. In many cases, there will be a rush of air and the presence of meconium encountered. Cultures are taken, the peritoneal cavity is irrigated with warm saline solution, and a Penrose drain is gently threaded into the abdomen and secured.",
"   </p>",
"   <p>",
"    The drain site is observed over the subsequent days. When there is no evidence of persistent intestinal or meconium drainage from the drain site, the drain is backed out daily until it is removed. After the return of bowel function, a trial of feeding can be started or the patency of the gastrointestinal tract can be determined with a contrast study.",
"   </p>",
"   <p>",
"    Laparotomy is indicated following PPD in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reaccumulation of free air after the drain is removed, indicating the perforated bowel did not seal.",
"     </li>",
"     <li>",
"      Fistula with intestinal drainage that fails to close after several weeks of observation.",
"     </li>",
"     <li>",
"      Bowel obstruction, either due to adhesions or, more commonly, a stricture at the site of the perforation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term survival of infants with spontaneous intestinal perforation (SIP) has improved over the past 30 years with reported survival rates of 64 to 90 percent, regardless of treatment with primary peritoneal drainage (PPD) or laparotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/4,5,27,28,33,36\">",
"     4,5,27,28,33,36",
"    </a>",
"    ]. The increase in survival is due to advances in neonatal care including improved parenteral nutrition and antibiotics.",
"   </p>",
"   <p>",
"    Both survivors of SIP and necrotizing enterocolitis (NEC) are at risk for functional impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/37\">",
"     37",
"    </a>",
"    ]. However, neurodevelopmental outcome appears to be better in patients with SIP than those with NEC as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a case series of 23 survivors of SIP and 39 survivors of surgically treated NEC, at one-year adjusted age, the mean Bayley mental and psychomotor developmental indices were greater in SIP survivors compared with those with NEC (91 versus 77, and 80 versus 68, respectively), and the risk of cerebral palsy was lower (15 versus 43 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/27\">",
"       27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/5/35928?source=see_link&amp;anchor=H18#H18\">",
"       \"Management of necrotizing enterocolitis in newborns\", section on 'Outcome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Another retrospective analysis from Cincinnati Children&rsquo;s Hospital Medical Center studied the neurodevelopmental outcomes at 18 to 22 months from former extremely low birth weight (ELBW) infants with medical NEC, surgical NEC, and SIP using Bayley Scales of Infant Development-II scores for Mental Developmental Index and Psychomotor Developmental Index. They found that there were no significant differences in neurodevelopmental outcomes in ELBW infants with medical NEC, surgical NEC, and SIP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, infants with SIP appear to be at increased risk to develop retinopathy of prematurity and periventricular leukomalacia compared with those without SIP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32247/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13814?source=see_link\">",
"     \"Long-term complications of the premature infant\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10762?source=see_link&amp;anchor=H8#H8\">",
"     \"Retinopathy of prematurity\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spontaneous intestinal perforation (SIP) of the newborn is a single intestinal perforation typically found at the terminal ileum.",
"     </li>",
"     <li>",
"      SIP occurs primarily in premature, very low birth weight (VLBW, birth weight &lt;1500 g) infants with a reported prevalence between 2 and 3 percent. Although prematurity is the only well established risk factor, other reported risk factors include severe chorioamnionitis, postnatal glucocorticoid therapy, and possibly postnatal",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/27/17848?source=see_link\">",
"       indomethacin",
"      </a>",
"      therapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SIP generally presents within the first 10 days of life as an acute onset of abdominal distension and hypotension. The classical physical finding is a black-bluish discoloration of the abdominal wall. In contrast, abdominal wall erythema, crepitus, and induration commonly seen with necrotizing enterocolitis (NEC) are not usually present in infants with SIP. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical diagnosis for SIP is based upon the clinical presentation and physical findings. Abdominal radiographs that demonstrate pneumoperitoneum without pneumatosis are supportive of the diagnosis. The definitive diagnosis is based upon direct visualization of the intestinal perforation in the setting of an otherwise healthy appearing small bowel. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NEC is the main disease in the differential diagnosis of SIP. Differentiation between the two disorders is usually based upon the clinical manifestations and abdominal radiographic findings, although there is considerable overlap between the two conditions. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial management for a neonate with SIP is directed towards stabilization of the patient. This includes discontinuing feeds and enteral medications, nasogastric suctioning, and supportive care, such as fluid resuscitation, antibiotics, and inotropic medications to correct hypotension. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment for SIP is surgical. We suggest primary peritoneal drainage as the initial treatment for SIP (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). An alternative option is laparotomy with bowel resection, and either primary anastomosis or creation of an ostomy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/1\">",
"      Meyer CL, Payne NR, Roback SA. Spontaneous, isolated intestinal perforations in neonates with birth weight less than 1,000 g not associated with necrotizing enterocolitis. J Pediatr Surg 1991; 26:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/2\">",
"      Holland AJ, Shun A, Martin HC, et al. Small bowel perforation in the premature neonate: congenital or acquired? Pediatr Surg Int 2003; 19:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/3\">",
"      Drewett MS, Burge DM. Recurrent neonatal gastro-intestinal problems after spontaneous intestinal perforation. Pediatr Surg Int 2007; 23:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/4\">",
"      Pumberger W, Mayr M, Kohlhauser C, Weninger M. Spontaneous localized intestinal perforation in very-low-birth-weight infants: a distinct clinical entity different from necrotizing enterocolitis. J Am Coll Surg 2002; 195:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/5\">",
"      Uceda JE, Laos CA, Kolni HW, Klein AM. Intestinal perforations in infants with a very low birth weight: a disease of increasing survival? J Pediatr Surg 1995; 30:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/6\">",
"      Alpan G, Eyal F, Vinograd I, et al. Localized intestinal perforations after enteral administration of indomethacin in premature infants. J Pediatr 1985; 106:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/7\">",
"      Kawase Y, Ishii T, Arai H, Uga N. Gastrointestinal perforation in very low-birthweight infants. Pediatr Int 2006; 48:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/8\">",
"      Blakely ML, Tyson JE, Lally KP, et al. Laparotomy versus peritoneal drainage for necrotizing enterocolitis or isolated intestinal perforation in extremely low birth weight infants: outcomes through 18 months adjusted age. Pediatrics 2006; 117:e680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/9\">",
"      Attridge JT, Herman AC, Gurka MJ, et al. Discharge outcomes of extremely low birth weight infants with spontaneous intestinal perforations. J Perinatol 2006; 26:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/10\">",
"      Resch B, Mayr J, Kuttnig-Haim M, et al. Spontaneous gastrointestinal perforation in very-low-birth-weight infants--a rare complication in a neonatal intensive care unit. Pediatr Surg Int 1998; 13:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/11\">",
"      Ragouilliaux CJ, Keeney SE, Hawkins HK, Rowen JL. Maternal factors in extremely low birth weight infants who develop spontaneous intestinal perforation. Pediatrics 2007; 120:e1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/12\">",
"      Attridge JT, Clark R, Walker MW, Gordon PV. New insights into spontaneous intestinal perforation using a national data set: (1) SIP is associated with early indomethacin exposure. J Perinatol 2006; 26:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/13\">",
"      Attridge JT, Clark R, Gordon PV. New insights into spontaneous intestinal perforation using a national data set (3): antenatal steroids have no adverse association with spontaneous intestinal perforation. J Perinatol 2006; 26:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/14\">",
"      Guthrie SO, Gordon PV, Thomas V, et al. Necrotizing enterocolitis among neonates in the United States. J Perinatol 2003; 23:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/15\">",
"      Wadhawan R, Oh W, Vohr BR, et al. Spontaneous intestinal perforation in extremely low birth weight infants: association with indometacin therapy and effects on neurodevelopmental outcomes at 18-22 months corrected age. Arch Dis Child Fetal Neonatal Ed 2013; 98:F127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/16\">",
"      Nakajima Y, Masaoka N, Yamamoto T. Obstetrical risk factors for focal intestinal perforation in very low birth weight infants. J Perinat Med 2011; 39:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/17\">",
"      Gordon PV, Young ML, Marshall DD. Focal small bowel perforation: an adverse effect of early postnatal dexamethasone therapy in extremely low birth weight infants. J Perinatol 2001; 21:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/18\">",
"      Stark AR, Carlo WA, Tyson JE, et al. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 2001; 344:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/19\">",
"      Gordon P, Rutledge J, Sawin R, et al. Early postnatal dexamethasone increases the risk of focal small bowel perforation in extremely low birth weight infants. J Perinatol 1999; 19:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/20\">",
"      Schmidt B, Davis P, Moddemann D, et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med 2001; 344:1966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/21\">",
"      Paquette L, Friedlich P, Ramanathan R, Seri I. Concurrent use of indomethacin and dexamethasone increases the risk of spontaneous intestinal perforation in very low birth weight neonates. J Perinatol 2006; 26:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/22\">",
"      Holland AJ. Comment on Kubota et al.: focal intestinal perforation in extremely-low-birth-weight neonates: etiological consideration from histological findings. Pediatr Surg Int 2008; 24:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/23\">",
"      Aschner JL, Deluga KS, Metlay LA, et al. Spontaneous focal gastrointestinal perforation in very low birth weight infants. J Pediatr 1988; 113:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/24\">",
"      Gordon PV. Understanding intestinal vulnerability to perforation in the extremely low birth weight infant. Pediatr Res 2009; 65:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/25\">",
"      Gordon PV, Herman AC, Marcinkiewicz M, et al. A neonatal mouse model of intestinal perforation: investigating the harmful synergism between glucocorticoids and indomethacin. J Pediatr Gastroenterol Nutr 2007; 45:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/26\">",
"      Chan KY, Leung FW, Lam HS, et al. Immunoregulatory protein profiles of necrotizing enterocolitis versus spontaneous intestinal perforation in preterm infants. PLoS One 2012; 7:e36977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/27\">",
"      Adesanya OA, O'Shea TM, Turner CS, et al. Intestinal perforation in very low birth weight infants: growth and neurodevelopment at 1 year of age. J Perinatol 2005; 25:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/28\">",
"      Adderson EE, Pappin A, Pavia AT. Spontaneous intestinal perforation in premature infants: a distinct clinical entity associated with systemic candidiasis. J Pediatr Surg 1998; 33:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/29\">",
"      Attridge JT, Clark R, Walker MW, Gordon PV. New insights into spontaneous intestinal perforation using a national data set: (2) two populations of patients with perforations. J Perinatol 2006; 26:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/30\">",
"      Harms K, L&uuml;dtke FE, Lepsien G, Speer CP. Idiopathic intestinal perforations in premature infants without evidence of necrotizing enterocolitis. Eur J Pediatr Surg 1995; 5:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/31\">",
"      Baird R, Puligandla PS, St Vil D, et al. The role of laparotomy for intestinal perforation in very low birth weight infants. J Pediatr Surg 2006; 41:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/32\">",
"      Blakely ML, Gupta H, Lally KP. Surgical management of necrotizing enterocolitis and isolated intestinal perforation in premature neonates. Semin Perinatol 2008; 32:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/33\">",
"      Cass DL, Brandt ML, Patel DL, et al. Peritoneal drainage as definitive treatment for neonates with isolated intestinal perforation. J Pediatr Surg 2000; 35:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/34\">",
"      Chiu B, Pillai SB, Almond PS, et al. To drain or not to drain: a single institution experience with neonatal intestinal perforation. J Perinat Med 2006; 34:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/35\">",
"      Rao SC, Basani L, Simmer K, et al. Peritoneal drainage versus laparotomy as initial surgical treatment for perforated necrotizing enterocolitis or spontaneous intestinal perforation in preterm low birth weight infants. Cochrane Database Syst Rev 2011; :CD006182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/36\">",
"      Zamir O, Goldberg M, Udassin R, et al. Idiopathic gastrointestinal perforation in the neonate. J Pediatr Surg 1988; 23:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/37\">",
"      Roze E, Ta BD, van der Ree MH, et al. Functional impairments at school age of children with necrotizing enterocolitis or spontaneous intestinal perforation. Pediatr Res 2011; 70:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32247/abstract/38\">",
"      Shah TA, Meinzen-Derr J, Gratton T, et al. Hospital and neurodevelopmental outcomes of extremely low-birth-weight infants with necrotizing enterocolitis and spontaneous intestinal perforation. J Perinatol 2012; 32:552.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5038 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C3286EAA3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_31_32247=[""].join("\n");
var outline_f31_31_32247=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Antenatal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Postnatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Age at presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Physical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Associated infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - PPD technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5038\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5038|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?14/1/14353\" title=\"diagnostic image 1\">",
"      SIP free air supine xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?7/42/7855\" title=\"diagnostic image 2\">",
"      SIP free air cross tab xray",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5038|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/47/32500\" title=\"picture 1\">",
"      Spontaneous intestinal perforation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/54/26464\" title=\"picture 2\">",
"      SIP blue abdomen distension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/39/41591?source=related_link\">",
"      Clinical features and diagnosis of necrotizing enterocolitis in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13814?source=related_link\">",
"      Long-term complications of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/5/35928?source=related_link\">",
"      Management of necrotizing enterocolitis in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/1002?source=related_link\">",
"      Management of patent ductus arteriosus in premature infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/17/3353?source=related_link\">",
"      Postnatal use of glucocorticoids in bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10762?source=related_link\">",
"      Retinopathy of prematurity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_31_32248="Malnutrition in developing countries: Clinical assessment";
var content_f31_31_32248=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Malnutrition in developing countries: Clinical assessment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/31/32248/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/31/32248/contributors\">",
"     Buford L Nichols, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/31/32248/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/31/32248/contributors\">",
"     William J Klish, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/31/32248/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/31/32248/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/31/32248/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/31/32248/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe malnutrition is primarily a problem in developing countries. Severely malnourished children typically are brought to medical attention when a health crisis, such as an infection, precipitates the transition between marasmus (a state of nutritional adaptation) and kwashiorkor, in which adaptation is no longer adequate.",
"   </p>",
"   <p>",
"    The clinical assessment of the child with malnutrition includes distinguishing between marasmus and kwashiorkor, assessing the severity of the malnutrition, and identifying acute life-threatening complications, including sepsis and acute dehydration. These children are at risk for micronutrient deficiencies, as detailed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/4/38983?source=see_link\">",
"     \"Micronutrient deficiencies associated with malnutrition in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of severe malnutrition is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/61/9178?source=see_link\">",
"     \"Severe malnutrition in children in developing countries: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROTEIN-ENERGY MALNUTRITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe malnutrition is uncommon in the United States. Clinical findings in children with chronic undernutrition usually include diminished height, poor weight gain, and deficits in lean body mass and adipose tissue. Other features include reduced physical activity, mental apathy, and retarded psychomotor and mental development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Worldwide, severe protein energy malnutrition is a leading cause of death among children younger than five years of age. Severe protein-energy malnutrition is associated with one of two classical syndromes, marasmus (wasting syndrome) and kwashiorkor, or with manifestations of both. Each type of protein-energy malnutrition may be classified as acute or chronic, depending upon the duration of nutritional deprivation. Children with acute malnutrition appear wasted, whereas children with chronic malnutrition have stunted linear growth. Malnourished children also suffer from numerous associated complications. They are more susceptible to infection, especially sepsis, pneumonia, and gastroenteritis. Vitamin deficiencies and deficiencies of minerals and trace elements can also be seen (",
"    <a class=\"graphic graphic_table graphicRef78426 \" href=\"mobipreview.htm?1/19/1341\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Marasmus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Marasmus is characterized by the wasting of muscle mass and the depletion of body fat stores. It is the most common form of PEM and is caused by inadequate intake of all nutrients, but especially dietary energy sources (total calories). Classically, children with marasmus may have severe constipation and are ravenously hungry once refeeding is in progress. Physical examination findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diminished weight and height for age",
"     </li>",
"     <li>",
"      Emaciated and weak appearance",
"     </li>",
"     <li>",
"      Bradycardia, hypotension, and hypothermia",
"     </li>",
"     <li>",
"      Thin, dry skin",
"     </li>",
"     <li>",
"      Redundant skin folds caused by loss of subcutaneous fat (",
"      <a class=\"graphic graphic_picture graphicRef54165 \" href=\"mobipreview.htm?37/37/38495\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Thin, sparse hair that is easily plucked",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Kwashiorkor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kwashiorkor is characterized by marked muscle atrophy with normal or increased body fat. Pure kwashiorkor is characterized by inadequate protein intake in the presence of fair to good energy intake. Anorexia is almost universal. Physical examination findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normal or nearly normal weight and height for age",
"     </li>",
"     <li>",
"      Anasarca (severe generalized edema)",
"     </li>",
"     <li>",
"      Pitting edema in the lower extremities and periorbitally",
"     </li>",
"     <li>",
"      Rounded prominence of the cheeks (\"moon-face\")",
"     </li>",
"     <li>",
"      Pursed appearance of the mouth",
"     </li>",
"     <li>",
"      Dry, atrophic, peeling skin with confluent areas of hyperkeratosis and hyperpigmentation (",
"      <a class=\"graphic graphic_picture graphicRef77512 \" href=\"mobipreview.htm?40/13/41182\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Dry, dull, hypopigmented hair that falls out or is easily plucked",
"     </li>",
"     <li>",
"      Hepatomegaly (from fatty liver infiltrates)",
"     </li>",
"     <li>",
"      Distended abdomen with dilated intestinal loops",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intermittent periods of adequate protein intake restores hair color, resulting in alternating loss of hair color interspersed between bands of normal pigmentation (flag sign) (",
"    <a class=\"graphic graphic_picture graphicRef75009 \" href=\"mobipreview.htm?7/32/7681\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mixed marasmus-kwashiorkor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mixed marasmus-kwashiorkor (edematous malnutrition) may occur in a child who has inadequate dietary intake of all nutrients and is triggered by a common infectious illness of childhood. Children with mixed marasmus-kwashiorkor often have anorexia, dermatitis, and sometimes neurological abnormalities (depression and flat affect) and hepatic steatosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/3\">",
"     3",
"    </a>",
"    ]. This is caused by the acute loss of nutrients associated with an inflammatory response, superimposed on the chronic wasting of body fat and muscle nutrient stores. The transition from marasmus to mixed marasmus-kwashiorkor is associated with particularly high morbidity and mortality, perhaps because of the frequent association with acute infection or perhaps because children with this clinical course are less well adapted metabolically than children with pure marasmus. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Sepsis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25698054\">",
"    <span class=\"h3\">",
"     Physiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The molecular mechanisms underlying the transition from marasmus to mixed marasmus-kwashiorkor have not been established, but studies have shown that children with edematous malnutrition have slower rates of protein breakdown, a depressed response of acute phase reactants to infection, and lower concentrations of antioxidants including glutathione, as compared with children with marasmus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Although edema is the key clinical sign of this transition, the disorder involves many organ systems:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiovascular system &ndash; In children with marasmus, cardiac output and stroke volume are reduced in proportion to the loss of lean body mass. Children with edematous malnutrition have fragile fluid balance; the infusion of saline may cause an increase in venous pressure and acute heart failure, whereas decrease in blood volume can compromise tissue perfusion.",
"     </li>",
"     <li>",
"      Liver &ndash; Hepatic synthesis of proteins is reduced, and abnormal metabolites of amino acids are produced. Hepatic metabolism and excretion of toxins are severely reduced, and energy production from substrates such as galactose and fructose is much slower than normal. Gluconeogenesis is reduced, which increases the risk of hypoglycemia.",
"     </li>",
"     <li>",
"      Genitourinary system &ndash; Glomerular filtration rate is reduced, and the capacity of the kidney to excrete sodium, excess acid, or a water load is greatly reduced. Urinary tract infection is common.",
"     </li>",
"     <li>",
"      Gastrointestinal tract &ndash; Production of gastric acid is reduced. The pancreas is atrophied and its production of digestive enzymes is reduced. The mucosa of the small intestine is atrophied, and production of digestive enzymes and membrane nutrient transporters is reduced. Intestinal motility is reduced, and luminal bacterial overgrowth is common. Absorption of nutrients is reduced when large amounts of foods are eaten.",
"     </li>",
"     <li>",
"      Immune system &ndash; A variety of immune functions are diminished. Lymph glands, tonsils, and the thymus are atrophied. Cell-mediated (T-cell) immunity, IgA levels in secretions, complement levels, and phagocytosis are all diminished. The acute phase immune response is also reduced, so typical signs of infection, such as leukocytosis and fever, are frequently absent. Septic shock is often associated with hypoglycemia and hypothermia. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Sepsis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Endocrine system &ndash; Insulin levels are reduced, and the child may be glucose intolerant. Growth hormone levels are increased, but levels of its downstream effector, insulin-like growth factor 1 (IGF-1), are reduced. Cortisol levels are usually increased.",
"     </li>",
"     <li>",
"      Metabolism and circulation &ndash; The basal metabolic rate is reduced by about 30 percent, but rises markedly during the recovery period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. Both heat generation and heat loss are impaired; the child becomes hypothermic in a cold environment and hyperthermic in a hot environment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cellular function &ndash; Sodium pump activity is reduced, and cell membranes are more permeable than normal, with an increase in intracellular sodium and a decrease in intracellular potassium and magnesium. Protein synthesis is reduced.",
"     </li>",
"     <li>",
"      Skin and glands &ndash; The skin and subcutaneous fat are atrophied, which causes loose skin folds. Many signs of dehydration are unreliable. As examples, the eyes may appear sunken because of loss of subcutaneous fat in the orbit, and the child may have dryness of mouth and eyes, and reduced sweat production because of atrophied sweat, tear, and salivary glands. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Distinguishing sepsis from dehydration'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF SEVERITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of acute and chronic malnutrition, characterized as ponderal wasting and linear stunting, respectively, can be assessed clinically using various anthropometric measurements (",
"    <a class=\"graphic graphic_table graphicRef60869 \" href=\"mobipreview.htm?12/59/13244\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60395 \" href=\"mobipreview.htm?17/25/17820\">",
"     table 3",
"    </a>",
"    ). The assessment methods are based upon the assumption that during periods of nutritional deprivation, weight deficits occur initially, followed by length or height deficits and, finally, by head circumference deficits. Estimates of the severity and duration of nutritional deprivation provide guidelines for the nutritional rehabilitation of the malnourished child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severity of wasting or stunting is defined by comparing a child's weight and height measurements to those of a population reference standard. New population standards were developed by the Centers for Disease Control (CDC) in 2000, and by the World Health Organization (WHO) in 2006. In most cases, the WHO reference standard will be appropriate, because this describes normal child growth from birth to five years from a variety of populations, under optimal environmental conditions. These charts are available at: (",
"    <a class=\"external\" href=\"file://www.who.int/childgrowth/standards/en/\">",
"     www.who.int/childgrowth/standards/en/",
"    </a>",
"    ). Standards prepared by the CDC also may be used but will result in higher estimates of undernutrition except during the first six months of life, as compared with WHO standards [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/14/31976?source=see_link\">",
"     \"Measurement of growth in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     WHO definitions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) has developed criteria for the classification of moderate or severe malnutrition in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/12\">",
"     12",
"    </a>",
"    ]. These criteria are based upon the degree of wasting, stunting, and the presence of edema (",
"    <a class=\"graphic graphic_table graphicRef60869 \" href=\"mobipreview.htm?12/59/13244\">",
"     table 2",
"    </a>",
"    ). The child's weight for his or her height, and the height for his or her age are expressed as Z-scores. Reference values based on Z-scores are shown on charts available at",
"    <a class=\"external\" href=\"file://www.who.int/childgrowth/standards/en/\">",
"     www.who.int/childgrowth/standards/en/",
"    </a>",
"    . Wasting and stunting are defined by the following (these diagnoses are not mutually exclusive):",
"   </p>",
"   <p>",
"    Wasting (indicates acute malnutrition): &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Moderate wasting &ndash;",
"      <span class=\"nowrap\">",
"       weight/height",
"      </span>",
"      Z-score &lt;-2 to -3 &nbsp;",
"     </li>",
"     <li>",
"      Severe wasting &ndash;",
"      <span class=\"nowrap\">",
"       weight/height",
"      </span>",
"      Z-score &lt;-3",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Stunting (indicates chronic malnutrition):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Moderate stunting &ndash; height or length Z-score &lt;-2 to -3",
"     </li>",
"     <li>",
"      Severe stunting &ndash; height or length Z-score &lt;-3",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Malnutrition:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Moderate malnutrition &ndash; moderate wasting or stunting",
"     </li>",
"     <li>",
"      Severe malnutrition &ndash; severe wasting, severe stunting, OR edematous malnutrition",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Calculators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Z-scores and percentiles may be calculated using the following calculators, which are based on the WHO child growth standards;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants zero to two years:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Boys (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?35/40/36485?source=see_link\">",
"       calculator 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Girls (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?36/1/36885?source=see_link\">",
"       calculator 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children two to five years:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Boys (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?29/32/30213?source=see_link\">",
"       calculator 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Girls (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?29/48/30469?source=see_link\">",
"       calculator 4",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Percent of median method",
"    </span>",
"    &nbsp;&mdash;&nbsp;A child's degree of wasting or stunting also can be classified by calculating his or her",
"    <span class=\"nowrap\">",
"     weight/height",
"    </span>",
"    or height for age as a percentage of the population median, as described by Waterlow and colleagues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. This method may be more practical than Z-scores for clinical use in some settings. It yields somewhat lower estimates of the prevalence of acute severe malnutrition than the WHO Z-score based methods, particularly when the new WHO reference standards are used instead of the older NCHS reference standards [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The severity of wasting is determined as a percentage of the expected weight for height for the population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The expected weight for height is determined by plotting the child's height on the 50th percentile line of the standard growth curve (usually reflecting the size of a younger child) to determine the child's height age and then finding the 50th percentile weight for that age. Severity is assigned as follows (",
"    <a class=\"graphic graphic_table graphicRef60395 \" href=\"mobipreview.htm?17/25/17820\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Less than 90 percent: First-degree (mild) acute malnutrition",
"     </li>",
"     <li>",
"      Less than 80 percent: Second-degree (moderate) acute malnutrition",
"     </li>",
"     <li>",
"      Less than 70 percent: Third-degree (severe) acute malnutrition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The severity of stunting is determined as a percentage of the expected height for age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The measured height is divided by the expected height for age and multiplied by 100. Severity is assigned as follows (",
"    <a class=\"graphic graphic_table graphicRef60395 \" href=\"mobipreview.htm?17/25/17820\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Less than 95 percent: First-degree (mild) chronic malnutrition",
"     </li>",
"     <li>",
"      Less than 90 percent: Second-degree (moderate) chronic malnutrition",
"     </li>",
"     <li>",
"      Less than 85 percent: Third-degree (severe) chronic malnutrition",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the above calculations, the expected height is usually considered to be the 50th percentile height for age for the population. However, if previous serial measurements of the individual child's height are available, then the height for that percentile at the child's age should be used as the expected height, because this provides a more accurate estimate of the child's height potential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Arm/head circumference",
"    </span>",
"    &nbsp;&mdash;&nbsp;McLaren described an alternative approach to estimate the degree of acute malnutrition in children younger than three years of age and for whom accurate measures of weight or height cannot be obtained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/17\">",
"     17",
"    </a>",
"    ]. This method uses the mid-upper arm circumference as a proxy for weight, and head circumference as a proxy for height. Its accuracy requires that no malformation of the head (eg, microcephaly or hydrocephalus) is present. The degree of acute malnutrition is calculated by dividing the mid-upper arm circumference by the fronto-occipital (head) circumference. Severity is assigned according to the ratio as follows (",
"    <a class=\"graphic graphic_table graphicRef60395 \" href=\"mobipreview.htm?17/25/17820\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Less than 0.31: First-degree (mild) acute malnutrition",
"     </li>",
"     <li>",
"      Less than 0.28: Second-degree (moderate) acute malnutrition",
"     </li>",
"     <li>",
"      Less than 0.25: Third-degree (severe) acute malnutrition",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10091096\">",
"    <span class=\"h2\">",
"     Mid upper arm circumference",
"    </span>",
"    &nbsp;&mdash;&nbsp;In settings in which time and equipment are very limited, such as famines and refugee crises, the mid upper-arm circumference (MUAC) is sometimes used to screen for malnutrition. This single measurement can be used to identify children for further evaluation because it is reasonably independent of age and gender between six months and five years of age. Historically, MUAC &lt;12.5 cm were used to detect children with global malnutrition, and MUAC &lt;11 cm was used to detect children with severe wasting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/18\">",
"     18",
"    </a>",
"    ]. However, an analysis comparing MUAC screening to the WHO Z-score criteria suggests that using a MUAC cutoff &lt;11.5 cm substantially improves sensitivity with little loss of specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with the other methods described above, children with edema should be considered malnourished regardless of the MUAC measurement. In addition, MUAC may overestimate the degree of malnutrition in patients with diseases that cause muscle wasting, such as AIDS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/3/3130?source=see_link&amp;anchor=H18840533#H18840533\">",
"     \"Natural history and classification of pediatric HIV infection\", section on 'Wasting syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SEPSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severely malnourished child is at high risk for infection because of diminished immune defenses, and is typically exposed to infection because of inadequate sanitation and food preservation. Dehydration is also common in these children because of acute or persistent diarrhea.",
"   </p>",
"   <p>",
"    The early differentiation between the hypovolemia of dehydration and shock from sepsis of infection is a clinically difficult task even in well-nourished subjects. It is even more important in the fragile child with kwashiorkor or marasmic-kwashiorkor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/12,20\">",
"     12,20",
"    </a>",
"    ]. Signs of hypovolemia are found in both conditions, and can progress rapidly if untreated.",
"   </p>",
"   <p>",
"    Many of the signs that are normally used to assess dehydration are unreliable in a child with severe malnutrition, making it difficult or impossible to detect dehydration reliably or determine its severity. Moreover, many signs of dehydration are also seen in septic shock. As a result, the frequency and severity of dehydration tend to be overestimated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Common features of dehydration and septic shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with severe malnutrition, the following findings can be caused by either dehydration or septic shock:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weak or absent radial pulse &ndash; This is a sign of shock, from either severe dehydration or sepsis. As hypovolemia develops, the pulse rate increases and the pulse becomes weaker. If the pulse in the carotid, femoral or brachial artery is weak, the child is at risk of dying and must be treated urgently [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/12,20\">",
"       12,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cold hands and feet &ndash; This is a sign of both severe dehydration and septic shock. It should be assessed with the back of the hand [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/12,20\">",
"       12,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Urine flow &ndash; Urine flow diminishes as dehydration or septic shock worsens. In severe dehydration or fully developed septic shock, no urine is formed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/12,20\">",
"       12,20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Distinguishing sepsis from dehydration",
"    </span>",
"    &nbsp;&mdash;&nbsp;To optimize safety and care, the clinician should attempt to distinguish between dehydration and septic shock, focusing on the distinguishing clinical features outlined below. Several features from the history and physical examination can help to distinguish between dehydration and septic shock (",
"    <a class=\"graphic graphic_table graphicRef63299 \" href=\"mobipreview.htm?33/41/34460\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    When clear, distinguishing features are not present, it is often necessary to treat the child for both dehydration and septic shock. The World Health Organization recommends antibiotic treatment for children with severe malnutrition, but the choice and course depends on whether there is clinical evidence of infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/61/9178?source=see_link&amp;anchor=H8#H8\">",
"     \"Severe malnutrition in children in developing countries: Treatment\", section on 'Antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Evidence of dehydration",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of diarrhea &ndash; A child with dehydration usually has a history of watery diarrhea. Small mucoid stools are commonly seen in severe malnutrition, but do not cause dehydration. A child with signs of dehydration, but without watery diarrhea, should be treated as having septic shock [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/12,20\">",
"       12,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thirst &ndash; Drinking eagerly is a reliable sign of mild dehydration. In infants this may be expressed as restlessness. Thirst is",
"      <strong>",
"       not",
"      </strong>",
"      a symptom of septic shock [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sunken eyes &ndash; These are a helpful sign of dehydration, but only when the mother says the sunken appearance is recent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Evidence of septic shock",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypothermia &ndash; When present, hypothermia is a sign of serious infection, including septic shock. It is",
"      <strong>",
"       not",
"      </strong>",
"      a sign of dehydration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/12,20\">",
"       12,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Features of incipient septic shock &ndash; The child is usually limp, apathetic, and profoundly anorexic, but is neither thirsty nor restless [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/12,20\">",
"       12,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Features of established septic shock &ndash; The superficial veins, such as the external jugular and scalp veins, are dilated rather than constricted. The veins in the lungs also may become engorged, making the lungs stiffer than normal. For this reason the child may groan, grunt, have a shallow cough, and appear to have difficulty breathing. As shock worsens, kidney, liver, intestinal, or cardiac failure may occur. There may be vomiting of blood mixed with stomach contents (\"coffee-ground vomit\"), blood in the stool, and abdominal distension with \"abdominal splash\"; intestinal fluid may be visible on X-ray. When a child reaches this stage, survival is unlikely [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/12,20\">",
"       12,20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIARRHEA AND DEHYDRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization defines diarrhea as the passage of loose or watery stools three or more times daily. The consistency of the stools is the most important characteristic for distinguishing diarrhea from normal stool patterns; frequent passing of formed stools is not diarrhea.",
"   </p>",
"   <p>",
"    Diarrheal stools are usually watery. Babies fed only breast milk often pass loose, \"pasty\" stools; this also is not diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Starved infants pass frequent green liquid stools of small volume (less than 10 grams). These \"starvation stools\" can be differentiated from diarrhea by inspection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Four types of diarrhea can be recognized, each reflecting the basic underlying pathology and altered physiology, and often associated with malnutrition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/20,23\">",
"     20,23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute watery diarrhea, which lasts several hours or days. The main danger is dehydration; acute malnutrition occurs if feeding is not continued.",
"     </li>",
"     <li>",
"      Acute bloody diarrhea, which is also called dysentery. The main dangers are intestinal damage, sepsis, and acute malnutrition; dehydration may also occur.",
"     </li>",
"     <li>",
"      Persistent diarrhea that lasts 14 days or longer. The main danger is chronic malnutrition and serious non-intestinal infection; dehydration may also occur.",
"     </li>",
"     <li>",
"      Diarrhea with marasmus or kwashiorkor. The main dangers are severe systemic infection, dehydration, heart failure, and vitamin and mineral deficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/12,20\">",
"       12,20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An approach to assessing the cause of diarrhea in a child in developing countries is discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/37/43609?source=see_link&amp;anchor=H9#H9\">",
"     \"Persistent diarrhea in children in developing countries\", section on 'Diagnostic approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Dehydration in the well-nourished child",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with diarrhea who do not meet criteria for malnutrition should be evaluated for dehydration using standard clinical signs and symptoms. Signs of early (mild) dehydration include thirst, decreased skin turgor, dry mucus membranes, sunken eyes, and absence of tears when crying. Signs of severe dehydration include altered consciousness, lack of urine output, feeble pulse, and poor perfusion (",
"    <a class=\"graphic graphic_table graphicRef72642 \" href=\"mobipreview.htm?13/45/14044\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/12,20\">",
"     12,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3607?source=see_link\">",
"     \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Dehydration in the severely malnourished child",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of hydration status in malnourished children is difficult because many of the above signs are unreliable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/12\">",
"     12",
"    </a>",
"    ]. Skin turgor appears poor in children with marasmus, owing to the absence of subcutaneous fat; their eyes may also appear sunken. Diminished skin turgor may be masked by edema in children with kwashiorkor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/12\">",
"     12",
"    </a>",
"    ]. In both types of malnutrition, the child's irritability or apathy makes assessment difficult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is often impossible to distinguish reliably between mild dehydration and severe dehydration-in children with severe malnutrition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/12\">",
"     12",
"    </a>",
"    ]. Signs that remain useful for assessing hydration status include eagerness to drink (a sign of mild dehydration), lethargy, cool and moist extremities, weak or absent radial pulse, and reduced or absent urine flow (signs of severe dehydration) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/12,20\">",
"     12,20",
"    </a>",
"    ]. It can also be difficult to distinguish severe dehydration from septic shock, because both conditions reflect hypovolemia and reduced blood flow to vital organs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/12,20\">",
"     12,20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Distinguishing sepsis from dehydration'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Diarrhea is a serious and often fatal event in children with severe malnutrition. Although treatment and prevention of dehydration are essential, care of these children must also focus on careful management of their malnutrition and treatment of other infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/12,20\">",
"     12,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management of dehydration in a child with malnutrition should take place in hospital. Rehydration and refeeding are discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/61/9178?source=see_link&amp;anchor=H9#H9\">",
"     \"Severe malnutrition in children in developing countries: Treatment\", section on 'Rehydration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OTHER INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to assessing hydration, the child should be evaluated for evidence of infection, by assessing for fever, bloody stool, and respiratory compromise. Fever may be caused by severe dehydration or by a nonintestinal infection, such as malaria or pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with bloody diarrhea are likely to have Shigella or Campylobacter infection, and can be treated empirically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/20\">",
"     20",
"    </a>",
"    ]. Empiric therapy generally should be directed against Shigella, based on the known sensitivities of local strains. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/37/43609?source=see_link&amp;anchor=H17#H17\">",
"     \"Persistent diarrhea in children in developing countries\", section on 'Antimicrobials'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with respiratory distress should be evaluated with a chest x-ray if available, but the radiographic signs of pneumonia may be less prominent in malnourished children than in well nourished children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/12\">",
"     12",
"    </a>",
"    ]. Children with presumed or established pneumonia should be treated with antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/61/9178?source=see_link\">",
"     \"Severe malnutrition in children in developing countries: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/61/9178?source=see_link&amp;anchor=H8#H8\">",
"     \"Severe malnutrition in children in developing countries: Treatment\", section on 'Antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DERMATOSIS OF KWASHIORKOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kwashiorkor can be accompanied by a nonspecific scaly dermatitis, which is often reddish-brown and resembles flaking paint (",
"    <a class=\"graphic graphic_table graphicRef63299 \" href=\"mobipreview.htm?33/41/34460\">",
"     table 4",
"    </a>",
"    ). It often involves the perineum, groin, limbs, ears, and armpits (",
"    <a class=\"graphic graphic_picture graphicRef77512 \" href=\"mobipreview.htm?40/13/41182\">",
"     picture 2",
"    </a>",
"    ). The lesions may be widespread and weep and easily become infected.",
"   </p>",
"   <p>",
"    These lesions should be washed with an antibacterial solution (eg, potassium permanganate) and covered with sterile dressings. Affected infants and children should be treated with systemic antibiotics to prevent infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/61/9178?source=see_link&amp;anchor=H8#H8\">",
"     \"Severe malnutrition in children in developing countries: Treatment\", section on 'Antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SPECIFIC NUTRIENT DEFICIENCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Essential nutrient deficiencies occur in two distinct patterns, according to the body's physiologic response to the deprivation of a nutrient.",
"   </p>",
"   <p>",
"    In cases of isolated deficiencies of certain micronutrients, the child develops clinical and biochemical evidence of the nutrient deficiency, but growth is not disturbed. Deficiencies of these nutrients are characterized by biochemical abnormalities or specific clinical symptoms, without anthropometric changes, a pattern that has been termed \"type I\" nutrient deficiency (",
"    <a class=\"graphic graphic_table graphicRef63827 \" href=\"mobipreview.htm?12/15/12541\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/22\">",
"     22",
"    </a>",
"    ]. This pattern is typical for deficiencies of vitamins A, D, folate, and iron, which are common among malnourished children.",
"   </p>",
"   <p>",
"    The initial evaluation of a malnourished child should assess for the following stigmata of specific micronutrient deficiencies (",
"    <a class=\"graphic graphic_table graphicRef78426 \" href=\"mobipreview.htm?1/19/1341\">",
"     table 1",
"    </a>",
"    ). When present, these require specific treatment in addition to usual nutritional rehabilitation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ocular findings suggestive of vitamin A deficiency &ndash; Corneal cloudiness, ulceration and xerosis (",
"      <a class=\"graphic graphic_picture graphicRef72297 \" href=\"mobipreview.htm?18/45/19156\">",
"       picture 4",
"      </a>",
"      ), and Bitot's spots (",
"      <a class=\"graphic graphic_picture graphicRef72148 \" href=\"mobipreview.htm?3/4/3136\">",
"       picture 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Beading of the ribs (rachitic rosary), widening of the wrists, or bowed legs suggest vitamin D deficiency (",
"      <a class=\"graphic graphic_picture graphicRef54617 \" href=\"mobipreview.htm?43/18/44320\">",
"       picture 6",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26967?source=see_link\">",
"       \"Overview of rickets in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Heart failure, aphonia, peripheral neuropathy, nystagmus, ophthalmoplegia, cerebellar ataxia, confusion, or coma consistent with wet or dry beriberi (thiamine deficiency).",
"     </li>",
"     <li>",
"      Acral dermatitis suggestive of zinc deficiency &ndash; This dermatitis typically occurs in the perioral and perianal areas of the body and is characterized by flaming red, easily denuded skin (",
"      <a class=\"graphic graphic_picture graphicRef59027 \" href=\"mobipreview.htm?4/3/4145\">",
"       picture 7",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Assessment for these nutrients in malnourished children is discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/4/38983?source=see_link\">",
"     \"Micronutrient deficiencies associated with malnutrition in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Deficiencies of other nutrients, including protein, potassium, sodium, phosphorus, sulfur, zinc and magnesium, tend to cause reduced growth rate without specific signs or diagnostic biochemical changes. Affected children frequently have persistent diarrhea and anorexia. Zinc deficiency is also associated with some specific signs and symptoms (eg, acral dermatitis), and appears to increase risk for diarrhea through unclear mechanisms. The deficiency of one of these nutrients often leads to losses of the remaining members of this group as growth is disrupted. The diagnosis of this type of deficiency is made by a growth response to a complete diet that includes sufficient quantities of these nutrients. If only type I supplements are given, no growth occurs, and a false assumption is made that the growth failure is not nutritional [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most cases of malnutrition in developing countries involve deficiencies of multiple micronutrients, protein, and energy; treatment requires restoration of all nutrients rather than targeted supplementation. Treatment protocols designed by the World Health Organization for children with severe malnutrition include supplementation of vitamin A and folate, with later addition of iron during the rehabilitation phase. A variety of other vitamins and minerals, including zinc, are also included in the standard vitamin and mineral supplements used for nutritional rehabilitation. Zinc supplementation is also recommended for infants and children with diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32248/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/61/9178?source=see_link\">",
"     \"Severe malnutrition in children in developing countries: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29753?source=see_link\">",
"     \"Zinc deficiency and supplementation in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Marasmus is characterized by the wasting of muscle mass and the depletion of body fat stores. It is the most common form of protein-energy malnutrition and is caused by inadequate intake of all nutrients, but especially dietary energy sources (total calories). Affected children have stunting as well as wasting. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Marasmus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Kwashiorkor is characterized by marked muscle atrophy with normal or increased body fat. It is caused by inadequate protein intake in the presence of fair to good energy intake. Affected children usually have edema, dermatoses, preserved linear growth, and secondary infections. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Kwashiorkor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute malnutrition typically causes wasting (with reduced",
"      <span class=\"nowrap\">",
"       weight/height),",
"      </span>",
"      while chronic malnutrition causes stunting (with reduced height for age). The severity of the malnutrition can be categorized based on standard deviations from the population mean (Z-scores) (",
"      <a class=\"graphic graphic_table graphicRef60869 \" href=\"mobipreview.htm?12/59/13244\">",
"       table 2",
"      </a>",
"      ), or based on the percentage of the population's median (",
"      <a class=\"graphic graphic_table graphicRef60395 \" href=\"mobipreview.htm?17/25/17820\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Assessment of severity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with malnutrition should be evaluated for sepsis and dehydration. Both sepsis and dehydration cause poor tissue perfusion, with weak pulses, cold hands and feet, and reduced urine flow. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Common features of dehydration and septic shock'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with dehydration tend to be thirsty, have a history of diarrhea, and may have sunken eyes (",
"      <a class=\"graphic graphic_table graphicRef72642 \" href=\"mobipreview.htm?13/45/14044\">",
"       table 5",
"      </a>",
"      ). Specific signs of septic shock include hypothermia and lack of thirst (",
"      <a class=\"graphic graphic_table graphicRef63299 \" href=\"mobipreview.htm?33/41/34460\">",
"       table 4",
"      </a>",
"      ). The features of dehydration and shock often overlap, particularly in advanced stages, so empiric treatment for both disorders is often appropriate. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Evidence of dehydration'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Evidence of septic shock'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In malnourished children, skin turgor is not a reliable measure of hydration status. Skin turgor may give the false appearance of dehydration in children with marasmus because of absent subcutaneous fat, or the false appearance of normal hydration in children with kwashiorkor because of edema. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Dehydration in the severely malnourished child'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Malnourished children usually have deficiencies of specific micronutrients, particularly vitamins A and D, folate, and iron. In addition, they are deficient in one or more nutrients required for growth, including protein, electrolytes, and zinc. These deficiencies are treated empirically during nutritional rehabilitation. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Specific nutrient deficiencies'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/4/38983?source=see_link\">",
"       \"Micronutrient deficiencies associated with malnutrition in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/61/9178?source=see_link\">",
"       \"Severe malnutrition in children in developing countries: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32248/abstract/1\">",
"      Balint JP. Physical findings in nutritional deficiencies. Pediatr Clin North Am 1998; 45:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32248/abstract/2\">",
"      Bergen DC. Effects of poverty on cognitive function: a hidden neurologic epidemic. Neurology 2008; 71:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32248/abstract/3\">",
"      Jahoor F, Badaloo A, Reid M, Forrester T. Protein metabolism in severe childhood malnutrition. Ann Trop Paediatr 2008; 28:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32248/abstract/4\">",
"      White DL, Li D, Nurgalieva Z, El-Serag HB. Genetic variants of glutathione S-transferase as possible risk factors for hepatocellular carcinoma: a HuGE systematic review and meta-analysis. Am J Epidemiol 2008; 167:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32248/abstract/5\">",
"      Reid M, Badaloo A, Forrester T, et al. In vivo rates of erythrocyte glutathione synthesis in children with severe protein-energy malnutrition. Am J Physiol Endocrinol Metab 2000; 278:E405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32248/abstract/6\">",
"      Reid M, Badaloo A, Forrester T, et al. The acute-phase protein response to infection in edematous and nonedematous protein-energy malnutrition. Am J Clin Nutr 2002; 76:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32248/abstract/7\">",
"      Ashworth A. Energy balance and growth: experience in treating children with malnutrition. Kidney Int 1978; 14:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32248/abstract/8\">",
"      Rao KS, Khan L. Basal energy metabolism in protein-calorie malnutrition and vitamin A deficiency. Am J Clin Nutr 1974; 27:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32248/abstract/9\">",
"      Ashworth A. Treatment of severe malnutrition. J Pediatr Gastroenterol Nutr 2001; 32:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32248/abstract/10\">",
"      Li Y, Guo G, Shi A, et al. Prevalence and correlates of malnutrition among children in rural minority areas of China. Pediatr Int 1999; 41:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32248/abstract/11\">",
"      de Onis M, Garza C, Onyango AW, Borghi E. Comparison of the WHO child growth standards and the CDC 2000 growth charts. J Nutr 2007; 137:144.",
"     </a>",
"    </li>",
"    <li>",
"     Management of severe malnutrition: a manual for physicians and other senior health workers, WHO, Geneva 1999. www.who.int/nutrition/publications/malnutrition/en/index.html (Accessed on November 17, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32248/abstract/13\">",
"      Waterlow JC. Classification and definition of protein-calorie malnutrition. Br Med J 1972; 3:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32248/abstract/14\">",
"      Waterlow JC. Note on the assessment and classification of protein-energy malnutrition in children. Lancet 1973; 2:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32248/abstract/15\">",
"      Seal A, Kerac M. Operational implications of using 2006 World Health Organization growth standards in nutrition programmes: secondary data analysis. BMJ 2007; 334:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32248/abstract/16\">",
"      Dale NM, Grais RF, Minetti A, et al. Comparison of the new World Health Organization growth standards and the National Center for Health Statistics growth reference regarding mortality of malnourished children treated in a 2006 nutrition program in Niger. Arch Pediatr Adolesc Med 2009; 163:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32248/abstract/17\">",
"      Kanawati AA, McLaren DS. Assessment of marginal malnutrition. Nature 1970; 228:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32248/abstract/18\">",
"      Myatt M, Khara T, Collins S. A review of methods to detect cases of severely malnourished children in the community for their admission into community-based therapeutic care programs. Food Nutr Bull 2006; 27:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32248/abstract/19\">",
"      Fern&aacute;ndez MA, Delchevalerie P, Van Herp M. Accuracy of MUAC in the detection of severe wasting with the new WHO growth standards. Pediatrics 2010; 126:e195.",
"     </a>",
"    </li>",
"    <li>",
"     The treatment of diarrhea; A manual for physicians and other senior health workers, WHO, Geneva 2005. Available at: file://www.who.int/child_adolescent_health/documents/9241593180/en/index.html (Accessed on November 17, 2009).",
"    </li>",
"    <li>",
"     Nichols BL. Managing dietary carbohydrate intolerance. In: Nutrition During Infancy, Tsang RC, Zlotkin SH, Nichols BL, Hansen JW (Eds), Digital Educational Publications, Cincinnati 1997. p.105.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32248/abstract/22\">",
"      Golden MH. The nature of nutritional deficiency in relation to growth failure and poverty. Acta Paediatr Scand Suppl 1991; 374:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32248/abstract/23\">",
"      Gracey M. Nutritional effects and management of diarrhoea in infancy. Acta Paediatr Suppl 1999; 88:110.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5883 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.96.59.103-93FDCDF71C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_31_32248=[""].join("\n");
var outline_f31_31_32248=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROTEIN-ENERGY MALNUTRITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Marasmus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Kwashiorkor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mixed marasmus-kwashiorkor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25698054\">",
"      - Physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ASSESSMENT OF SEVERITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      WHO definitions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Calculators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Percent of median method",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Arm/head circumference",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10091096\">",
"      Mid upper arm circumference",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SEPSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Common features of dehydration and septic shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Distinguishing sepsis from dehydration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Evidence of dehydration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Evidence of septic shock",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIARRHEA AND DEHYDRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Dehydration in the well-nourished child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Dehydration in the severely malnourished child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OTHER INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DERMATOSIS OF KWASHIORKOR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SPECIFIC NUTRIENT DEFICIENCIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5883\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5883|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/37/38495\" title=\"picture 1\">",
"      Marasmus wasting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/13/41182\" title=\"picture 2\">",
"      Kwashiorkor dermatos",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/32/7681\" title=\"picture 3\">",
"      Flag sign in malnutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/45/19156\" title=\"picture 4\">",
"      Cornea vit A defic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/4/3136\" title=\"picture 5\">",
"      Bitots spot caused by vitamin A deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/18/44320\" title=\"picture 6\">",
"      Rickets bow-legs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/3/4145\" title=\"picture 7\">",
"      Dermatitis zinc defic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5883|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/19/1341\" title=\"table 1\">",
"      Signs of nutritional deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/59/13244\" title=\"table 2\">",
"      WHO classification malnutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/25/17820\" title=\"table 3\">",
"      Percent of median classification of malnutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/41/34460\" title=\"table 4\">",
"      Dehydration vs septic shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/45/14044\" title=\"table 5\">",
"      WHO dehydration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/15/12541\" title=\"table 6\">",
"      Clinical symptoms of selected vitamin deficiencies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?35/40/36485?source=related_link\" title=\"calculator 1\">",
"      Calculator: WHO Assessment of Malnutrition in Boys 0 to 2 Years Old",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?36/1/36885?source=related_link\" title=\"calculator 2\">",
"      Calculator: WHO Assessment of Malnutrition in Girls 0 to 2 Years Old",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?29/32/30213?source=related_link\" title=\"calculator 3\">",
"      Calculator: WHO Assessment of Malnutrition in Boys 2 to 5 years Old",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?29/48/30469?source=related_link\" title=\"calculator 4\">",
"      Calculator: WHO Assessment of Malnutrition in Girls 2 to 5 years Old",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3607?source=related_link\">",
"      Clinical assessment and diagnosis of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/14/31976?source=related_link\">",
"      Measurement of growth in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/4/38983?source=related_link\">",
"      Micronutrient deficiencies associated with malnutrition in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/3/3130?source=related_link\">",
"      Natural history and classification of pediatric HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26967?source=related_link\">",
"      Overview of rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/37/43609?source=related_link\">",
"      Persistent diarrhea in children in developing countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/61/9178?source=related_link\">",
"      Severe malnutrition in children in developing countries: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29753?source=related_link\">",
"      Zinc deficiency and supplementation in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_31_32249="Genetic testing for hereditary breast and ovarian cancer syndrome";
var content_f31_31_32249=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Genetic testing for hereditary breast and ovarian cancer syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/31/32249/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/31/32249/contributors\">",
"     Claudine Isaacs, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/31/32249/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/31/32249/contributors\">",
"     Beth N Peshkin, MS, CGC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/31/32249/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/31/32249/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/31/32249/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/31/32249/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/31/32249/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/31/32249/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a family history of breast",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ovarian cancer is common in women diagnosed with breast or ovarian cancer, less than 10 percent of all breast cancers and less than 15 percent of ovarian cancers are associated with germline (inherited) genetic mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The majority of hereditary breast and ovarian cancers are associated with mutations in two genes: breast cancer type 1 and 2 susceptibility genes (BRCA1 and BRCA2) (",
"    <a class=\"graphic graphic_table graphicRef79724 \" href=\"mobipreview.htm?29/43/30395\">",
"     table 1",
"    </a>",
"    ). Less commonly, breast cancer is due to other hereditary cancer syndromes, such as Li-Fraumeni and Cowden syndromes, which are related to mutations in the TP53 and PTEN genes, respectively (",
"    <a class=\"graphic graphic_table graphicRef66808 \" href=\"mobipreview.htm?11/38/11884\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29530?source=see_link\">",
"     \"PTEN hamartoma tumor syndrome, including Cowden syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/6/12391?source=see_link\">",
"     \"Li-Fraumeni syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    BRCA1 and BRCA2 mutations and genetic testing for these mutations are reviewed here. Other hereditary cancer syndromes associated with increased susceptibility to breast and ovarian cancer, management of patients with hereditary breast and ovarian cancer syndrome, and the genetic counseling process, which is mandatory if genetic testing is to be undertaken, are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44025?source=see_link\">",
"       \"Characteristics of hereditary breast and ovarian cancer syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17418?source=see_link\">",
"       \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/60/5064?source=see_link\">",
"       \"Genetic risk assessment for individuals at risk for hereditary breast and ovarian cancer syndromes\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BRCA1 AND BRCA2 GENES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause for hereditary breast and ovarian cancers is hereditary breast and ovarian cancer (HBOC) syndrome, which is associated with germline mutations in the tumor suppressor genes, breast cancer type 1 and 2 susceptibility genes (BRCA1 and BRCA2). It is estimated that HBOC syndrome accounts for approximately 5 percent of breast cancer cases in the United States annually, about 65 percent of families with four or more cases of breast cancer, and more than 90 percent of families with multiple cases of breast and ovarian cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/2,5,6\">",
"     2,5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Gene function",
"    </span>",
"    &nbsp;&mdash;&nbsp;BRCA1 and BRCA2 are tumor suppressor genes and play a number of roles in the maintenance of genome integrity; they are involved in repair of double-strand DNA breaks, control of cell cycle checkpoint responses, and chromosomal segregation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/5,7\">",
"     5,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The BRCA1 gene is located on chromosome 17q21. BRCA1, through interaction with a number of genes including BARD1, BRCA2, CHK1, and RAD51, is involved in double-strand break repair, cell cycle checkpoint activation, which allows cells time to repair damage before progressing to mitosis, and DNA damage response activation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/5\">",
"     5",
"    </a>",
"    ]. The BRCA2 gene is located on chromosome 13q. BRCA2 binds and regulates the strand invasion recombinase, RAD51, which is required for homologous recombination of double-strand DNA breaks.",
"   </p>",
"   <p>",
"    Germ line mutations in BRCA1 and BRCA2 result in mutation carriers having loss of one of their wild type alleles and thus they have only one rather than two functional alleles of these genes in their cells. This leads to an increase in genomic instability and tumorigenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/6,8-11\">",
"     6,8-11",
"    </a>",
"    ]. Tumors in carriers tend to demonstrate loss of the other wild type allele either through loss of heterozygosity or other somatic mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/5\">",
"     5",
"    </a>",
"    ]. The reason why BRCA1 and BRCA2 mutations predispose mainly to breast and ovarian cancers is unclear. At least some data suggest that intact BRCA1 inhibits ligand-independent transcriptional activation of the estrogen receptor-alpha and that functional inactivation could lead to altered hormonal regulation of mammary and ovarian epithelial proliferation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Over a thousand different mutations in BRCA1 and BRCA2 have been reported. Mutations occur throughout the entire coding region, but most lead to a truncated protein when translated. Despite the strong variability in mutations detected in families, founder effects have led to some mutations being very prevalent in certain populations of defined geographical or ethnic background. (See",
"    <a class=\"local\" href=\"#H106889456\">",
"     'Ethnicity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In BRCA1 but not BRCA2 associated tumors, additional molecular genetic abnormalities that are commonly found include mutations in the tumor protein 53 (TP53) gene, microdeletions, and other chromosomal alterations involving both the TP53 and phosphatase and tensin homolog (PTEN) tumor suppressor genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/15\">",
"     15",
"    </a>",
"    ]. Both BRCA1 and BRCA2 genes are involved in Fanconi anemia, an autosomal recessive disorder characterized by a high cancer incidence, developmental disorders, and a hypersensitivity to DNA cross-linking agents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/13/26842?source=see_link&amp;anchor=H4#H4\">",
"     \"Inherited aplastic anemia in children\", section on 'Fanconi anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data also suggest a potential role of BRCA1 and BRCA2 mutations in sporadic breast and ovarian cancers, in particular triple-negative (ie, breast cancers which lack expression of the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 [HER2]) breast cancers, some of which exhibit hypermethylation of BRCA1",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    BRCA2 or other downstream genes, leading to abnormal gene expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/16-22\">",
"     16-22",
"    </a>",
"    ]. The genomic instability of BRCA1- and BRCA2- deficient cells in hereditary and triple-negative breast cancer provide an opportunity for therapeutic development, especially drugs that target DNA repair pathways. This includes platinum-type drugs that generate double-stranded DNA breaks or poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors, which are involved in the repair of DNA single-strand breaks. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/40/34441?source=see_link&amp;anchor=H624350409#H624350409\">",
"     \"Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer\", section on 'BRCAness'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3892426\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The population frequency of mutations in the BRCA1 and BRCA2 genes is generally estimated to be",
"    <span class=\"nowrap\">",
"     1/800",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     1/1000",
"    </span>",
"    per gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Higher prevalence is found among individuals with a personal history of breast cancer",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a family history of breast and ovarian cancer, especially if associated with young age of onset, multiple tumors, and involvement of male family members affected with breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/9,26-32\">",
"     9,26-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of BRCA1 and BRCA2 mutations also varies among ethnic groups and geographic area. This has been attributed to founder effects, where a gene mutation is observed with high frequency in a population founded by a small ancestral group that was once geographically or culturally isolated, in which one or more of the founders was a carrier of the mutant gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/2\">",
"     2",
"    </a>",
"    ]. As an example, the prevalence of BRCA mutations is high among Ashkenazi Jews, of whom approximately 2 percent carry a deleterious BRCA1 or BRCA2 mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/8,33-36\">",
"     8,33-36",
"    </a>",
"    ]. Certain founder mutations have also been identified in populations from the Netherlands, Sweden, Hungary, Iceland, and French Canada.",
"   </p>",
"   <p>",
"    Individuals with a personal history of breast cancer, especially if younger than 50 years of age",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    with the so-called triple-negative type of breast cancer (ie, estrogen receptor, progesterone receptor, and HER2-negative) or medullary histology, may also have a higher prevalence of BRCA mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5411316\">",
"     'Genetic testing criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cancer risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the BRCA1 and BRCA2 genes are inherited in an autosomal dominant fashion and are highly penetrant; therefore, several generations in affected families may have breast and ovarian cancer. However, the development of cancer in carriers of BRCA1 and BRCA2 genes is variable, as is the age of onset. There is accumulating evidence that gene-gene interactions (eg, the position of the mutation in the BRCA1 or BRCA2 gene and genetic variation in other genes) and gene-environment interactions, including age, hormonal or reproductive factors, and lifestyle factors, account for this variability. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44025?source=see_link&amp;anchor=H15#H15\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\", section on 'Cancer risk modifiers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cancer risks for individuals with BRCA1 and BRCA2 mutations (HBOC syndrome) are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Women with BRCA1 and BRCA2 mutations have markedly elevated risks of breast cancer and ovarian cancer, with a lifetime risk of breast cancer of 50 to 85 percent and a 15 to 40 percent chance of developing ovarian cancer.���&nbsp;There is also an increased risk of a second breast cancer diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44025?source=see_link&amp;anchor=H10#H10\">",
"       \"Characteristics of hereditary breast and ovarian cancer syndromes\", section on 'Breast cancer'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Male BRCA1 and BRCA2 mutation carriers have increased risk of breast cancer and prostate cancer. There is an undefined increased lifetime risk of breast cancer and prostate cancer in men with a BRCA1 gene mutation. In men with a BRCA2 gene mutation, the lifetime risk of breast cancer appears to be less than 10 percent and the lifetime risk of prostate cancer is elevated five to seven fold. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/36/26186?source=see_link&amp;anchor=H7#H7\">",
"       \"Breast cancer in men\", section on 'Inherited conditions'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31562?source=see_link&amp;anchor=H8#H8\">",
"       \"Risk factors for prostate cancer\", section on 'BRCA2 and BRCA1'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Both men and women with HBOC syndrome have increased risks for other cancers. For example, many studies have confirmed an increased risk of pancreatic cancer in BRCA1 and especially BRCA2 carriers. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44025?source=see_link&amp;anchor=H14#H14\">",
"       \"Characteristics of hereditary breast and ovarian cancer syndromes\", section on 'Other cancers'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The management of cancer risk among patients with hereditary breast and ovarian cancer syndrome, including cancer surveillance, risk-reducing surgery, and chemoprevention, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17418?source=see_link\">",
"     \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5411316\">",
"    <span class=\"h1\">",
"     GENETIC TESTING CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic testing is expensive, and selection of individuals most appropriate for genetic testing for mutations in BRCA1 and BRCA2 is important. Individuals suspected of having a hereditary predisposition to breast",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ovarian cancer based upon personal and family history should be referred to a genetic counselor for formal risk assessment. Maternal and paternal history should be considered independently. Characteristics of the history that increase the risk of a hereditary syndrome include the number of affected relatives, the closeness of the relationship between the proband and the affected individual, young age at diagnosis, and multiple primaries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/3,40\">",
"     3,40",
"    </a>",
"    ]. Genetic counseling for hereditary breast and ovarian cancer syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/60/5064?source=see_link\">",
"     \"Genetic risk assessment for individuals at risk for hereditary breast and ovarian cancer syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Genetic testing criteria may differ among different populations and countries based upon mutation prevalence. Some use a numerical probability of finding a mutation based upon predictive models, and others use less specific criteria based upon features of personal and family history. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have a family history of breast cancer have a lifetime risk of breast cancer that is about twofold higher than that of the general population (",
"    <a class=\"graphic graphic_table graphicRef59120 \" href=\"mobipreview.htm?16/23/16764\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/28,41\">",
"     28,41",
"    </a>",
"    ]. A family history of breast cancer, however, is not synonymous with an inherited genetic mutation. Most individuals or families with breast cancer do not have germline mutations predisposing to this disease. Instead, familial cancers may be associated with chance clustering of sporadic cancer cases within families, genetic variation in lower penetrance genes, a shared environment, or a combination of these factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A family history suggestive of hereditary breast and ovarian cancer (HBOC) syndrome is characterized by young age at diagnosis, individuals diagnosed with two breast cancer primaries or breast cancer and ovarian cancer (including fallopian tubal and peritoneal cancer), multiple affected family members with early onset breast or ovarian cancer, and male breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/2,42-46\">",
"     2,42-46",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The presence of BRCA1 or BRCA2 mutations accounts for much of the increased risk of breast cancer among families with a strong history of breast cancer. Less commonly, breast cancer is due to other hereditary cancer syndromes, such as Li-Fraumeni and Cowden syndromes, which are related to mutations in the TP53 and PTEN genes. Families with characteristics suggestive of these syndromes may be appropriate for specific gene mutation testing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44025?source=see_link\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106889456\">",
"    <span class=\"h2\">",
"     Ethnicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several founder effects, which describe the varied prevalence of BRCA1 and BRCA2 mutations among ethnic groups and geographic area, have been observed. The founder effect among Ashkenazi Jews has been well documented, but founder mutations have also been reported worldwide in populations from the Netherlands, Sweden, Hungary, Iceland, Italy, France, South Africa, Pakistan, Asia, French Canada, and among Hispanics and African Americans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3892426\">",
"     'Incidence'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The well-described example of a founder effect is that of the Ashkenazi Jewish population, which is comprised of Jews who have ancestors from Eastern and Central Europe (including Germany, Poland, Lithuania, Ukraine, and Russia). Today, most of the Ashkenazi Jews live in the United States, Israel, South America, South Africa, Australia, and New Zealand. Between 50 and 90 percent of Ashkenazi Jewish families with strong histories of breast and ovarian cancer and 12 percent of Ashkenazi Jewish women with breast cancer harbor one of three founder mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/33,49,50\">",
"     33,49,50",
"    </a>",
"    ]. Among individuals of Ashkenazi Jewish descent, two BRCA1 mutations, 187delAG and 5385insC, and one BRCA2 mutation, 6174delT, occur with a frequency of 2.6 percent, compared with a rate of 0.2 percent in BRCA mutation carriers in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/8,49\">",
"     8,49",
"    </a>",
"    ]. In addition, the 187delAG mutation is strongly associated with the onset of breast cancer in Ashkenazi Jewish women before the age of 40 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For an individual of ethnicity associated with higher mutation frequency, in particular Ashkenazi Jews, a personal or family history of early-onset breast cancer, including male breast cancer or ovarian cancer at any age is sufficient to warrant consideration of BRCA testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1971688\">",
"    <span class=\"h2\">",
"     Patients with limited family structure",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important limitation of genetic risk assessment with models and guideline criteria that are largely dependent on family history is that the probability of a mutation may be underestimated if there are too few female relatives (or too few surviving beyond 45 years of age). One study found that when compared to an adequate family structure (two or more first- or second-degree female relatives over age 45 on both the maternal and paternal side), a limited family structure was strongly associated with the presence of a deleterious mutation (odds ratio 2.8, 95% CI 1.19-6.73) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/51\">",
"     51",
"    </a>",
"    ]. Despite this, none of the risk assessment models (Couch, Myriad, BRCAPRO) evaluated in this study demonstrated significantly different mean pretest mutation probabilities when the families were stratified as having limited or adequate family structure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1971989\">",
"    <span class=\"h2\">",
"     Patients with triple-negative breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a strong association between BRCA mutations and the diagnosis of triple-negative (hormone-receptor and human epidermal growth factor 2 [HER2] receptor negative) breast cancer. Up to 80 percent of BRCA mutation-associated breast cancers are triple-negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/52\">",
"     52",
"    </a>",
"    ]. In addition, among patients with triple-negative breast cancers, the risk of harboring a BRCA mutation ranges from 10 to 39 percent, with mutations in BRCA1 more common than BRCA2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/45,52-55\">",
"     45,52-55",
"    </a>",
"    ]. The association between BRCA mutation status and triple-negative breast cancer was illustrated in a 2012 retrospective study of 199 patients who underwent BRCA mutation analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/53\">",
"     53",
"    </a>",
"    ]. Among these patients, 44 percent had no family history (of breast or ovarian cancer).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall prevalence of BRCA mutation was 11 percent. In patients with a family history of any breast or ovarian cancer, the overall prevalence of a BRCA mutation was 15 percent (16 of 108). In patients without a family history of breast cancer, the prevalence was 5 percent (5 of 88 patients).",
"     </li>",
"     <li>",
"      BRCA1 mutations were more common than BRCA2 mutations (7 and 4 percent, respectively). Compared to BRCA2 mutations, the prevalence of BRCA1 mutations was higher among patients with a positive family history (10 versus 5 percent with a BRCA2 mutation). However, the frequency of BRCA1 and BRCA2 mutations was similar among patients with no family history (2 versus 3 percent).",
"     </li>",
"     <li>",
"      BRCA mutations were commonly identified in women less than 50 years at diagnosis of triple-negative breast cancer compared to older women (15 versus 7 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In light of the association of particularly BRCA1 mutations with triple negative breast cancer, we recommend that women diagnosed before 60 years with a triple-negative breast cancer undergo BRCA mutation testing regardless of family history. This is consistent with guidelines from the National Comprehensive Cancer Network [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/56\">",
"     56",
"    </a>",
"    ]. Further discussion of triple-negative breast cancer is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/40/34441?source=see_link\">",
"     \"Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106889210\">",
"    <span class=\"h2\">",
"     Predictive models",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is no consensus, it has been suggested that at least a 10 percent likelihood of detecting a mutation in BRCA1 or BRCA2 within a family is a reasonable threshold for offering genetic testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/32,40,57\">",
"     32,40,57",
"    </a>",
"    ]. However, limited family history information, small family size, and other mitigating factors also need to be considered in making a clinical judgment about the appropriateness of testing.",
"   </p>",
"   <p>",
"    Several probabilistic models have been developed to estimate breast cancer risk and to calculate pretest probability of finding a BRCA mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/44,45,58-67\">",
"     44,45,58-67",
"    </a>",
"    ]. Of these,",
"    <a class=\"external\" href=\"file://bcb.dfci.harvard.edu/bayesmendel/brcapro.php\">",
"     BRCAPRO",
"    </a>",
"    and the",
"    <a class=\"external\" href=\"https://www.afcri.upenn.edu:8022/itacc/penn2/index.asp\">",
"     Penn II Risk model",
"    </a>",
"    are commonly used within the US, while the",
"    <a class=\"external\" href=\"file://www.ems-trials.org/riskevaluator/\">",
"     IBIS Breast Cancer Risk Evaluation Tool",
"    </a>",
"    is commonly used in Europe as well as some centers in the US.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BRCAPRO is a Bayesian probability model that incorporates estimates of gene penetrance and Mendelian analysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/61,62\">",
"       61,62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Penn II Risk model utilizes logistic regression to analyze breast cancer risk. While it is easy to use, it is not as well validated as BRCAPRO [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/59,68\">",
"       59,68",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      The IBIS Breast Cancer Risk Evaluation tool incorporates the Gail model and other parameters along with detailed family history assessment to inform breast cancer risk. It is used to provide risks in unaffected women only [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each of these models has various strengths and limitations, and each has undergone different degrees of validation. Breast cancer risk prediction and an overview of some risk assessment tools are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/51/2872?source=see_link\">",
"     \"Risk prediction models for breast cancer screening\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Models such as those described above can be cumbersome to use, particularly for clinicians who must decide which patients to refer for genetic testing. Therefore, recommendations are moving away from numerical cutoff values for determining when the risk of hereditary breast cancer is high enough to warrant referral for genetic testing. Guidelines have been developed by several groups, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/2,3,40,69,70\">",
"     2,3,40,69,70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The National Comprehensive Cancer Network (",
"      <a class=\"graphic graphic_table graphicRef56222 \" href=\"mobipreview.htm?21/58/22445\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/2,56\">",
"       2,56",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The United States Preventive Services Task Force (",
"      <a class=\"graphic graphic_table graphicRef57434 \" href=\"mobipreview.htm?27/17/27931\">",
"       table 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The Clinical Cancer Genetics Program at Ohio State University (",
"      <a class=\"graphic graphic_table graphicRef51428 \" href=\"mobipreview.htm?35/53/36700\">",
"       table 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, criteria for BRCA mutation testing include features associated with an increased likelihood of detecting a mutation in BRCA1 and BRCA2. These include family history of breast or ovarian cancer, young age of onset of breast cancer (especially if triple-negative), ovarian cancer, and ethnic group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/3,40\">",
"     3,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8913506\">",
"    <span class=\"h1\">",
"     GENETIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who meet criteria for genetic testing (and those who desire genetic testing), expertise is required to ensure that the test will be adequately interpreted and that the results will aid in diagnosis or influence management of the patient or family members at risk for hereditary cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Tests for BRCA1 and BRCA2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood and buccal DNA tests for BRCA1 and BRCA2 mutations are available commercially. However, the BRCA genes are large and hundreds of different mutations have been identified. As a result, complete analysis of the BRCA1 and BRCA2 genes to exclude both known (ie, relatively common) and novel (or rare) mutations is often desired, and this testing is expensive (around 3000 dollars in the United States). The commercial lab in the United States that offers this testing includes sequencing and testing for five large rearrangements. Additional testing for gene rearrangements is also available and may be most appropriate for the highest-risk women who receive uninformative negative results after the initial phase of testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. However, recent data in patients at high risk and patients with moderate risk family histories indicate that although the identification of large rearrangements from additional testing is overall low, individuals with certain ethnic or racial backgrounds, such as those of African, Latin",
"    <span class=\"nowrap\">",
"     American/Caribbean,",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     Near/Mideast,",
"    </span>",
"    may have a higher chance of testing positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/74\">",
"     74",
"    </a>",
"    ]. It is important to counsel all patients about the testing options, costs, and possible",
"    <span class=\"nowrap\">",
"     advantages/disadvantages",
"    </span>",
"    to additional testing. For those patients who want the most comprehensive",
"    <span class=\"nowrap\">",
"     BRCA1/2",
"    </span>",
"    testing available and especially for those in whom the utility of a positive result will be high, they may wish to pursue additional rearrangement testing. &nbsp;",
"   </p>",
"   <p>",
"    For most Ashkenazi Jewish women, limited testing of the three founder mutations is sufficient, since the vast majority of Ashkenazi Jews have one of these mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/73\">",
"     73",
"    </a>",
"    ]. However, Jewish individuals with mixed ancestry",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    those who are at the highest risk of testing positive (eg, because of male breast cancer or breast plus ovarian cancer in the family) may wish to consider full testing. In addition, once a mutation is identified in a family, targeted analysis for the specific mutation can be performed in relatives and is much less expensive.",
"   </p>",
"   <p>",
"    A list of testing laboratories is available through the Gene Tests website, at",
"    <a class=\"external\" href=\"file://www.genetests.org/\">",
"     www.genetests.org",
"    </a>",
"    . Full sequencing of all exons and adjacent base-pairs in the noncoding introns as well as rearrangement testing is provided in the United States by only one commercial laboratory, Myriad Genetic Laboratories&reg;.",
"   </p>",
"   <p>",
"    The decision to undergo genetic testing for hereditary breast cancer should be made by a patient only after thorough genetic counseling and after signing an informed consent statement. The meaning of positive or negative results should be clearly explained. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/60/5064?source=see_link\">",
"     \"Genetic risk assessment for individuals at risk for hereditary breast and ovarian cancer syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who have a deleterious mutation should be advised of management strategies, including risk-reducing surgery, surveillance, and chemoprevention. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17418?source=see_link\">",
"     \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Insurance reimbursement",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, most insurance companies will cover 90 percent or more of the costs of commercial BRCA testing in appropriate candidates. In some instances, a letter of medical necessity is required to state the potential impact of a positive test result on surveillance or surgical recommendations for an individual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Positive results",
"    </span>",
"    &nbsp;&mdash;&nbsp;A positive result means that a deleterious mutation was identified in BRCA1 or BRCA2. Most mutations are protein truncating, while others may result in an abnormal amount or conformation of the BRCA1 or BRCA2 protein. Some mutations have been reported only once or a few times. A compendium of disease-conferring mutations is available online [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/75\">",
"     75",
"    </a>",
"    ]. Access to this information is free but requires registration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Negative results",
"    </span>",
"    &nbsp;&mdash;&nbsp;A true negative result occurs when an individual tests negative for a mutation that has already been identified in his or her family, usually a close relative.",
"   </p>",
"   <p>",
"    A true negative result in a woman from a family with a known BRCA mutation has significant implications since these individuals can usually be reassured that their cancer risks are much lower than they would be if they had inherited the mutation. Some studies have suggested that the risk of developing breast cancer may still be elevated in these individuals as compared to the general population risk owing to other shared genetic, environmental, or reproductive risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/76-81\">",
"     76-81",
"    </a>",
"    ]. However, because these data are inconsistent, women are generally counseled that their risk is the same as the general population. Such risks may be modified based on other risk factors, such as suggestive family history of the non-carrier parent and traditional reproductive risk factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Uninformative findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most difficult results to interpret are those in which no deleterious mutation is identified in a high-risk individual who is the first to be tested in a family. This is termed an uninformative result. Negative results can arise due to a number of possibilities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/72,82-85\">",
"     72,82-85",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A deleterious mutation could be present in BRCA1 or BRCA2, which cannot detected by available methods",
"     </li>",
"     <li>",
"      Another gene mutation could be present but is rare",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      not yet isolated",
"     </li>",
"     <li>",
"      The individual being tested could have developed sporadic rather than hereditary cancer",
"     </li>",
"     <li>",
"      A BRCA1 or BRCA2 alteration is identified but its significance is unclear (also termed a \"variant of uncertain significance\"). In this instance, it is unclear if the variant is an as yet undefined deleterious mutation, a benign polymorphism, or variant with an intermediate risk of cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with cancer who come from a high-risk family should be offered further testing if they have a negative test result for a BRCA1 or BRCA2 mutation, as a genetic mutation may be present involving another gene. In one study of 300 probands from high-risk families who tested negative for BRCA1 and BRCA2 mutations, 12 percent carried a large genomic deletion or duplication in either BRCA1 or BRCA2 and approximately 5 percent carried a mutation in CHEK2 or TP53 genes, which are associated with other hereditary breast and ovarian cancer syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/72\">",
"     72",
"    </a>",
"    ]. An alternative to stepwise of testing in mutations in other genes is to test using massive parallel sequencing. For example, researchers are assessing the utility of a panel of 21 tumor suppressor genes known to cause inherited ovarian or breast carcinomas, including BRCA1 and BRCA2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. In one series of 360 unselected women with ovarian cancer, 24 percent carried a germ-line mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32249/abstract/86\">",
"     86",
"    </a>",
"    ]. Of these, &gt;30 percent had no family history of breast or ovarian cancer and &gt;35 percent were found in women &ge;60 years. This type of next generation sequencing is clinically available, although the associated cancer risks and clinical utility of all genes on the panel is not known. In addition, information is limited about how well this type of testing is covered by insurance companies. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44025?source=see_link\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/26/27043?source=see_link\">",
"       \"Patient information: Genetic testing for breast and ovarian cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/15/30963?source=see_link\">",
"       \"Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause for hereditary breast and ovarian cancers are hereditary breast and ovarian cancer (HBOC) syndrome, which is associated with germline mutations in the tumor suppressor genes, breast cancer type 1 and 2 susceptibility genes (BRCA1 and 2).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with BRCA1 and BRCA2 mutations have markedly elevated risks of breast cancer and ovarian cancer, with a lifetime risk of breast cancer of 50 to 85 percent and a 15 to 40 percent chance of developing ovarian cancer.��� Male BRCA1 and BRCA2 mutation carriers have increased risk of breast cancer and prostate cancer. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Cancer risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the population frequency of mutations in the BRCA1 and BRCA2 genes is generally estimated to be less than 0.1 percent, much higher prevalence is found among populations with a personal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      family history of breast cancer, especially if associated with young age of onset, multiple tumors, triple-negative (ie, estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative) or medullary histology, involvement of male family members, history of ovarian cancer, and certain ethnic groups. (See",
"      <a class=\"local\" href=\"#H3892426\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both men and women at risk for hereditary predisposition to breast and ovarian cancer should be identified by taking a thorough personal and family history, with a focus on both the maternal and paternal sides of the family, and referred to a genetic counselor for a formal genetic assessment. (See",
"      <a class=\"local\" href=\"#H5411316\">",
"       'Genetic testing criteria'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/60/5064?source=see_link\">",
"       \"Genetic risk assessment for individuals at risk for hereditary breast and ovarian cancer syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Individuals with a strong family or personal history suggestive of HBOC syndrome can be identified for genetic testing based upon an a priori probability of finding a BRCA mutation or consensus guideline criteria outlined above. (See",
"      <a class=\"local\" href=\"#H106889210\">",
"       'Predictive models'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5411316\">",
"       'Genetic testing criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complete sequencing of the BRCA1 and BRCA2 genes is often desired. However, for most Ashkenazi Jewish women, limited testing of the three founder mutations is sufficient, and for individuals from a family with a known BRCA1 or BRCA2 mutation, targeted analysis for the specific mutation is performed. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Tests for BRCA1 and BRCA2'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/1\">",
"      Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med 2008; 359:2143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/2\">",
"      Daly MB, Axilbund JE, Buys S, et al. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw 2010; 8:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/3\">",
"      Narod SA. BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol 2010; 7:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/4\">",
"      Schorge JO, Modesitt SC, Coleman RL, et al. SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol 2010; 119:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/5\">",
"      O'Donovan PJ, Livingston DM. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis 2010; 31:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/6\">",
"      Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/7\">",
"      Huen MS, Sy SM, Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol 2010; 11:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/8\">",
"      Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/9\">",
"      John EM, Miron A, Gong G, et al. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA 2007; 298:2869.",
"     </a>",
"    </li>",
"    <li>",
"     Goldgar, D, Eeles, R, Easton, D, et, al. BRCA1 syndrome. In: World Health organization Classification of Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs, Tavassoli, FA, and Devilee, P (Eds), IARC Press, Lyon 2003. p.338.",
"    </li>",
"    <li>",
"     Eeles, R, Piver, S, Lakhani, SR, et, al. BRCA2 syndrome. In: World Health organization Classification of Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs, Tavassoli, FA, and Devilee, P (Eds), IARC Press, Lyon 2003. p.346.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/12\">",
"      Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002; 108:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/13\">",
"      Zheng L, Annab LA, Afshari CA, et al. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc Natl Acad Sci U S A 2001; 98:9587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/14\">",
"      Hosey AM, Gorski JJ, Murray MM, et al. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst 2007; 99:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/15\">",
"      Saal LH, Gruvberger-Saal SK, Persson C, et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 2008; 40:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/16\">",
"      Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 92:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/17\">",
"      Wilson CA, Ramos L, Villase&ntilde;or MR, et al. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 1999; 21:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/18\">",
"      Bi&egrave;che I, Nogu&egrave;s C, Lidereau R. Overexpression of BRCA2 gene in sporadic breast tumours. Oncogene 1999; 18:5232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/19\">",
"      Chan KY, Oz&ccedil;elik H, Cheung AN, et al. Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Res 2002; 62:4151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/20\">",
"      Hughes-Davies L, Huntsman D, Ruas M, et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 2003; 115:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/21\">",
"      Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007; 26:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/22\">",
"      Potapova A, Hoffman AM, Godwin AK, et al. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. Cancer Res 2008; 68:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/23\">",
"      Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995; 57:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/24\">",
"      Newman B, Austin MA, Lee M, King MC. Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. Proc Natl Acad Sci U S A 1988; 85:3044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/25\">",
"      Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006; 98:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/26\">",
"      Newman B, Mu H, Butler LM, et al. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 1998; 279:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/27\">",
"      Malone KE, Daling JR, Doody DR, et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res 2006; 66:8297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/28\">",
"      Pharoah PD, Day NE, Duffy S, et al. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer 1997; 71:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/29\">",
"      Kerber RA, Slattery ML. The impact of family history on ovarian cancer risk. The Utah Population Database. Arch Intern Med 1995; 155:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/30\">",
"      Claus EB, Schildkraut J, Iversen ES Jr, et al. Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. J Natl Cancer Inst 1998; 90:1824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/31\">",
"      Kaufman DJ, Struewing JP. Re: Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. J Natl Cancer Inst 1999; 91:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/32\">",
"      Balma&ntilde;a J, Diez O, Rubio I, et al. BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2010; 21 Suppl 5:v20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/33\">",
"      Warner E, Foulkes W, Goodwin P, et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 1999; 91:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/34\">",
"      FitzGerald MG, MacDonald DJ, Krainer M, et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 1996; 334:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/35\">",
"      Muto MG, Cramer DW, Tangir J, et al. Frequency of the BRCA1 185delAG mutation among Jewish women with ovarian cancer and matched population controls. Cancer Res 1996; 56:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/36\">",
"      Abeliovich D, Kaduri L, Lerer I, et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 1997; 60:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/37\">",
"      Collins LC, Martyniak A, Kandel MJ, et al. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. Am J Surg Pathol 2009; 33:1093.",
"     </a>",
"    </li>",
"    <li>",
"     Kandel MJ, Stadler Z, Masciari S, et al. Prevalence of BRCA1 mutations in triple negative breast cancer (BC). J Clin Oncol 2006; 24:18S(abstr #508).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/39\">",
"      Iau PT, Marafie M, Ali A, et al. Are medullary breast cancers an indication for BRCA1 mutation screening? A mutation analysis of 42 cases of medullary breast cancer. Breast Cancer Res Treat 2004; 85:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/40\">",
"      Kwon JS, Gutierrez-Barrera AM, Young D, et al. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol 2010; 28:4214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/41\">",
"      Yang Q, Khoury MJ, Rodriguez C, et al. Family history score as a predictor of breast cancer mortality: prospective data from the Cancer Prevention Study II, United States, 1982-1991. Am J Epidemiol 1998; 147:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/42\">",
"      Greene MH. Genetics of breast cancer. Mayo Clin Proc 1997; 72:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/43\">",
"      Shattuck-Eidens D, McClure M, Simard J, et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA 1995; 273:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/44\">",
"      Frank TS, Manley SA, Olopade OI, et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 1998; 16:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/45\">",
"      Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002; 20:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/46\">",
"      Pruthi S, Gostout BS, Lindor NM. Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer. Mayo Clin Proc 2010; 85:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/47\">",
"      Szabo CI, King MC. Population genetics of BRCA1 and BRCA2. Am J Hum Genet 1997; 60:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/48\">",
"      Ferla R, Cal&ograve; V, Cascio S, et al. Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol 2007; 18 Suppl 6:vi93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/49\">",
"      Tonin P, Weber B, Offit K, et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 1996; 2:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/50\">",
"      Schubert EL, Mefford HC, Dann JL, et al. BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and ovarian cancer. Genet Test 1997; 1:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/51\">",
"      Weitzel JN, Lagos VI, Cullinane CA, et al. Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA 2007; 297:2587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/52\">",
"      Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008; 26:4282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/53\">",
"      Hartman AR, Kaldate RR, Sailer LM, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer 2012; 118:2787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/54\">",
"      Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003; 95:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/55\">",
"      Young SR, Pilarski RT, Donenberg T, et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 2009; 9:86.",
"     </a>",
"    </li>",
"    <li>",
"     NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 1.2012. file://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf (Accessed on August 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/57\">",
"      Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol 1996; 14:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/58\">",
"      Shattuck-Eidens D, Oliphant A, McClure M, et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 1997; 278:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/59\">",
"      Couch FJ, DeShano ML, Blackwood MA, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997; 336:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/60\">",
"      Vahteristo P, Eerola H, Tamminen A, et al. A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Br J Cancer 2001; 84:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/61\">",
"      Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998; 62:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/62\">",
"      Berry DA, Iversen ES Jr, Gudbjartsson DF, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 2002; 20:2701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/63\">",
"      Brose MS, Rebbeck TR, Calzone KA, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002; 94:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/64\">",
"      Thompson D, Easton DF, Breast Cancer Linkage Consortium. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 94:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/65\">",
"      Barcenas CH, Hosain GM, Arun B, et al. Assessing BRCA carrier probabilities in extended families. J Clin Oncol 2006; 24:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/66\">",
"      Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004; 23:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/67\">",
"      Antoniou AC, Pharoah PP, Smith P, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 2004; 91:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/68\">",
"      Evans GR, Lalloo F. Development of a scoring system to screen for BRCA1/2 mutations. Methods Mol Biol 2010; 653:237.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines available online at www.nccn.org (Accessed on August 24, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/70\">",
"      Hampel H, Sweet K, Westman JA, et al. Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J Med Genet 2004; 41:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/71\">",
"      Robson ME, Storm CD, Weitzel J, et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 2010; 28:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/72\">",
"      Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006; 295:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/73\">",
"      Palma MD, Domchek SM, Stopfer J, et al. The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. Cancer Res 2008; 68:7006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/74\">",
"      Judkins T, Rosenthal E, Arnell C, et al. Clinical significance of large rearrangements in BRCA1 and BRCA2. Cancer 2012; 118:5210.",
"     </a>",
"    </li>",
"    <li>",
"     The National Human Genome Research Institute: Breast Cancer Information Core Database. file://research.nhgri.nih.gov/bic/ (Accessed on February 16, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/76\">",
"      Dite GS, Jenkins MA, Southey MC, et al. Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations. J Natl Cancer Inst 2003; 95:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/77\">",
"      Smith A, Moran A, Boyd MC, et al. Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening. J Med Genet 2007; 44:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/78\">",
"      Katki HA, Gail MH, Greene MH. Breast-cancer risk in BRCA-mutation-negative women from BRCA-mutation-positive families. Lancet Oncol 2007; 8:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/79\">",
"      Kauff ND, Mitra N, Robson ME, et al. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. J Natl Cancer Inst 2005; 97:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/80\">",
"      Metcalfe KA, Finch A, Poll A, et al. Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation. Br J Cancer 2009; 100:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/81\">",
"      Korde LA, Mueller CM, Loud JT, et al. No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families. Breast Cancer Res Treat 2011; 125:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/82\">",
"      Unger MA, Nathanson KL, Calzone K, et al. Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. Am J Hum Genet 2000; 67:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/83\">",
"      G&oacute;mez-Garc&iacute;a EB, Ambergen T, Blok MJ, van den Wijngaard A. Patients with an unclassified genetic variant in the BRCA1 or BRCA2 genes show different clinical features from those with a mutation. J Clin Oncol 2005; 23:2185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/84\">",
"      Spurdle AB, Lakhani SR, Healey S, et al. Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab Investigators. J Clin Oncol 2008; 26:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/85\">",
"      Spearman AD, Sweet K, Zhou XP, et al. Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance. J Clin Oncol 2008; 26:5393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/86\">",
"      Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A 2011; 108:18032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32249/abstract/87\">",
"      Walsh T, Lee MK, Casadei S, et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A 2010; 107:12629.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 753 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-961E418322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_31_32249=[""].join("\n");
var outline_f31_31_32249=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BRCA1 AND BRCA2 GENES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Gene function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3892426\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cancer risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5411316\">",
"      GENETIC TESTING CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106889456\">",
"      Ethnicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1971688\">",
"      Patients with limited family structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1971989\">",
"      Patients with triple-negative breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106889210\">",
"      Predictive models",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8913506\">",
"      GENETIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Tests for BRCA1 and BRCA2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Insurance reimbursement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Positive results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Negative results",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Uninformative findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/753\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/753|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/43/30395\" title=\"table 1\">",
"      Breast cancer risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/38/11884\" title=\"table 2\">",
"      Breast cancer genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/23/16764\" title=\"table 3\">",
"      Family history breast ca risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/58/22445\" title=\"table 4\">",
"      BRCA testing NCCN criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/17/27931\" title=\"table 5\">",
"      BRCA testing USPSTF guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/53/36700\" title=\"table 6\">",
"      Algorithm genet couns refer BRCA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/36/26186?source=related_link\">",
"      Breast cancer in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/40/34441?source=related_link\">",
"      Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/60/5064?source=related_link\">",
"      Genetic risk assessment for individuals at risk for hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/13/26842?source=related_link\">",
"      Inherited aplastic anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/6/12391?source=related_link\">",
"      Li-Fraumeni syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17418?source=related_link\">",
"      Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29530?source=related_link\">",
"      PTEN hamartoma tumor syndrome, including Cowden syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/15/30963?source=related_link\">",
"      Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/26/27043?source=related_link\">",
"      Patient information: Genetic testing for breast and ovarian cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31562?source=related_link\">",
"      Risk factors for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/51/2872?source=related_link\">",
"      Risk prediction models for breast cancer screening",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_31_32250="Epidemiology, pathobiology, and clinical manifestations of esophageal cancer";
var content_f31_31_32250=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, pathobiology, and clinical manifestations of esophageal cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/31/32250/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/31/32250/contributors\">",
"     Richard E Sampliner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/31/32250/contributors\">",
"     Michael K Gibson, MD, PhD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/31/32250/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/31/32250/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/31/32250/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/31/32250/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/31/32250/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/31/32250/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of esophageal cancers are squamous cell or adenocarcinoma. Although the incidence of squamous cell carcinoma (SCC) is decreasing in the United States, the incidence of adenocarcinoma arising out of Barrett&rsquo;s esophagus is rising dramatically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, etiologic factors, and clinical manifestations of adenocarcinoma and SCC of the esophagus will be reviewed here. Small cell carcinoma and sarcomas arising in the esophagus as well as the diagnosis, staging, and treatment of esophageal cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/31/3578?source=see_link\">",
"     \"Extrapulmonary small cell cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7898?source=see_link\">",
"     \"Diagnosis and staging of esophageal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34938?source=see_link&amp;anchor=H5#H5\">",
"     \"Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract\", section on 'Esophagus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, an estimated 17,990 cases of esophageal cancer will be diagnosed in 2013, and 15,210 deaths are expected from the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/2\">",
"     2",
"    </a>",
"    ]. Worldwide, an estimated 482,300 new esophageal cancer cases and 406,800 deaths occurred in 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Incidence rates vary internationally by nearly 16-fold, with the highest rates found in Southern and Eastern Africa and Eastern Asia, and the lowest rates in Western and Middle Africa and Central America in both males and females (",
"    <a class=\"external\" href=\"file://onlinelibrary.wiley.com/doi/10.3322/caac.20107/full\">",
"     esophageal cancer incidence by world area",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/3\">",
"     3",
"    </a>",
"    ]. In the highest-risk area, stretching from Northern Iran through the central Asian republics to North-Central China (often referred to as the &ldquo;esophageal cancer belt&rdquo;), 90 percent of cases are squamous cell carcinomas (SCC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Major risk factors in these areas are not well understood, but are thought to include poor nutritional status, low intake of fruits and vegetables, and drinking beverages at high temperatures. In contrast, in low-risk areas such as the United States and several Western countries, smoking and excessive alcohol consumption account for about 90 percent of the total cases of esophageal SCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/6\">",
"     6",
"    </a>",
"    ]. Country-specific rates of incidence and mortality are available in the World Health Organization",
"    <a class=\"external\" href=\"file://globocan.iarc.fr/\">",
"     GLOBOCAN database",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Smoking and alcohol'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Temporal trends in incidence vary for the two major histologic types of esophageal cancer. Incidence rates for adenocarcinoma of the esophagus have been increasing in several Western countries, in part due to increases in known risk factors such as overweight and obesity. In contrast, rates for SCC have been steadily decreasing in these same countries because of long-term reductions in tobacco use and alcohol consumption. However, SCC of the esophagus has been increasing in certain Asian countries such as Taiwan, probably as a result of increases in tobacco and alcohol consumption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2100395\">",
"    <span class=\"h1\">",
"     ETIOLOGIC FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hereditary factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial aggregation of esophageal cancer has been described in regions with a high incidence of esophageal SCC, such as China [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Familial aggregation of Barrett's esophagus has also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/10\">",
"     10",
"    </a>",
"    ]. Whether this represents common environmental risk factors or inherited predisposition is unknown. Discordant data regarding familial clustering have been published in reports from other regions including Sweden and the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. Thus, the extent to which hereditary factors are involved in the pathogenesis of esophageal cancer remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Squamous cell carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of esophageal SCC varies considerably among geographic regions. The highest rates are found in Asia (particularly in China and Singapore), Africa, and Iran (the so-called &ldquo;esophageal cancer belt&rdquo;) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/3,15,16\">",
"     3,15,16",
"    </a>",
"    ]. Geographic variation has also been reported within individual countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/17\">",
"     17",
"    </a>",
"    ]. Within China, for example, rates of esophageal cancer range from 1.4 to 140 per 100,000 in the Hebi and Hunyuan counties, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have described risk factors associated with esophageal SCC, which will be described below. Their relative importance (from a public health perspective) was estimated in a study that determined the population attributable risk for several of the major risk factors that have been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/6\">",
"     6",
"    </a>",
"    ]. The authors estimated that a history of smoking, alcohol consumption, and diets low in fruits and vegetables accounted for almost 90 percent of esophageal SCC in the United States. The relative importance of specific risk factors may be substantially different in other parts of the world [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/19\">",
"     19",
"    </a>",
"    ]. &nbsp;As noted above, the major risk factors for SCC in the &ldquo;esophageal cancer belt&rdquo; of Iran and Asia are not well understood, but are thought to include poor nutritional status, low intake of fruits and vegetables, and drinking beverages at high temperatures. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Dietary factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Demographic and socioeconomic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Worldwide differences in the rates of SCC have provided insight into risk factors associated with the disease. The importance of specific risk factors varies within different geographic regions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In high incidence regions, the disease has no gender specificity. In contrast, SCC is more common in men in low incidence regions.",
"     </li>",
"     <li>",
"      The incidence is higher in urban areas (compared to rural areas) of the United States, particularly among African-American men. In one report, the incidence among African-American men in Washington D.C. was 28.6 per 100,000 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/20\">",
"       20",
"      </a>",
"      ]. This compares to an overall incidence of approximately 3 to 4 per 100,000 in other parts of the United States.",
"     </li>",
"     <li>",
"      Lower socioeconomic status was associated with esophageal SCC in a large population-based study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Smoking and alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, Western Europe and some other regions of the world, cigarette smoking and alcohol consumption are major risk factors for esophageal SCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Cigarette smoking is also becoming a major risk factor in Asia, as smoking is gaining in popularity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An increase in risk of esophageal SCC has been associated with cigar and pipe smoking, although the magnitude of risk appears to be less than with cigarettes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Tobacco and alcohol may synergistically increase risk, as they do in SCC of the head and neck. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20583?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology and risk factors for head and neck cancer\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Smoking and alcohol are also risk factors for other aerodigestive cancers, including head and neck and lung. Head and neck cancers are found in approximately 10 to 15 percent of patients diagnosed with esophageal cancer. In addition, patients with one aerodigestive malignancy have an increased risk of synchronous and second primary tumors of the aerodigestive tract. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20583?source=see_link\">",
"     \"Epidemiology and risk factors for head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The type and quantity of alcoholic beverages consumed may affect the risk of esophageal SCC. Hard liquor may have a higher risk than wine or beer; however, the cumulative amount of alcohol rather than the type is probably more important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Individual susceptibility to alcohol may also be involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. In one report, for example, variations in the alcohol dehydrogenase genes were protective against aerodigestive cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Dietary factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several dietary associations with esophageal SCC have been uncovered in Asia. Foods containing N-nitroso compounds have long been implicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. These compounds are carcinogens that may exert their mutagenic potential by inducing alkyl adducts in DNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/35\">",
"     35",
"    </a>",
"    ]. Certain types of pickled vegetables and other food-products consumed in high-risk endemic areas are rich in N-nitroso compounds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Toxin-producing fungi have also been identified in food sources within endemic areas and may, in part, exert their mutagenic potential by reducing nitrates to nitroso compounds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chewing of areca nuts or betel quid (areca nuts wrapped in betel leaves), which is widespread in certain regions of Asia, have been implicated in the development of esophageal SCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. The mechanism may involve the release of copper with resulting induction of collagen synthesis by fibroblasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High temperature beverages and foods may increase the risk of esophageal cancer by causing thermal injury to the esophageal mucosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. In a systematic review of 59 studies, more than 50 percent of the studies found that higher temperatures of fluid intake were associated with a statistically significant increase in the risk of esophageal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/42\">",
"     42",
"    </a>",
"    ]. For coffee and tea, there was little evidence for an association between the amount of use (unrelated to temperature) and esophageal cancer risk. Few studies reported the results for SCC and adenocarcinoma separately.",
"   </p>",
"   <p>",
"    An association with drinking hot tea was noted in a case-control study from northern Iran in which drinking hot tea (60 to 64 degrees C) or very hot tea (&ge;65 degrees C), and drinking tea within three minutes of its being poured was significantly associated with an increased risk of esophageal SCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several other dietary factors affect the risk of esophageal cancer; most of these studies come from regions with a high frequency of SCC. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A positive association between red meat intake and risk of esophageal SCC has been described [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/45,46\">",
"       45,46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Low",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"       selenium",
"      </a>",
"      levels increase risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/47,48\">",
"       47,48",
"      </a>",
"      ], while selenium supplementation has been associated with reduced risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/49-53\">",
"       49-53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Zinc deficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/54\">",
"       54",
"      </a>",
"      ], which may act by enhancing the carcinogenic effects of nitrosamines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/55-57\">",
"       55-57",
"      </a>",
"      ] and by overexpression of cyclooxygenase (COX)-2 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis of epidemiologic studies suggested an association between increased dietary folate and a reduced risk of esophageal cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Underlying esophageal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of specific preexisting esophageal diseases (such as achalasia and caustic strictures) increases the risk of esophageal SCC as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a population-based study including 1062 patients with achalasia, the risk of esophageal SCC was increased more than 16-fold during the first 1 to 24 years following diagnosis; cancer was detected an average of 14 years after the diagnosis of achalasia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/60\">",
"       60",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/26/14759?source=see_link&amp;anchor=H262982107#H262982107\">",
"       \"Clinical manifestations and diagnosis of achalasia\", section on 'Risk of esophageal cancer'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a review of 2414 patients with esophageal SCC, 63 had a history of caustic esophageal injury due to ingestion of lye during childhood; the average time to diagnosis of SCC was 41 years (range 13 to 71 years) following the ingestion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/61\">",
"       61",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/38/40551?source=see_link&amp;anchor=H16#H16\">",
"       \"Caustic esophageal injury in adults\", section on 'Esophageal squamous cell carcinoma'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3449516\">",
"    <span class=\"h3\">",
"     Prior gastrectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have undergone a partial gastrectomy may be at increased risk of esophageal SCC. One series found that 12 of 115 patients with esophageal SCC (10 percent) had undergone a partial gastrectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/62\">",
"     62",
"    </a>",
"    ]. This may represent common risk factors for disorders predisposing to esophageal SCC and the need for partial gastrectomy such as smoking or alcohol. However, another report found that the risk of esophageal SCC and adenocarcinoma was not affected by prior gastric surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5257549\">",
"    <span class=\"h3\">",
"     Atrophic gastritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrophic gastritis and other conditions that cause gastric atrophy are associated with an approximately twofold increased risk of esophageal SCC (but not adenocarcinoma) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/39/24185?source=see_link&amp;anchor=H122606258#H122606258\">",
"     \"Metaplastic (chronic) atrophic gastritis\", section on 'Esophageal squamous cell carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Human papilloma virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain infectious agents have been implicated in the pathogenesis of esophageal SCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/65\">",
"     65",
"    </a>",
"    ]. Human papilloma virus (HPV, particularly serotypes 16 and 18) has received the most scrutiny. Although more than 100 studies have investigated the relationship between HPV and esophageal SCC, evidence of an association is inconclusive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Arguments in support of an association include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The detection of HPV DNA in esophageal SCCs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/67-72\">",
"       67-72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The proximity of the esophagus and oropharynx, and the histologic similarities between esophageal and oral squamous epithelia; HPV associated oropharyngeal SCC is a well-described entity. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/55/887?source=see_link\">",
"       \"Human papillomavirus associated head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Evidence of an association between HPV and bovine esophageal SCC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Arguments against an association include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wide variation (0 to 100 percent) in the prevalence of HPV DNA detected in esophageal SCC tissue among studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inconsistent conclusions among serologic studies of HPV and esophageal SCC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/74-79\">",
"       74-79",
"      </a>",
"      ]. In one of these studies, the strongest evidence of an association was for HPV serotypes (HPV6 and HPV11) that would be expected to have a limited role in squamous carcinogenesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/74\">",
"       74",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/6/21610?source=see_link&amp;anchor=H746850#H746850\">",
"       \"Epidemiology of human papillomavirus infections\", section on 'Disease associations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It seems unlikely that HPV represents an important risk factor for esophageal SCC, although certain subtypes may be involved in a small subset of cancers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Tylosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tylosis is a rare disease associated with hyperkeratosis of the palms of the hands and soles of the feet, and a high rate of esophageal SCC (",
"    <a class=\"graphic graphic_picture graphicRef74683 \" href=\"mobipreview.htm?25/42/26272\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/80\">",
"     80",
"    </a>",
"    ]. The inherited type of tylosis (Howell-Evans syndrome) has been most strongly linked to esophageal SCC. The disease has an autosomal dominant mode of inheritance; a gene locus has been mapped to chromosome 17q25.1, which probably contains a tumor suppressor gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/81\">",
"     81",
"    </a>",
"    ]. Deletions in this gene have also been implicated in sporadic forms of esophageal SCC, occurring in 70 percent of patients with esophageal SCC in one series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/81\">",
"     81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21802?source=see_link\">",
"     \"Cutaneous manifestations of internal malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A guideline issued by the American Society for Gastrointestinal Endoscopy recommends beginning endoscopic surveillance at age 30 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/82\">",
"     82",
"    </a>",
"    ]. The time interval of endoscopic surveillance is not yet established. Generally, endoscopic examination should not be conducted more frequently than every one to three years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of oral bisphosphonates has been linked to esophageal adenocarcinoma and SCC in post-marketing surveillance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/83\">",
"     83",
"    </a>",
"    ]. The finding of crystalline material similar to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    in biopsies of patients with drug-related erosive esophagitis, and the persistence of the abnormalities after healing of the esophagitis suggested the potential for carcinogenicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. As a result of these observations, the FDA recommended that oral bisphosphonates not be used in patients with Barrett's esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the association between oral bisphosphonates and esophageal cancer was called into question by a cohort study using the United Kingdom General Practice Research Database in which 41,826 members who were treated with oral bisphosphonates between 1996 and 2006 were compared to a one-to-one matched control group (same sex, year of birth, and general practice, regardless of bisphosphonate use) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/86\">",
"     86",
"    </a>",
"    ]. At a mean follow-up of over four years, there was no difference in the risk of esophageal or gastric cancer combined, or esophageal cancer alone (adjusted hazard ratio [HR] 1.07, 95% CI 0.77 to 1.49) between the cohorts for any bisphosphonate group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Upper aerodigestive tract cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have described an association between a current or past history of SCC of the head and neck (ie, oral cavity, oropharynx, hypopharynx, or larynx), lung or esophagus with synchronous or metachronous SCC of the esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/82,87-94\">",
"     82,87-94",
"    </a>",
"    ]. This probably reflects similar risk factors such as smoking or alcohol. In prospective studies of men with head and neck cancer, the incidence of synchronous or metachronous esophageal cancer has range from 3 to 14 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/89-92,94,95\">",
"     89-92,94,95",
"    </a>",
"    ]. Metachronous lesions appeared at varying time intervals and there is no clear decrease in risk with time.",
"   </p>",
"   <p>",
"    These observations have led some authorities to recommend periodic screening endoscopy but the benefits of such an approach have not been established. A guideline issued by the American Society of Gastrointestinal Endoscopy recommends that there are insufficient data to support routine endoscopic surveillance for patients with previous aerodigestive SCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/82\">",
"     82",
"    </a>",
"    ]. However, a single endoscopy may be indicated to identify synchronous esophageal cancer.",
"   </p>",
"   <p>",
"    Panendoscopy (with laryngoscopy, bronchoscopy and endoscopy) has also been proposed for surveillance; however, guidelines from the American Head and Neck Society do not specifically recommend routine panendoscopy in this setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/58/36775?source=see_link\">",
"     \"Posttreatment surveillance of squamous carcinoma of the head and neck\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Adenocarcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most of the twentieth century, SCC comprised the vast majority of esophageal cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. In the 1960s, SCC accounted for more than 90 percent of all esophageal tumors in the United States, whereas esophageal adenocarcinomas were considered so uncommon that some authorities questioned their existence. For the past three decades, however, the frequency of adenocarcinoma of the esophagus, esophagogastric junction (EGJ) and gastric cardia has increased dramatically in Western countries so that adenocarcinoma now occurs with greater frequency than SCC (",
"    <a class=\"graphic graphic_picture graphicRef77175 graphicRef77666 \" href=\"mobipreview.htm?22/27/22962\">",
"     picture 2A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef56220 \" href=\"mobipreview.htm?33/10/33957\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/97-102\">",
"     97-102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study of a cancer registry in the United States estimated that the age-adjusted incidence rates of esophageal adenocarcinoma rose progressively from 1.8 per 100,000 in 1987 to 1991 to 2.5 per 100,000 during 1992 to 1996 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/103\">",
"     103",
"    </a>",
"    ]. Whites were affected five times more often than blacks, and men eight times more often than women, although the incidence among white women has also increased (see below). A significant increase in the incidence was observed among persons aged 45 to 65.",
"   </p>",
"   <p>",
"    A later registry study found that between 2000 and 2004 the incidence among white men was 5.69 per 100,000 and among white women it was 0.74 per 100,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/104\">",
"     104",
"    </a>",
"    ]. Compared with the period between 1975 and 1979, this represented an increase of 463 percent among men and 335 percent among women.",
"   </p>",
"   <p>",
"    In contrast, the incidence of gastric cardia adenocarcinoma reached its highest level of 3.3 per 100,000 in 1987 to 1991, subsequently declining to 3.1 per 100,000 in 1992 to 1996. Whites were affected twice as often as blacks, and men five times as often as women. Most patients were older than 60 with no increase among younger cohorts.",
"   </p>",
"   <p>",
"    Estimates of the incidence of these tumors from registries may be limited by problems related to how the tumors were classified. This was illustrated for gastric cardia adenocarcinoma in a study in which its incidence was estimated from a cancer registry in Sweden, and the results were compared to a gold-standard population in which classification was based upon detailed review of patient records [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/105\">",
"     105",
"    </a>",
"    ]. It was estimated that the true gastric cardia incidence could be up to 45 percent higher or 15 percent lower than estimates provided by analysis of the cancer registry. The degree to which this observation accounts for the changing epidemiology of gastric cardia adenocarcinoma requires further clarification. A large database study in the United States concluded that rising incidence of esophageal adenocarcinoma represented a real increase in disease burden and not a reclassification of SCC or adjacent gastric carcinoma or an overdiagnosis of esophageal adenocarcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have described risk factors associated with esophageal adenocarcinoma, which will be described below. Their relative importance (from a public health perspective) was estimated in a study that determined the population attributable risk for several of the major risk factors that have been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/6\">",
"     6",
"    </a>",
"    ]. The authors estimated that a history of smoking, a body mass index higher than the lowest quartile, gastroesophageal reflux disease, and a diet that was low in fruits and vegetables accounted for almost 80 percent of cases of esophageal adenocarcinoma in the United States.",
"   </p>",
"   <p>",
"    At least some data suggest that interactions between risk factors may be more important that individual risk factors. In a study of 305 patients with esophageal adenocarcinoma and 339 age- and sex-matched controls, reflux was the strongest individual risk factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/107\">",
"     107",
"    </a>",
"    ]. However, overall risk was substantially associated with gene-environment interactions (smoking, body mass index, and genetic polymorphisms in five apoptotic genes) that differed in individuals with and without reflux symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Gastroesophageal reflux disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most, if not all, esophageal adenocarcinoma arises from a region of Barrett's metaplasia, which is due to gastroesophageal reflux disease (GERD). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/12/8391?source=see_link\">",
"     \"Pathogenesis of Barrett's esophagus and its malignant transformation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of chronic reflux as an independent risk factor for esophageal adenocarcinoma has not been well defined since more than 50 percent of cases of adenocarcinoma have no history of symptomatic reflux disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/101\">",
"     101",
"    </a>",
"    ]. However, reflux symptoms were associated with adenocarcinoma of the esophagus (odds ratio 7.7) and gastric cardia (odds ratio 2.0) in a large case control study from Sweden [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/108\">",
"     108",
"    </a>",
"    ]. The risk was greatest among patients with long-standing (&gt;20 years) and severe symptoms (odds ratio 43.5 and 4.4 for esophageal and gastric cardia adenocarcinoma, respectively). A meta-analysis concluded that at least weekly symptoms of GERD increased the odds of esophageal adenocarcinoma fivefold, whereas daily symptoms increased the odds sevenfold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/109\">",
"     109",
"    </a>",
"    ]. The increased risk of developing adenocarcinoma of the esophagus and gastric cardia persisted even after antireflux surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/110,111\">",
"     110,111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients who have Barrett&rsquo;s esophagus, the risk of developing esophageal cancer is increased at least 30-fold above that of the general population, but the absolute risk of developing cancer in patients with Barrett's metaplasia is low (estimated annual cancer incidence 0.12 percent in one population-based Danish study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/112\">",
"     112",
"    </a>",
"    ]). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/61/35802?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of Barrett's esophagus\", section on 'Influence of Barrett's esophagus on mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to screening for Barrett&rsquo;s metaplasia in patients with GERD are addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/8/1161?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Barrett's esophagus\", section on 'Screening patients for Barrett's esophagus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking increases the risk of adenocarcinoma, particularly in patients with Barrett's esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    As an example, in a pooled analysis of 10 population-based case-control studies and two cohort studies from the International BEACON (Barrett&rsquo;s Esophagus and Esophageal Adenocarcinoma) Consortium, the risk of adenocarcinoma of the esophagus or EGJ was 2.08 times greater in smokers than in a control group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/113\">",
"     113",
"    </a>",
"    ]. The risk rose with total dose (pack-years of smoking), and it was reduced after smoking cessation, although not to the level of never-smokers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of 20 case-control and four cohort studies including a total of 5500 cases concluded that there was no association between alcohol drinking and esophageal adenocarcinoma risk, even at higher levels of consumption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity has been linked to esophageal adenocarcinoma and adenocarcinoma of the gastric cardia. A meta-analysis of case control and cohort studies identified a relative risk for esophageal or gastric cardia adenocarcinoma of 1.71 (95% CI 1.5-1.96) for BMI between 25 and 30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    and 2.34 (95% CI 1.95-2.81) for BMI &ge;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/116\">",
"     116",
"    </a>",
"    ]. Obesity does not appear to increase the risk of esophageal squamous cell carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Obesity appears to be an indirect risk factor for both esophageal adenocarcinoma and Barrett's esophagus because it increases the risk of GERD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]. Central adiposity (rather than body mass index) appears to be the strongest predictor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/119,120\">",
"     119,120",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13928?source=see_link\">",
"     \"Pathophysiology of reflux esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193366386\">",
"    <span class=\"h3\">",
"     Epidermal growth factor polymorphisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain polymorphisms of the epidermal growth factor gene have been associated with higher serum levels of EGF, an increased risk of esophageal adenocarcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/121\">",
"     121",
"    </a>",
"    ], particularly in patients with Barrett&rsquo;s esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Helicobacter pylori infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observation that Helicobacter pylori (H. pylori) can colonize areas of gastric metaplasia in the esophagus suggested a potential role in the pathogenesis of esophageal adenocarcinoma. However, several studies have demonstrated that H. pylori is not more common and does not have a different distribution in patients with Barrett's esophagus than in controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/122-124\">",
"     122-124",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, H. pylori may be a significant factor for cardia inflammation and intestinal metaplasia, a precursor lesion for cardia adenocarcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/125\">",
"     125",
"    </a>",
"    ]. Cardiac adenocarcinoma may be difficult to distinguish from cancers arising in the distal esophagus, particularly when the disease is advanced. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2634?source=see_link\">",
"     \"Association between Helicobacter pylori infection and gastrointestinal malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The absence of H. pylori may be a risk factor for the development of esophageal adenocarcinoma, although disparate data have also been published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/126-129\">",
"     126-129",
"    </a>",
"    ]. A meta-analysis found a significant inverse relationship between the prevalence of H. pylori infection and esophageal adenocarcinoma (OR 0.52, 95% CI 0.37-0.73) but not SCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/130\">",
"     130",
"    </a>",
"    ]. In a subsequent case control study, this inverse relationship was found to be independent of environmental and genetic modifiers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/131\">",
"     131",
"    </a>",
"    ]. A significant inverse association was also observed for Barrett's esophagus (OR 0.64, 95% CI 0.43-0.94) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/130\">",
"     130",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/46/9959?source=see_link\">",
"     \"Helicobacter pylori and gastroesophageal reflux disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Increased esophageal acid exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acid hypersecretory states (such as Zollinger-Ellison syndrome) or other conditions that are associated with gastroesophageal reflux (such as surgical myotomy or balloon dilation of the lower esophageal sphincter or scleroderma), may be at increased risk for esophageal AC. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14504?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/35/41529?source=see_link\">",
"     \"Gastrointestinal manifestations of systemic sclerosis (scleroderma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Use of drugs that decrease lower esophageal sphincter pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association of chronic reflux with the development of esophageal adenocarcinoma suggests that drugs known to decrease the pressure of the lower esophageal sphincter (and hence predispose to reflux) may be a risk factor for Barrett's esophagus and possibly adenocarcinoma. However, the strength of this association remains uncertain.",
"   </p>",
"   <p>",
"    A case control trial involving 189 patients with newly diagnosed esophageal carcinoma who were compared to 262 patients with adenocarcinoma of the gastric cardia, 167 patients with esophageal SCC, and 820 population-based controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/132\">",
"     132",
"    </a>",
"    ]. Past use of drugs known to relax the LES (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    , anticholinergics, beta adrenergic agonists,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/19/14648?source=see_link\">",
"     aminophylline",
"    </a>",
"    , and benzodiazepines) was positively associated with the risk of esophageal adenocarcinoma (Odds ratio 3.8 (95% CI 2.2 to 6.4) for use &gt;5 years). Assuming a causal relationship, it was estimated that approximately 10 percent of esophageal adenocarcinomas occurring in men older than age 60 may be attributable to intake of these drugs.",
"   </p>",
"   <p>",
"    By contrast, in another case control study, an association was detected only between asthma medications (xanthines and beta agonists and not nitrates, calcium channel blockers or benzodiazepines) and Barrett's esophagus among persons younger than age 70 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/133\">",
"     133",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Cholecystectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A population-based study from Sweden suggested a possible link between cholecystectomy and esophageal adenocarcinoma (standardized incidence ratio 1.3, 95 percent CI 1.0 to 1.8) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/134\">",
"     134",
"    </a>",
"    ]. The authors speculated that the increased risk may be due to the toxic effect of refluxed duodenal juice containing bile on esophageal mucosa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Nitrosative stress",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, exposure to nitroso compounds derived from dietary sources has been associated with carcinogenesis. The mechanisms by which this might occur are not well-understood. A novel mechanism of nitrosative stress from dietary nitrate for the development of adenocarcinoma of the gastroesophageal junction has been proposed based upon preliminary human data and in vitro models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/135-137\">",
"     135-137",
"    </a>",
"    ]. High luminal concentrations of nitric oxide are generated at the gastroesophageal junction and within Barrett's esophagus by the reduction of salivary nitrate to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    by acidic gastric juice. A laboratory model demonstrated nitric oxide production and diffusion into the epithelial compartment where potentially carcinogenic N-nitroso products were generated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/137\">",
"     137",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Possible protective effect of cereal fiber and other nutrients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain components of the diet have been associated with esophageal adenocarcinoma",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A population-based study from Sweden found an inverse relationship between total dietary cereal fiber intake and the risk of gastric cardia adenocarcinoma (odds ratio 0.3 for the highest versus lowest quartile of fiber intake) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/138\">",
"       138",
"      </a>",
"      ]. \"Highest\" was defined as &ge;14.7",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      of cereal fiber from whole-grain bread, crisp bread, oats, muesli, and other cold and hot breakfast cereals, pasta, and rice. High intake of cereal fiber was also associated with a moderately decreased risk of esophageal adenocarcinoma, but not SCC. The authors hypothesized that the protective effects may be due to the ability of wheat fiber to neutralized mutagen formation from the conversion of salivary nitrites to nitrosamines. These data require confirmation before any specific recommendations can be made.",
"     </li>",
"     <li>",
"      Another report found that diets high in fiber,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      , folate, and vitamins C and B6 were protective while diets high in dietary cholesterol, animal protein and vitamin B12 were associated with an increased risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/139\">",
"       139",
"      </a>",
"      ]. A meta-analysis found a protective effect from diets high in folate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dietary antioxidants, fruits, and vegetables were protective against Barrett's esophagus in a case-control study of a US population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/140\">",
"       140",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Possible protective effect of NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic data suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and other NSAIDs, which inhibit cyclooxygenase (COX), might protect against development of esophageal cancer, particularly in the setting of Barrett's esophagus. In a pooled analysis of individual data from five case control and one cohort studies derived from the BEACON (Barrett&rsquo;s and Esophageal Adenocarcinoma) Consortium, compared with nonusers, NSAID users had a significantly reduced risk of esophageal adenocarcinoma (odds ratio [OR] 0.68, 95% CI 0.56-0.83), and there was a trend toward reduced risk of esophagogastric junction (EGJ) adenocarcinoma (OR 0.83, 95% CI 0.66-1.03). The highest levels of frequency (daily or more) and duration of use (&ge;10 years) were associated with an approximately 40 percent reduction in both esophageal (OR 0.56, 95% CI 0.43-0.73) and EGJ adenocarcinoma (OR 0.63, 95% CI 0.45-0.90). A similar protective effect of NSAIDs was observed among individuals with and without symptomatic gastroesophageal reflux. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Despite these data, at least one trial failed to support benefit for COX2 inhibitor as a chemopreventive agent in patients with Barrett&rsquo;s esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/141\">",
"     141",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/61/35802?source=see_link&amp;anchor=H22#H22\">",
"     \"Management of Barrett's esophagus\", section on 'Chemoprevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Risk factor differences from squamous cell carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The difference in the risk factors for adenocarcinoma, principally Barrett's esophagus and chronic reflux, suggests that its pathobiology is different from SCC:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adenocarcinoma is largely a disease of Caucasians and males, the latter outnumbering females by as much as 6 to 1 in incidence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/142\">",
"       142",
"      </a>",
"      ]. One of the largest population-based studies in the United States to examine ethnic differences in the incidence of esophageal and gastric cardia cancer found that the incidence of esophageal adenocarcinoma in Caucasian males was 4.2 per 100,000 per year, double that of Hispanics and fourfold higher than those of blacks and Asians [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/143\">",
"       143",
"      </a>",
"      ]. By contrast, esophageal SCC incidence rates were highest in blacks (8.8 per 100,000 per year), and Asians (3.9 per 100,000 per year). The incidence of gastric cardia adenocarcinoma was also increased in Caucasian males (3.4 per 100,000 per year). However, the ethnic differences were less and the sex ratio was comparable for all ethnicities.",
"     </li>",
"     <li>",
"      Alcohol is probably not an important risk factor for adenocarcinoma, and consumption of wine may even be protective. This was illustrated in a large population-based study that included 554 patients with newly diagnosed esophageal or gastric cardia adenocarcinomas, 589 patients with newly diagnosed esophageal SCC, and 695 control subjects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/21\">",
"       21",
"      </a>",
"      ]. The risk of esophageal adenocarcinoma was unrelated to beer or liquor consumption, and was significantly lessened with wine consumption (odds ratio 0.6).",
"     </li>",
"     <li>",
"      Obesity has been associated with adenocarcinoma but not SCC.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     PATHOBIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Squamous cell carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of SCCs are located in the midportion of the esophagus. SCC arises from small polypoid excrescences, denuded epithelium, or plaques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/144\">",
"     144",
"    </a>",
"    ]. These early lesions are usually subtle, and can easily be missed on endoscopy. In a series from Linxian China (where SCC is endemic), 25 of 31 patients had biopsy specimens containing moderately dysplastic changes or cancer which were obtained from sites classified as having either \"friability, a focal red area, erosion, plaque, or nodule\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/145\">",
"     145",
"    </a>",
"    ]. Furthermore, 15 of 16 patients (94 percent) with moderate dysplasia or carcinoma would have been missed had biopsies been restricted to these visibly abnormal areas.",
"   </p>",
"   <p>",
"    Tissue staining with Lugol iodide solution during endoscopy (chromoendoscopy) may facilitate diagnosis of early lesions, although the technique is uncommonly used in clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/146\">",
"     146",
"    </a>",
"    ]. Lugol solution is a compound iodine solution that stains normal squamous epithelium containing glycogen. Malignant squamous cells do not stain since they are usually devoid of glycogen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15370?source=see_link\">",
"     \"Chromoendoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More advanced lesions are characterized by infiltrating and ulcerated masses, which may be circumferential (",
"    <a class=\"graphic graphic_picture graphicRef82670 \" href=\"mobipreview.htm?40/9/41118\">",
"     picture 4",
"    </a>",
"    ). SCC invades the submucosa at an early stage, and extends along the wall of the esophagus usually in a cephalad direction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/147\">",
"     147",
"    </a>",
"    ]. Local lymph node invasion occurs early and quickly because the lymphatics in the esophagus are located in the lamina propria, in contrast to the rest of the gastrointestinal tract, in which they are located beneath the muscularis mucosa. The tumor spreads to regional lymph nodes along the esophagus, the celiac area, and adjacent to the aorta. Invasion of local structures may result in fistula formation (such as to the trachea). Erosion into the aorta can be associated with massive upper gastrointestinal hemorrhage.",
"   </p>",
"   <p>",
"    Distant metastases to the liver, bone, and lung are seen in nearly 30 percent of patients. In addition, bone marrow invasion can be detected in 40 percent when monoclonal antibodies are used to stain for malignant cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/148\">",
"     148",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Adenocarcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much more is known about the early pathology of adenocarcinoma of the esophagus because of recognition of early cancer during surveillance of patients with Barrett's esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/149\">",
"     149",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/61/35802?source=see_link\">",
"     \"Management of Barrett's esophagus\"",
"    </a>",
"    .) The majority of cases are located near the gastroesophageal junction and are associated with endoscopic evidence of Barrett's esophagus. Adenocarcinoma arising in Barrett's esophagus may present as an ulcer, a nodule, an altered mucosal pattern, or no visible endoscopic abnormality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/150\">",
"     150",
"    </a>",
"    ]. Early adenocarcinoma not associated with Barrett's esophagus arises from an ulcer, plaque, or nodule near the gastroesophageal junction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/151\">",
"     151",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to SCC, lymph node metastases occur early to adjacent or regional lymph nodes. Involvement of celiac and perihepatic nodes is more common with adenocarcinoma because of the location of the tumor at the gastroesophageal junction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/31/32250/abstract/152\">",
"     152",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both adenocarcinoma and SCC have similar clinical presentations except that adenocarcinoma arises much more commonly in the distal",
"    <span class=\"nowrap\">",
"     esophagus/GEJ.",
"    </span>",
"    Among patients with locally advanced esophageal cancer, obstruction of the esophagus by the tumor causes progressive solid food dysphagia often accompanied by weight loss. This usually occurs once the esophageal lumen diameter is less than 13 mm, which indicates advanced disease. Weight loss is due to dysphagia, changes in diet, and tumor-related anorexia.",
"   </p>",
"   <p>",
"    Early symptoms of esophageal cancer are subtle and nonspecific. Transient \"sticking\" of apples, meat, hard-boiled eggs, or bread, which can be easily overcome by the patient with careful chewing, may precede frank dysphagia. Patients may also notice retrosternal discomfort or a burning sensation.",
"   </p>",
"   <p>",
"    Regurgitation of saliva or food uncontaminated by gastric secretions can also occur in patients with advanced disease. Aspiration pneumonia is infrequent. Hoarseness may occur if the recurrent laryngeal nerve is invaded.",
"   </p>",
"   <p>",
"    Chronic gastrointestinal blood loss from esophageal cancer is common and may result in iron deficiency anemia. However, patients seldom notice melena, hematemesis or blood in regurgitated food. Similarly, acute upper gastrointestinal bleeding is rare and is a result of tumor erosion into the aorta or pulmonary or bronchial arteries.",
"   </p>",
"   <p>",
"    Tracheobronchial fistulas are a late complication of esophageal cancer. The fistulas are caused by direct invasion through the esophageal wall and into the main stem bronchus. Such patients often present with intractable coughing or frequent pneumonias. Life expectancy is less than four weeks following the development of this complication.",
"   </p>",
"   <p>",
"    Most early (superficial) esophageal cancers in the United States are detected serendipitously or during screening for or surveillance of Barrett's esophagus. Early intramucosal cancers are not specifically symptomatic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/60/20426?source=see_link\">",
"     \"Management of superficial esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/17/9491?source=see_link\">",
"       \"Patient information: Esophageal cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Familial aggregation of esophageal cancer has been described in regions with a high incidence of esophageal squamous cell carcinoma (SCC), such as China. Familial aggregation of Barrett's esophagus has also been described. Whether this represents common environmental risk factors or inherited predisposition is unknown. Thus, the extent to which hereditary factors are involved in the pathogenesis of esophageal cancer remains uncertain. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Hereditary factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major risk factors for SCC of the esophagus in the United States are smoking and alcohol consumption but other risk factors may be important in specific regions of the world. The major risk factors for SCC in the &ldquo;esophageal cancer belt&rdquo; of Iran and Asia are not well understood, but are thought to include poor nutritional status, low intake of fruits and vegetables, and drinking beverages at high temperatures. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Squamous cell carcinoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major risk factors for adenocarcinoma of the esophagus are Barrett's esophagus, gastroesophageal reflux disease, smoking, and a high body mass index. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Adenocarcinoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with advanced esophageal carcinoma usually present with progressive dysphagia and weight loss. Early intramucosal adenocarcinomas that are recognized at endoscopy in an area of Barrett's esophagus are not specifically symptomatic. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/1\">",
"      Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev 2010; 19:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/2\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/3\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/4\">",
"      Gholipour C, Shalchi RA, Abbasi M. A histopathological study of esophageal cancer on the western side of the Caspian littoral from 1994 to 2003. Dis Esophagus 2008; 21:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/5\">",
"      Tran GD, Sun XD, Abnet CC, et al. Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer 2005; 113:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/6\">",
"      Engel LS, Chow WH, Vaughan TL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003; 95:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/7\">",
"      Lu CL, Lang HC, Luo JC, et al. Increasing trend of the incidence of esophageal squamous cell carcinoma, but not adenocarcinoma, in Taiwan. Cancer Causes Control 2010; 21:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/8\">",
"      Chang-Claude J, Becher H, Blettner M, et al. Familial aggregation of oesophageal cancer in a high incidence area in China. Int J Epidemiol 1997; 26:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/9\">",
"      Li JY, Ershow AG, Chen ZJ, et al. A case-control study of cancer of the esophagus and gastric cardia in Linxian. Int J Cancer 1989; 43:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/10\">",
"      Chak A, Lee T, Kinnard MF, et al. Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut 2002; 51:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/11\">",
"      Hemminki K, Jiang Y. Familial and second esophageal cancers: a nation-wide epidemiologic study from Sweden. Int J Cancer 2002; 98:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/12\">",
"      Lagergren J, Ye W, Lindgren A, Nyr&eacute;n O. Heredity and risk of cancer of the esophagus and gastric cardia. Cancer Epidemiol Biomarkers Prev 2000; 9:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/13\">",
"      Dhillon PK, Farrow DC, Vaughan TL, et al. Family history of cancer and risk of esophageal and gastric cancers in the United States. Int J Cancer 2001; 93:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/14\">",
"      Ji J, Hemminki K. Familial risk for esophageal cancer: an updated epidemiologic study from Sweden. Clin Gastroenterol Hepatol 2006; 4:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/15\">",
"      Parkin DM, L&auml;&auml;r&auml; E, Muir CS. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 1988; 41:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/16\">",
"      Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Lancet 2002; 360:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/17\">",
"      Marjani HA, Biramijamal F, Hossein-Nezhad A, et al. Prevalence of esophageal cancer risk factors among Turkmen and non-Turkmen ethnic groups in a high incidence area in Iran. Arch Iran Med 2010; 13:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/18\">",
"      Yang CS. Research on esophageal cancer in China: a review. Cancer Res 1980; 40:2633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/19\">",
"      He Z, Zhao Y, Guo C, et al. Prevalence and risk factors for esophageal squamous cell cancer and precursor lesions in Anyang, China: a population-based endoscopic survey. Br J Cancer 2010; 103:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/20\">",
"      Pottern LM, Morris LE, Blot WJ, et al. Esophageal cancer among black men in Washington, D.C. I. Alcohol, tobacco, and other risk factors. J Natl Cancer Inst 1981; 67:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/21\">",
"      Gammon MD, Schoenberg JB, Ahsan H, et al. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1997; 89:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/22\">",
"      Thun MJ, Peto R, Lopez AD, et al. Alcohol consumption and mortality among middle-aged and elderly U.S. adults. N Engl J Med 1997; 337:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/23\">",
"      Pandeya N, Williams G, Green AC, et al. Alcohol consumption and the risks of adenocarcinoma and squamous cell carcinoma of the esophagus. Gastroenterology 2009; 136:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/24\">",
"      Islami F, Fedirko V, Tramacere I, et al. Alcohol drinking and esophageal squamous cell carcinoma with focus on light-drinkers and never-smokers: a systematic review and meta-analysis. Int J Cancer 2011; 129:2473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/25\">",
"      Chen ZM, Xu Z, Collins R, et al. Early health effects of the emerging tobacco epidemic in China. A 16-year prospective study. JAMA 1997; 278:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/26\">",
"      Iribarren C, Tekawa IS, Sidney S, Friedman GD. Effect of cigar smoking on the risk of cardiovascular disease, chronic obstructive pulmonary disease, and cancer in men. N Engl J Med 1999; 340:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/27\">",
"      Randi G, Scotti L, Bosetti C, et al. Pipe smoking and cancers of the upper digestive tract. Int J Cancer 2007; 121:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/28\">",
"      Tuyns AJ, P&eacute;quignot G, Abbatucci JS. Oesophageal cancer and alcohol consumption; importance of type of beverage. Int J Cancer 1979; 23:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/29\">",
"      Brown LM, Hoover R, Gridley G, et al. Drinking practices and risk of squamous-cell esophageal cancer among Black and White men in the United States. Cancer Causes Control 1997; 8:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/30\">",
"      Hori H, Kawano T, Endo M, Yuasa Y. Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and human esophageal squamous cell carcinoma susceptibility. J Clin Gastroenterol 1997; 25:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/31\">",
"      Hashibe M, McKay JD, Curado MP, et al. Multiple ADH genes are associated with upper aerodigestive cancers. Nat Genet 2008; 40:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/32\">",
"      Druesne-Pecollo N, Tehard B, Mallet Y, et al. Alcohol and genetic polymorphisms: effect on risk of alcohol-related cancer. Lancet Oncol 2009; 10:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/33\">",
"      Lu SH, Montesano R, Zhang MS, et al. Relevance of N-nitrosamines to esophageal cancer in China. J Cell Physiol Suppl 1986; 4:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/34\">",
"      Islami F, Ren JS, Taylor PR, Kamangar F. Pickled vegetables and the risk of oesophageal cancer: a meta-analysis. Br J Cancer 2009; 101:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/35\">",
"      Wang L, Zhu D, Zhang C, et al. Mutations of O6-methylguanine-DNA methyltransferase gene in esophageal cancer tissues from Northern China. Int J Cancer 1997; 71:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/36\">",
"      Cheng SJ, Sala M, Li MH, Chouroulinkov I. Esophageal cancer in Linxian county, China: a possible etiology and mechanism (initiation and promotion). Carcinog Compr Surv 1982; 7:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/37\">",
"      Siddiqi M, Tricker AR, Preussmann R. The occurrence of preformed N-nitroso compounds in food samples from a high risk area of esophageal cancer in Kashmir, India. Cancer Lett 1988; 39:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/38\">",
"      Chu FS, Li GY. Simultaneous occurrence of fumonisin B1 and other mycotoxins in moldy corn collected from the People's Republic of China in regions with high incidences of esophageal cancer. Appl Environ Microbiol 1994; 60:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/39\">",
"      Pickwell SM, Schimelpfening S, Palinkas LA. 'Betelmania'. Betel quid chewing by Cambodian women in the United States and its potential health effects. West J Med 1994; 160:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/40\">",
"      Akhtar S, Sheikh AA, Qureshi HU. Chewing areca nut, betel quid, oral snuff, cigarette smoking and the risk of oesophageal squamous-cell carcinoma in South Asians: a multicentre case-control study. Eur J Cancer 2012; 48:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/41\">",
"      Trivedy C, Baldwin D, Warnakulasuriya S, et al. Copper content in Areca catechu (betel nut) products and oral submucous fibrosis. Lancet 1997; 349:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/42\">",
"      Islami F, Boffetta P, Ren JS, et al. High-temperature beverages and foods and esophageal cancer risk--a systematic review. Int J Cancer 2009; 125:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/43\">",
"      Islami F, Pourshams A, Nasrollahzadeh D, et al. Tea drinking habits and oesophageal cancer in a high risk area in northern Iran: population based case-control study. BMJ 2009; 338:b929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/44\">",
"      Wu M, Liu AM, Kampman E, et al. Green tea drinking, high tea temperature and esophageal cancer in high- and low-risk areas of Jiangsu Province, China: a population-based case-control study. Int J Cancer 2009; 124:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/45\">",
"      Cross AJ, Freedman ND, Ren J, et al. Meat consumption and risk of esophageal and gastric cancer in a large prospective study. Am J Gastroenterol 2011; 106:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/46\">",
"      Keszei AP, Schouten LJ, Goldbohm RA, van den Brandt PA. Red and processed meat consumption and the risk of esophageal and gastric cancer subtypes in The Netherlands Cohort Study. Ann Oncol 2012; 23:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/47\">",
"      Mark SD, Qiao YL, Dawsey SM, et al. Prospective study of serum selenium levels and incident esophageal and gastric cancers. J Natl Cancer Inst 2000; 92:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/48\">",
"      Steevens J, van den Brandt PA, Goldbohm RA, Schouten LJ. Selenium status and the risk of esophageal and gastric cancer subtypes: the Netherlands cohort study. Gastroenterology 2010; 138:1704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/49\">",
"      Li B, Taylor PR, Li JY, et al. Linxian nutrition intervention trials. Design, methods, participant characteristics, and compliance. Ann Epidemiol 1993; 3:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/50\">",
"      Blot WJ, Li JY, Taylor PR, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993; 85:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/51\">",
"      Blot WJ, Li JY. Some considerations in the design of a nutrition intervention trial in Linxian, People's Republic of China. Natl Cancer Inst Monogr 1985; 69:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/52\">",
"      Mark SD, Liu SF, Li JY, et al. The effect of vitamin and mineral supplementation on esophageal cytology: results from the Linxian Dysplasia Trial. Int J Cancer 1994; 57:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/53\">",
"      Limburg PJ, Wei W, Ahnen DJ, et al. Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. Gastroenterology 2005; 129:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/54\">",
"      Abnet CC, Lai B, Qiao YL, et al. Zinc concentration in esophageal biopsy specimens measured by x-ray fluorescence and esophageal cancer risk. J Natl Cancer Inst 2005; 97:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/55\">",
"      Fong LY, Sivak A, Newberne PM. Zinc deficiency and methylbenzylnitrosamine-induced esophageal cancer in rats. J Natl Cancer Inst 1978; 61:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/56\">",
"      Fong LY, Magee PN. Dietary zinc deficiency enhances esophageal cell proliferation and N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumor incidence in C57BL/6 mouse. Cancer Lett 1999; 143:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/57\">",
"      Fong LY, Nguyen VT, Farber JL. Esophageal cancer prevention in zinc-deficient rats: rapid induction of apoptosis by replenishing zinc. J Natl Cancer Inst 2001; 93:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/58\">",
"      Fong LY, Zhang L, Jiang Y, Farber JL. Dietary zinc modulation of COX-2 expression and lingual and esophageal carcinogenesis in rats. J Natl Cancer Inst 2005; 97:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/59\">",
"      Larsson SC, Giovannucci E, Wolk A. Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis. Gastroenterology 2006; 131:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/60\">",
"      Sandler RS, Nyr&eacute;n O, Ekbom A, et al. The risk of esophageal cancer in patients with achalasia. A population-based study. JAMA 1995; 274:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/61\">",
"      Appelqvist P, Salmo M. Lye corrosion carcinoma of the esophagus: a review of 63 cases. Cancer 1980; 45:2655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/62\">",
"      Tachibana M, Abe S, Yoshimura H, et al. Squamous cell carcinoma of the esophagus after partial gastrectomy. Dysphagia 1995; 10:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/63\">",
"      Birgisson S, Rice TW, Easley KA, Richter JE. The lack of association between adenocarcinoma of the esophagus and gastric surgery: a retrospective study. Am J Gastroenterol 1997; 92:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/64\">",
"      Islami F, Sheikhattari P, Ren JS, Kamangar F. Gastric atrophy and risk of oesophageal cancer and gastric cardia adenocarcinoma--a systematic review and meta-analysis. Ann Oncol 2011; 22:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/65\">",
"      Chang F, Syrj&auml;nen S, Wang L, Syrj&auml;nen K. Infectious agents in the etiology of esophageal cancer. Gastroenterology 1992; 103:1336.",
"     </a>",
"    </li>",
"    <li>",
"     IARC Monorgraphs Working Group. IARC Monographs on the Evaluation of Carcinogenic Risks to Hymans: International Agency for Research on Cancer. Volume 100 Part B: Biological Agents. Lyon, France: IARC; 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/67\">",
"      Lam KY, He D, Ma L, et al. Presence of human papillomavirus in esophageal squamous cell carcinomas of Hong Kong Chinese and its relationship with p53 gene mutation. Hum Pathol 1997; 28:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/68\">",
"      Chang F, Syrj&auml;nen S, Shen Q, et al. Human papillomavirus involvement in esophageal carcinogenesis in the high-incidence area of China. A study of 700 cases by screening and type-specific in situ hybridization. Scand J Gastroenterol 2000; 35:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/69\">",
"      Far AE, Aghakhani A, Hamkar R, et al. Frequency of human papillomavirus infection in oesophageal squamous cell carcinoma in Iranian patients. Scand J Infect Dis 2007; 39:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/70\">",
"      Shuyama K, Castillo A, Aguayo F, et al. Human papillomavirus in high- and low-risk areas of oesophageal squamous cell carcinoma in China. Br J Cancer 2007; 96:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/71\">",
"      Castillo A, Aguayo F, Koriyama C, et al. Human papillomavirus in esophageal squamous cell carcinoma in Colombia and Chile. World J Gastroenterol 2006; 12:6188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/72\">",
"      Syrj&auml;nen KJ. HPV infections and oesophageal cancer. J Clin Pathol 2002; 55:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/73\">",
"      Campo MS. Papillomas and cancer in cattle. Cancer Surv 1987; 6:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/74\">",
"      Sitas F, Egger S, Urban MI, et al. InterSCOPE study: Associations between esophageal squamous cell carcinoma and human papillomavirus serological markers. J Natl Cancer Inst 2012; 104:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/75\">",
"      Dillner J, Knekt P, Schiller JT, Hakulinen T. Prospective seroepidemiological evidence that human papillomavirus type 16 infection is a risk factor for oesophageal squamous cell carcinoma. BMJ 1995; 311:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/76\">",
"      Bj&oslash;rge T, Hakulinen T, Engeland A, et al. A prospective, seroepidemiological study of the role of human papillomavirus in esophageal cancer in Norway. Cancer Res 1997; 57:3989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/77\">",
"      Lagergren J, Wang Z, Bergstr&ouml;m R, et al. Human papillomavirus infection and esophageal cancer: a nationwide seroepidemiologic case-control study in Sweden. J Natl Cancer Inst 1999; 91:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/78\">",
"      Han C, Qiao G, Hubbert NL, et al. Serologic association between human papillomavirus type 16 infection and esophageal cancer in Shaanxi Province, China. J Natl Cancer Inst 1996; 88:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/79\">",
"      Sitas F, Urban M, Stein L, et al. The relationship between anti-HPV-16 IgG seropositivity and cancer of the cervix, anogenital organs, oral cavity and pharynx, oesophagus and prostate in a black South African population. Infect Agent Cancer 2007; 2:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/80\">",
"      Stevens HP, Kelsell DP, Bryant SP, et al. Linkage of an American pedigree with palmoplantar keratoderma and malignancy (palmoplantar ectodermal dysplasia type III) to 17q24. Literature survey and proposed updated classification of the keratodermas. Arch Dermatol 1996; 132:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/81\">",
"      Iwaya T, Maesawa C, Ogasawara S, Tamura G. Tylosis esophageal cancer locus on chromosome 17q25.1 is commonly deleted in sporadic human esophageal cancer. Gastroenterology 1998; 114:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/82\">",
"      Hirota WK, Zuckerman MJ, Adler DG, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc 2006; 63:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/83\">",
"      Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009; 360:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/84\">",
"      Ribeiro A, DeVault KR, Wolfe JT 3rd, Stark ME. Alendronate-associated esophagitis: endoscopic and pathologic features. Gastrointest Endosc 1998; 47:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/85\">",
"      Abraham SC, Cruz-Correa M, Lee LA, et al. Alendronate-associated esophageal injury: pathologic and endoscopic features. Mod Pathol 1999; 12:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/86\">",
"      Cardwell CR, Abnet CC, Cantwell MM, Murray LJ. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010; 304:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/87\">",
"      Ribeiro U Jr, Posner MC, Safatle-Ribeiro AV, Reynolds JC. Risk factors for squamous cell carcinoma of the oesophagus. Br J Surg 1996; 83:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/88\">",
"      Cooper JS, Pajak TF, Rubin P, et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys 1989; 17:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/89\">",
"      Erkal HS, Mendenhall WM, Amdur RJ, et al. Synchronous and metachronous squamous cell carcinomas of the head and neck mucosal sites. J Clin Oncol 2001; 19:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/90\">",
"      Shiozaki H, Tahara H, Kobayashi K, et al. Endoscopic screening of early esophageal cancer with the Lugol dye method in patients with head and neck cancers. Cancer 1990; 66:2068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/91\">",
"      Tincani AJ, Brandalise N, Altemani A, et al. Diagnosis of superficial esophageal cancer and dysplasia using endoscopic screening with a 2% lugol dye solution in patients with head and neck cancer. Head Neck 2000; 22:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/92\">",
"      Petit T, Georges C, Jung GM, et al. Systematic esophageal endoscopy screening in patients previously treated for head and neck squamous-cell carcinoma. Ann Oncol 2001; 12:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/93\">",
"      Muto M, Hironaka S, Nakane M, et al. Association of multiple Lugol-voiding lesions with synchronous and metachronous esophageal squamous cell carcinoma in patients with head and neck cancer. Gastrointest Endosc 2002; 56:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/94\">",
"      Atabek U, Mohit-Tabatabai MA, Rush BF, et al. Impact of esophageal screening in patients with head and neck cancer. Am Surg 1990; 56:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/95\">",
"      Ina H, Shibuya H, Ohashi I, Kitagawa M. The frequency of a concomitant early esophageal cancer in male patients with oral and oropharyngeal cancer. Screening results using Lugol dye endoscopy. Cancer 1994; 73:2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/96\">",
"      Spechler SJ. Barrett's esophagus. Semin Oncol 1994; 21:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/97\">",
"      Bollschweiler E, Wolfgarten E, Gutschow C, H&ouml;lscher AH. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001; 92:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/98\">",
"      Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/99\">",
"      Blot WJ. Esophageal cancer trends and risk factors. Semin Oncol 1994; 21:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/100\">",
"      Daly JM, Karnell LH, Menck HR. National Cancer Data Base report on esophageal carcinoma. Cancer 1996; 78:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/101\">",
"      Bytzer P, Christensen PB, Damkier P, et al. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study. Am J Gastroenterol 1999; 94:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/102\">",
"      Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am 2002; 11:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/103\">",
"      El-Serag HB, Mason AC, Petersen N, Key CR. Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut 2002; 50:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/104\">",
"      Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 2008; 100:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/105\">",
"      Ekstr&ouml;m AM, Signorello LB, Hansson LE, et al. Evaluating gastric cancer misclassification: a potential explanation for the rise in cardia cancer incidence. J Natl Cancer Inst 1999; 91:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/106\">",
"      Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/107\">",
"      Zhai R, Chen F, Liu G, et al. Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma. J Clin Oncol 2010; 28:2445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/108\">",
"      Lagergren J, Bergstr&ouml;m R, Lindgren A, Nyr&eacute;n O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/109\">",
"      Rubenstein JH, Taylor JB. Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther 2010; 32:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/110\">",
"      Ye W, Chow WH, Lagergren J, et al. Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology 2001; 121:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/111\">",
"      Lagergren J, Ye W, Lagergren P, Lu Y. The risk of esophageal adenocarcinoma after antireflux surgery. Gastroenterology 2010; 138:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/112\">",
"      Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011; 365:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/113\">",
"      Cook MB, Kamangar F, Whiteman DC, et al. Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst 2010; 102:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/114\">",
"      Tramacere I, La Vecchia C, Negri E. Tobacco smoking and esophageal and gastric cardia adenocarcinoma: a meta-analysis. Epidemiology 2011; 22:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/115\">",
"      Tramacere I, Pelucchi C, Bagnardi V, et al. A meta-analysis on alcohol drinking and esophageal and gastric cardia adenocarcinoma risk. Ann Oncol 2012; 23:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/116\">",
"      Turati F, Tramacere I, La Vecchia C, Negri E. A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma. Ann Oncol 2013; 24:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/117\">",
"      Lagergren J, Bergstr&ouml;m R, Nyr&eacute;n O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999; 130:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/118\">",
"      Cook MB, Greenwood DC, Hardie LJ, et al. A systematic review and meta-analysis of the risk of increasing adiposity on Barrett's esophagus. Am J Gastroenterol 2008; 103:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/119\">",
"      Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology 2007; 133:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/120\">",
"      Edelstein ZR, Farrow DC, Bronner MP, et al. Central adiposity and risk of Barrett's esophagus. Gastroenterology 2007; 133:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/121\">",
"      Lanuti M, Liu G, Goodwin JM, et al. A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome. Clin Cancer Res 2008; 14:3216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/122\">",
"      Newton M, Bryan R, Burnham WR, Kamm MA. Evaluation of Helicobacter pylori in reflux oesophagitis and Barrett's oesophagus. Gut 1997; 40:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/123\">",
"      Loffeld RJ, Ten Tije BJ, Arends JW. Prevalence and significance of Helicobacter pylori in patients with Barrett's esophagus. Am J Gastroenterol 1992; 87:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/124\">",
"      Csendes A, Smok G, Cerda G, et al. Prevalence of Helicobacter pylori infection in 190 control subjects and in 236 patients with gastroesophageal reflux, erosive esophagitis or Barrett's esophagus. Dis Esophagus 1997; 10:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/125\">",
"      Goldblum JR, Vicari JJ, Falk GW, et al. Inflammation and intestinal metaplasia of the gastric cardia: the role of gastroesophageal reflux and H. pylori infection. Gastroenterology 1998; 114:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/126\">",
"      Xia HH, Talley NJ. Helicobacter pylori infection, reflux esophagitis, and atrophic gastritis: an unexplored triangle. Am J Gastroenterol 1998; 93:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/127\">",
"      Labenz J, Blum AL, Bayerd&ouml;rffer E, et al. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/128\">",
"      Vicari JJ, Peek RM, Falk GW, et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998; 115:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/129\">",
"      Ye W, Held M, Lagergren J, et al. Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst 2004; 96:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/130\">",
"      Rokkas T, Pistiolas D, Sechopoulos P, et al. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol 2007; 5:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/131\">",
"      Whiteman DC, Parmar P, Fahey P, et al. Association of Helicobacter pylori infection with reduced risk for esophageal cancer is independent of environmental and genetic modifiers. Gastroenterology 2010; 139:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/132\">",
"      Lagergren J, Bergstr&ouml;m R, Adami HO, Nyr&eacute;n O. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med 2000; 133:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/133\">",
"      Corley DA, Levin TR, Habel LA, Buffler PA. Barrett's esophagus and medications that relax the lower esophageal sphincter. Am J Gastroenterol 2006; 101:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/134\">",
"      Freedman J, Ye W, N&auml;slund E, Lagergren J. Association between cholecystectomy and adenocarcinoma of the esophagus. Gastroenterology 2001; 121:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/135\">",
"      Suzuki H, Henry E, McElroy K, et al. In Barrett's esophagus, acid reflux generates high luminal concentrations of nitric oxide from dietary nitrate (abstract). Gastroenterology 2003; 124(Suppl):A32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/136\">",
"      Suzuki H, Iijima K, Moriya A, et al. Conditions for acid catalysed luminal nitrosation are maximal at the gastric cardia. Gut 2003; 52:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/137\">",
"      Iijima K, Grant J, McElroy K, et al. Novel mechanism of nitrosative stress from dietary nitrate with relevance to gastro-oesophageal junction cancers. Carcinogenesis 2003; 24:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/138\">",
"      Terry P, Lagergren J, Ye W, et al. Inverse association between intake of cereal fiber and risk of gastric cardia cancer. Gastroenterology 2001; 120:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/139\">",
"      Mayne ST, Risch HA, Dubrow R, et al. Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 2001; 10:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/140\">",
"      Kubo A, Levin TR, Block G, et al. Dietary antioxidants, fruits, and vegetables and the risk of Barrett's esophagus. Am J Gastroenterol 2008; 103:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/141\">",
"      Heath EI, Canto MI, Piantadosi S, et al. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 2007; 99:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/142\">",
"      MacDonald WC, MacDonald JB. Adenocarcinoma of the esophagus and/or gastric cardia. Cancer 1987; 60:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/143\">",
"      Kubo A, Corley DA. Marked multi-ethnic variation of esophageal and gastric cardia carcinomas within the United States. Am J Gastroenterol 2004; 99:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/144\">",
"      H&ouml;lscher AH, Bollschweiler E, Schneider PM, Siewert JR. Prognosis of early esophageal cancer. Comparison between adeno- and squamous cell carcinoma. Cancer 1995; 76:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/145\">",
"      Dawsey SM, Wang GQ, Weinstein WM, et al. Squamous dysplasia and early esophageal cancer in the Linxian region of China: distinctive endoscopic lesions. Gastroenterology 1993; 105:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/146\">",
"      Acosta MM, Boyce HW Jr. Chromoendoscopy--where is it useful? J Clin Gastroenterol 1998; 27:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/147\">",
"      Meltzer SJ. The molecular biology of esophageal carcinoma. Recent Results Cancer Res 1996; 142:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/148\">",
"      Thorban S, Roder JD, Nekarda H, et al. Immunocytochemical detection of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma. J Natl Cancer Inst 1996; 88:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/149\">",
"      Cameron AJ, Lomboy CT, Pera M, Carpenter HA. Adenocarcinoma of the esophagogastric junction and Barrett's esophagus. Gastroenterology 1995; 109:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/150\">",
"      Paraf F, Fl&eacute;jou JF, Pignon JP, et al. Surgical pathology of adenocarcinoma arising in Barrett's esophagus. Analysis of 67 cases. Am J Surg Pathol 1995; 19:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/151\">",
"      Johansson J, Johnsson F, Walther B, et al. Adenocarcinoma in the distal esophagus with and without Barrett esophagus. Differences in symptoms and survival rates. Arch Surg 1996; 131:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/31/32250/abstract/152\">",
"      Lieberman MD, Shriver CD, Bleckner S, Burt M. Carcinoma of the esophagus. Prognostic significance of histologic type. J Thorac Cardiovasc Surg 1995; 109:130.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2274 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-8B92F8E3C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_31_32250=[""].join("\n");
var outline_f31_31_32250=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2100395\">",
"      ETIOLOGIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hereditary factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Demographic and socioeconomic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Smoking and alcohol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Dietary factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Underlying esophageal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3449516\">",
"      - Prior gastrectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5257549\">",
"      - Atrophic gastritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Human papilloma virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Tylosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Upper aerodigestive tract cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Gastroesophageal reflux disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Smoking",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Alcohol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Obesity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H193366386\">",
"      - Epidermal growth factor polymorphisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Increased esophageal acid exposure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Use of drugs that decrease lower esophageal sphincter pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Nitrosative stress",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Possible protective effect of cereal fiber and other nutrients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Possible protective effect of NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Risk factor differences from squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      PATHOBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2274\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2274|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/42/26272\" title=\"picture 1\">",
"      Tylosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/16/8463\" title=\"picture 2A\">",
"      Esophageal adenocarcinoma endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/60/18383\" title=\"picture 2B\">",
"      Esophageal adenocarcinoma retroflexed CPC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/10/33957\" title=\"picture 3\">",
"      Esophageal adenocarcinoma CPC Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/9/41118\" title=\"picture 4\">",
"      Squamous cell carcinoma of the distal esophagus Endosc",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2634?source=related_link\">",
"      Association between Helicobacter pylori infection and gastrointestinal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/38/40551?source=related_link\">",
"      Caustic esophageal injury in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15370?source=related_link\">",
"      Chromoendoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14504?source=related_link\">",
"      Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/26/14759?source=related_link\">",
"      Clinical manifestations and diagnosis of achalasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21802?source=related_link\">",
"      Cutaneous manifestations of internal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7898?source=related_link\">",
"      Diagnosis and staging of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20583?source=related_link\">",
"      Epidemiology and risk factors for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/6/21610?source=related_link\">",
"      Epidemiology of human papillomavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/8/1161?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/31/3578?source=related_link\">",
"      Extrapulmonary small cell cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/35/41529?source=related_link\">",
"      Gastrointestinal manifestations of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/46/9959?source=related_link\">",
"      Helicobacter pylori and gastroesophageal reflux disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/55/887?source=related_link\">",
"      Human papillomavirus associated head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34938?source=related_link\">",
"      Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/61/35802?source=related_link\">",
"      Management of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/60/20426?source=related_link\">",
"      Management of superficial esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/39/24185?source=related_link\">",
"      Metaplastic (chronic) atrophic gastritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/12/8391?source=related_link\">",
"      Pathogenesis of Barrett's esophagus and its malignant transformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13928?source=related_link\">",
"      Pathophysiology of reflux esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/17/9491?source=related_link\">",
"      Patient information: Esophageal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/58/36775?source=related_link\">",
"      Posttreatment surveillance of squamous carcinoma of the head and neck",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_31_32251="Treatment of hepatosplenic candidiasis";
var content_f31_31_32251=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F87678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F87678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of hepatosplenic candidiasis (chronic disseminated candidiasis) in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Primary",
"       </td>",
"       <td class=\"subtitle2\">",
"        Alternative",
"       </td>",
"       <td class=\"subtitle2\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          For stable patients:",
"         </strong>",
"         fluconazole 400 mg (6 mg/kg) orally daily",
"        </p>",
"        <p>",
"         <strong>",
"          For severely ill patients:",
"         </strong>",
"         a lipid formulation of amphotericin B 3 to 5 mg/kg IV daily or amphotericin B deoxycholate 0.5 to 0.7 mg/kg IV daily",
"        </p>",
"        After patient is stable, change to fluconazole",
"       </td>",
"       <td>",
"        An echinocandin* for several weeks followed by fluconazole",
"       </td>",
"       <td>",
"        Transition from a lipid formulation of amphotericin B or amphotericin B deoxycholate to fluconazole is favored after several weeks in stable patients. Duration of therapy is until lesions have resolved (usually months) and should continue through periods of immunosuppression (eg, chemotherapy and transplantation).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Echinocandin dosing in adults is as follows: anidulafungin, 200 mg IV loading dose, then 100 mg IV daily; caspofungin, 70 mg IV loading dose, then 50 mg IV daily; and micafungin, 100 mg IV daily.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infections Diseases Society of America. Clin Infect Dis 2009; 48:503. Copyright &copy; 2009 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_31_32251=[""].join("\n");
var outline_f31_31_32251=null;
var title_f31_31_32252="TTP HUS HELLP";
var content_f31_31_32252=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of frequency of signs, symptoms, and laboratory findings in TTP, HUS, and HELLP",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        TTP",
"       </td>",
"       <td class=\"subtitle1\">",
"        HUS",
"       </td>",
"       <td class=\"subtitle1\">",
"        HELLP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal pain",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low ADAMST13 activity",
"       </td>",
"       <td>",
"        +/++",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anemia",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevated lactic dehydrogenase",
"       </td>",
"       <td>",
"        ++ very high values",
"       </td>",
"       <td>",
"        ++ very high values",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevated transaminases",
"       </td>",
"       <td>",
"        -/+",
"       </td>",
"       <td>",
"        -/+",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Headache or visual disturbance",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertension",
"       </td>",
"       <td>",
"        +/++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jaundice",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nausea and vomiting",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proteinuria",
"       </td>",
"       <td>",
"        + and hematuria",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombocytopenia",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        von Willebrand factor",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TTP: thrombotic thrombocytopenic purpura; HUS: hemolytic uremic syndrome; HELLP: hemolysis, elevated liver function tests, low platelets; + indicates prevalence of finding in affected patients.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Stella, CL, Dacus, J, Guzman, E, et al. The diagnostic dilemma of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the obstetric triage and emergency department: lessons from 4 tertiary hospitals. Am J Obstet Gynecol 2009; 200:381. Original Table 4.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_31_32252=[""].join("\n");
var outline_f31_31_32252=null;
var title_f31_31_32253="Basic medical history";
var content_f31_31_32253=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F69716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F69716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Basic medical history for preconceptional counseling",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Endocrine disorder",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Thyroid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Adrenal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Diabetes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Cardiovascular disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Hypertension",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Arrhythmia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Atherosclerotic disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Congenital anomalies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Rheumatic fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Thromboembolic disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Kidney disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Pyelonephritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Urinary tract infections",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Anomalies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Neurologic or muscular disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Seizure disorder",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Myotonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Aneurysm",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Arteriovenous malformation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Gastrointestinal disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Hepatitis or other liver disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Gall bladder disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Inflammatory bowel disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Psychiatric problems",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Eating disorder",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Depression",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Psychosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"_left\">",
"            Domestic violence",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Autoimmune disorder",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Systemic lupus erythematosus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Rheumatoid arthritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"\">",
"            History of blood transfusion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"_left\">",
"            History of trauma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Pulmonary disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Asthma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Tuberculosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"\">",
"            Breast disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Infectious diseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Herpes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Gonorrhea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Chlamydia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Syphilis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            HIV",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Human papillomavirus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Hematological problems",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Coagulation disorder",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Easy bruising",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"_left\">",
"            Surgical procedures",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"\">",
"            Allergies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"_left\">",
"            Medications",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Substance abuse",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Alcohol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cigarettes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            llicit drugs",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_31_32253=[""].join("\n");
var outline_f31_31_32253=null;
var title_f31_31_32254="Exam childhood cataracts";
var content_f31_31_32254=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Important aspects of the physical examination in children with cataracts",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Feature",
"       </td>",
"       <td class=\"subtitle1\">",
"        Potential clinical implications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Growth parameters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Birth weight",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &gt;4 kg",
"       </td>",
"       <td>",
"        Maternal diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Weight",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Failure to thrive",
"       </td>",
"       <td>",
"        Chondrodysplasia punctata (Conradi-Hunermann syndrome), galactosemia, Lowe syndrome, Refsum disease (infantile form), Smith-Lemli-Opitz syndrome, Wolf-Hirschhorn syndrome, Zellweger syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Obesity",
"       </td>",
"       <td>",
"        Bardet-Biedl syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Length/stature",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Short stature",
"       </td>",
"       <td>",
"        Cockayne syndrome, Down syndrome, chondrodysplasia punctata, Hallermann-Streiff syndrome, incontinentia pigmenti, Lowe syndrome, Marinesco-Sjogren syndrome, Marshall syndrome, nail-patella syndrome, Rothmund-Thomson syndrome, Rubinstein-Taybi syndrome, Smith-Lemli-Opitz syndrome, Turner syndrome, Werner syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Head Circumference",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Microcephaly",
"       </td>",
"       <td>",
"        Cockayne syndrome, cri-du-chat syndrome, Hallermann-Streiff syndrome, incontinentia pigmenti, intrauterine infection, Marinesco-Sjogren syndrome, Meckel-Gruber syndrome, Norrie disease, oculodentodigital dysplasia, Rubinstein-Taybi syndrome, Smith-Lemli-Opitz syndrome, trisomy 13, Walker-Warburg syndrome, Wolf-Hirschhorn syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Macrocephaly",
"       </td>",
"       <td>",
"        Mannosidosis, Zellweger syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sebaceous cysts",
"       </td>",
"       <td>",
"        Lowe syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Subcutaneous nodules",
"       </td>",
"       <td>",
"        Lowe syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hyperpigmented whorls",
"       </td>",
"       <td>",
"        Incontinentia pigmentii",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Telangectasias",
"       </td>",
"       <td>",
"        Rothmund-Thomson syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Angiokeratomas",
"       </td>",
"       <td>",
"        Fabry disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Jaundice",
"       </td>",
"       <td>",
"        Galactosemia, intrauterine infection, maternal diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Scaly skin",
"       </td>",
"       <td>",
"        Alport syndrome, ichthyosis, chondrodysplasia punctata, Refsum disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rash",
"       </td>",
"       <td>",
"        Intrauterine infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Decreased/absent sweating",
"       </td>",
"       <td>",
"        Anhidrotic and hypohidrotic ectodermal dysplasia, Cockayne syndrome, Fabry disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Nails",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypoplastic, dysplastic or absent",
"       </td>",
"       <td>",
"        Hidrotic ectodermal dysplasia, incontinentia pigmenti, nail-patella syndrome, Rothmund-Thomson syndrome, trisomy 18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Head",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Craniosynostosis",
"       </td>",
"       <td>",
"        Apert syndrome, Crouzon syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Micrognathia",
"       </td>",
"       <td>",
"        Cri-du-chat syndrome, Hallermann-Streiff syndrome, Marshall syndrome, Meckel-Gruber syndrome, Pierre-Robin syndrome, progeria, Rubinstein-Taybi syndrome, Smith-Lemli-Opitz syndrome, Stickler syndrome, trisomy 18, Wolf-Hirschhorn syndrome, Zellweger syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sparse hair or alopecia",
"       </td>",
"       <td>",
"        Anhidrotic and hypohidrotic ectodermal dysplasia, chondrodysplasia punctata, Hallermann-Streiff syndrome incontinentia pigmenti, oculodentodigital dysplasia, progeria, Rothmund-Thomson syndrome, Werner syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypertrichosis",
"       </td>",
"       <td>",
"        Mannosidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Ears",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Small ears",
"       </td>",
"       <td>",
"        Down syndrome, Walker-Warburg syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Low set ears",
"       </td>",
"       <td>",
"        Cri-du-chat syndrome, Hallermann-Streiff syndrome, Meckel-Gruber syndrome, Rubinstein-Taybi syndrome, Smith-Lemli-Opitz syndrome, trisomy 18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Conductive hearing loss",
"       </td>",
"       <td>",
"        Apert syndrome, Down syndrome, oculodentodigital dysplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sensorineural deafness",
"       </td>",
"       <td>",
"        Alport syndrome, Cockayne syndrome, congenital cytomegalovirus, congenital rubella, mannosidosis, Marshall syndrome, Refsum disease, Stickler syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Oropharynx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cleft palate",
"       </td>",
"       <td>",
"        Marshall syndrome, Meckel-Gruber syndrome, nail-patella syndrome, oculodentodigital dysplasia, Pierre-Robin syndrome, Smith-Lemli-Opitz syndrome, Stickler syndrome, trisomy 13, Walker-Warburg syndrome, Wolf-Hirschhorn syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gingival hypertrophy",
"       </td>",
"       <td>",
"        Mannosidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Abdomen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hepatomegaly",
"       </td>",
"       <td>",
"        Cockayne syndrome, congenital cytomegalovirus, congenital rubella, congenital syphilis, congenital toxoplasmosis, galactosemia, mannosidosis, Refsum disease, Zellweger syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Cardiac",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cardiac malformations",
"       </td>",
"       <td>",
"        Apert syndrome, Bardet-Biedl syndrome, congenital rubella, Down syndrome, Meckel-Gruber syndrome, Refsum disease (infantile form), Rubinstein-Taybi syndrome, Smith-Lemli-Opitz syndrome, trisomy 13, trisomy 18, Turner syndrome, Wolf-Hirschhorn syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Conduction disturbance",
"       </td>",
"       <td>",
"        Myotonic dystrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Musculoskeletal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Transverse palmar crease",
"       </td>",
"       <td>",
"        Down syndrome, trisomy 13, Wolf-Hirschhorn syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Absent or hypoplastic patella; radial head subluxation",
"       </td>",
"       <td>",
"        Nail-patella syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Joint contractures",
"       </td>",
"       <td>",
"        Chondrodysplasia punctata, Marinesco-Sjogren syndrome, Walker-Warburg syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Broad thumbs",
"       </td>",
"       <td>",
"        Rubinstein-Taybi syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Polydactyly",
"       </td>",
"       <td>",
"        Bardet-Beidl syndrome, Meckel-Gruber syndrome, Rubinstein-Taybi syndrome, Smith-Lemli-Opitz syndrome, trisomy 13, Wolf-Hirschhorn syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Syndactyly",
"       </td>",
"       <td>",
"        Apert syndrome (mitten hand), Meckel-Gruber syndrome, Smith-Lemli-Opitz syndrome&nbsp;(2nd and 3rd toes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Talipes equinovarus (club feet)",
"       </td>",
"       <td>",
"        Chondrodysplasia punctata, nail-patella syndrome, Rothmund-Thomson syndrome, Wolf-Hirschhorn syndrome, Zellweger syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rocker bottom feet",
"       </td>",
"       <td>",
"        Zellweger syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Neurologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypotonia",
"       </td>",
"       <td>",
"        Cri-du-chat syndrome, Down syndrome, galactosemia, Lowe syndrome (neonatal), mannosidosis, Marinesco-Sjogren syndrome, myotonic dystrophy, Refsum disease, Smith-Lemli-Opitz syndrome (early infancy), Walker-Warburg syndrome, Zellweger syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Seizures",
"       </td>",
"       <td>",
"        Cockayne syndrome, congenital cytomegalovirus, congenital herpes simplex virus, congenital toxoplasmosis, hypoparathyroidism, incontinentia pigmenti, Lowe syndrome, Smith-Lemli-Opitz syndrome, Walker-Warburg syndrome, Zellweger syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Decreased/absent reflexes",
"       </td>",
"       <td>",
"        Lowe syndrome, Refsum disease (infantile form), Zellweger syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Increased reflexes",
"       </td>",
"       <td>",
"        Mannosidosis, oculodentodigital dysplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mental retardation",
"       </td>",
"       <td>",
"        Cockayne syndrome, chondrodysplasia punctata, cri-du-chat syndrome, Down syndrome, Hallermann-Streiff syndrome, incontinentia pigmenti, Lowe syndrome, Marinesco-Sjogren syndrome, oculodentodigital dysplasia, Refsum disease (infantile form), Smith-Lemli-Opitz syndrome, Zellweger syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Weakness",
"       </td>",
"       <td>",
"        Myotonic dystrophy, Marinesco-Sjogren syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Genitourinary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cryptorchidsim and/or hypogonadism",
"       </td>",
"       <td>",
"        Apert syndrome, Bardet-Biedl syndrome, Cockayne syndrome, Hallermann-Streiff syndrome, Lowe syndrome, Meckel-Gruber syndrome, myotonic dystrophy, Refsum disease, Rothmund-Thomson syndrome, Rubinstein-Taybi syndrome, Smith-Lemli-Opitz syndrome, trisomy 13, trisomy 18, Wolf-Hirschhorn syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_31_32254=[""].join("\n");
var outline_f31_31_32254=null;
var title_f31_31_32255="Posterior vaginal wall prolapse 8";
var content_f31_31_32255=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Repair of posterior vaginal wall prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 443px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Example of a transverse defect.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Walters, MD, Karram, MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright &copy;2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_31_32255=[""].join("\n");
var outline_f31_31_32255=null;
